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ABSTRACT
Traditional medical systems contributed significantly to medicine with a number of their
phytochemicals found to possess good biological properties. Recently, Dr. Youyou Tu was
awarded the Nobel Prize (2015) for her discovery/isolation of Artemisinin from the TCM plant
Artemisia annua. Our first aim is to identify active phytochemicals against botulinum neurotoxin
A (BoNT/A), and diabetes from Ayurveda and TCM, respectively, by using in silico, in vitro and
in vivo approaches. In our second aim, we wanted to enantioselectively synthesize scalable
quantities of phytoestrogenic isoflavans such as equol and sativan. The following three chapters
summarize results of the three research goals.
Chapter II describes our approach to identify the small molecules effective against
BoNT/A, one of the most lethal toxins known to humans, with none of the current known its
inhibitors reaching even the clinical trial stages. Ayurvedic literature was analyzed and a number
of plants were identified based on their usage, frequency and utility in various formulations, for
treating diseases with symptoms similar to botulism. The phytochemicals of these plants were
studied by docking into the catalytic domain of BoNT/A. From the docking results, thirty-one
compounds and their analogues were identified and tested in vitro using liquid chromatographybased protease assay. From these results, seven compounds were further tested using ex vivo
mouse phrenic nerve hemidiaphragm assay (MPNHDA). Results showed a number of
compounds including acoric acid 1, and galangin 3 possessed inhibitory activities of around 40-
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50% against BoNT/A in the in vitro assay, and in the MPNHDA, initial studies showed that at 20
μM, acoric acid 1 possessed marginal protection. Further testing of the active compounds like
acoric acid 1 and their analogues and using more sensitive, reproducible bioassays could yield
more active compounds.
Chapter III deals with the identification of small-molecule antidiabetic compounds from
the TCM plant, Goji (Lycium barbarum and Lycium chinense), widely used for treating various
diseases including diabetes and hypertension Current clinical antidiabetic drugs, like
rosiglitazone display severe side effects like edema, weight gain and heart failure. By docking
the twenty-seven selected reported compounds of Goji into the partial and full agonist binding
sites of PPARγ (target of rosiglitazone), tyramine derivatives were found to possess good
docking scores and binding poses. Henceforth, twenty-four cinnamomyl phenylethyl amide
derivatives (termed as tyramine-derivatives) were synthesized and were tested in vitro using
PPARγ-PPARα luciferase assay. Three compounds showed similar or higher fold induction than
the positive control, rosiglitazone. One tyramine-derivative 08, and tyramine derivativesenriched fraction (21%) of the root bark of L. chinense were further studied in vivo using diabetic
db/db mice. However, both of them did not possess antidiabetic properties in the tested mice
model. In vivo results indicate that the antidiabetic property of Lycium species is not due to
tyramine derivatives.
Chapter IV describes the first large-scale, enantioselective synthesis of both antipodes of
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phytoestrogenic isoflavans, equol and sativan, synthesized in >98% ee, with good overall yields
starting from the commercially available starting material. Syntheses of these isoflavans were
performed using Evans’ aldol condensation as a chiral inducing step at C-3 position of isoflavan
scaffold. The same flexible methodology can be applied for syntheses of other C-3 chiral
isoflavans.
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CHAPTER 1
TRADITIONAL MEDICINE AND DRUG DISCOVERY
1. Contribution of natural products to drug discovery
Natural products continue to be the basis of new drugs, contributing either by acting
directly as drugs or by acting as a source of new drugs. According to a review by Newmann et
al. in 2010, over the last 30 years (1980 to 2010), natural products (including natural productderived compounds, natural product-derived botanicals, synthetic compounds with core of
natural products) contributed to the bulk of the drugs approved for clinical usage (Figures 1-1
and 1-2) [1]. Among these drugs classes, since 1940s, 75% of the small molecule anticancer
drugs were other than synthetics and 48% were actually based on natural product scaffolds.
Synthetic approaches were used successful to identify clinically better natural product analogues.
However, combinatorial-chemistry approaches contributed to very few de novo drugs. Hence,
drug discovery based on natural products is still relevant to identify novel agents to find
treatments against health care challenges. Recently, the contribution of sources other than plants
in drug discovery, especially from the microbial sources, has risen and is projected to rise with a
number of them in clinical trials [1].
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Figure 1-1. Classification of the approved drugs from 1981 to 2010.
(permitted by Newmann et al, 2010).
The total number of newly approved drugs from 1981 to 2010 is 1355. B = biological, N =
natural product, NB = natural product botanical, ND = derived from a natural product, S = totally
synthetic drug, often found by random screening/modification of an existing agent, S* = made by
total synthesis, but the pharmacophore is/was from a natural product, and V = vaccine.

Figure 1-2. Percentage of natural products in the approved new chemical entities from 1981 to
2010 [1].
(permitted by Newmann et al, 2010).
The contribution of natural products to human health is significant. Two scientists,
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Alexander Flemming (Medicine, 1942) and Selman Waksman (Medicine, 1952) were awarded
the Nobel Prize for their discoveries of penicillin and streptomycin, from fungi and bacteria,
respectively. Very recently, the significance of natural products in human health has also gained
enormous publicity with the announcement of the Nobel Prize (for 2015) in medicine to three
natural product scientists: Youyou Tu, Satoshi Ōmura and William Cambell (Table 1-1).
Yougou Tu, isolated artemisinin form a plant named sweet worm wood, which was used
traditionally in China for treatment of fever [2]. The antimalarial effect of sweet worm wood
(Artemisia annua) was recorded in the compendium of Materia medica written by Shizhen Li
(1518 -1593). Currently, artimisinin and its derivatives are clinically used for the treatment of
malaria around the world. In 1978 Satoshi Ōmura succeeded in culturing a strain from which
William Campbell purified a substance, avermectin, which, in a chemically modified form
(ivermectin), proved to be active against round worm infections.
2. Ethnomedicine/traditional medicine
Since prehistoric periods, plants have been a major source for medical treatments across
the world. In countries like Greece, Egypt, India, Tibet and China etc., there have been
archeological and ancient textual references about the usage of plants for the treatment of
diseases or disease symptoms [3]. Ethnomedicine is defined as the use of plants as medicine,
which includes traditional forms of treatment like TCM and Ayurveda. Ethonopharmacology is
“a much diversified approach to drug discovery involving observation, description and
experimental investigation of indigenous drugs and their biological activities. This involves
highly interrelated studies of botany, geology, biochemistry, pharmacology, and other
disciplines” [4].
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Table 1-1. Three natural product scientists awarded the Nobel Prize for their contribution to
human health.
Youyou Tu

William C. Campbell

Satoshi Ōmura

Ivermectin chemically modified from

Artemisinin

Avermectin (isolated from bacteria)

Novel therapy against Malaria
Traditional Chinese medicine
o uses sweet wormwood to treat
fever
o extracted artemisinin, which
inhibits the malaria parasite.



Novel

therapy

against

infections:

Lymphatic filariasis, or elephantiasis, effective
against river blindness
Ethnomedicine contributed to the identification of a number of drugs. According to the
2001 review by Farnsworth et al., a total of 122 compounds were identified to be obtained from
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plants used in traditional medicine, and among these 80% of the compounds were used for the
same or related ethnomedical use (Table 1-2) [4]. Compounds from these ethnomedical plants
also serve as precursors for the synthesis of new drugs like papaverine, which acted as a
precursor for verapamil, galegine, which acted as a precursor for metformin (Figure 1-3).

Figure 1-3. Drugs derived from natural products: verapamil from papaverine and galegine from
metformin [4]
Traditional medicine is a broad term representing all forms of non-western medicine,
including eastern medical systems which originated in China and India, and have been practiced
for over thousands of years. Traditional Chinese medicine (TCM) and traditional Indian
medicine (Ayurveda, Yoga, Siddha, Unani and Homeopathy etc.) are well documented (Table 13) for a number of centuries with a number of prescriptions mainly plant-based are used for
treatment. Till today, traditional medicine is still very popular among a majority of populations
of the world, with WHO estimates of 1995, indicating that 65% of the world’s population
continue to be treated with traditional medical treatments [4].
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Table 1-2. Some examples of phytochemical drugs with similar enthomedical properties as their
traditional uses. [4]
Drug
Agrimophol
Atropine
Cocaine
Codeine
Cynarin
Deslanoside
Gossypol
Khellin
Picrotoxin

Action or clinical use
Anthelmintic
Anticholinergic
Local anesthetic
Analgesic; antitussive
Choleretic
Cardiotonic
Male contraceptive
Bronchodilator
Analeptic

Reserpine
Rotundine
Scillarin A
Theophylline
Tubocurarine

Antihypertensive,
tranquillizer
Analgesic; sedative
Cardiotonic
Diuretic; bronchodilator
Skeletal muscle relaxant

Yohimbine

Aphrodisiac

Plant source
Agrimonia eupatoria L.
Atropa belladonna L.
Erythroxylum coca Lamk.
Papaver somniferum L.
Cynara scolymus L.
Digitalis lanata Ehrh.
Gossypium spp.
Ammi visnaga (L.) Lamk.
Anamirta cocculus (L.)
W.&A.
Rauvolfia serpentina (L.)
Benth ex. Kurz
Stephania sinica Diels
Urginea maritima (L.) Baker
Camellia sinensis (L.) Kuntze
Chondodendron tomentosum
R. & P.
Pausinystalia yohimbe
(K.Schum.) Pierre

3. Ayurveda and TCM
Both TCM and Ayurvedic systems are based on health principles, and aim to promote
both health and quality of life [5]. They mainly use plant-based formulations along with animal
and other metals.
According to TCM, the world is made up of elements—water, earth, metal, wood and
fire, and two relatively opposite aspects represented as Yin and Yang, which act like positive and
negative opposites, and are interchangeable. The amount of Yin reduces while Yang increases
and vice versa. In TCM, human body is the center of the universe with the four bodily humors
(qui, blood, moisture, essence) and internal organ systems (Zang fu) playing an important role in
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balancing the Yin and Yang in the body. Any disease condition is stated to be due to an
imbalance of the body. TCM has contributed to a number of breakthrough drugs like ephedra
(from Ma hung, isolated in 1885), artemisinin (anti-malarial) and paclitaxel (anti-cancer). The
antimalarial effect of the artemisinin plant, Artimisia annula was recorded in the compendium of
Materia medica written by Shizhen Li (1518-1593).
Table 1-3. Historical progress of the literature in TCM [6] and Ayurvedic [7].
TCM
Period
~300 BC

221 BC–220
AD

581–960 AD

960–1368 AD

1368–1643 AD

Ayurveda
Literature

Period

Prescriptions for fifty-two
1000 BC
diseases (300 BC),
anonymous.
Shen Nong Ben Cao Jing (25 100 AD
–220 AD), anonymous.
Shang Han Za Bing Lun (210
AD), written by Zhang
Zhong-Jing.
Xin Xiu Ben Cao (659 AD), 800 AD
written by Li Ji and Su Jing et
al.
Wai Tai Mi Yao (752 AD),
written by Wang Tao.
Zheng Lei Ben Cao (1082
AD), written by Tang ShenWei.
Sheng Ji Zong Lu (1111–
1117 AD), compiled by Zhao
Ji.
Ben Cao Gang Mu (1578
AD), written by Li Shi-Zhen.
Pu Ji Fang (1406 AD),
written by Zhu Di.

Literature
Charak Samhita

Sushrut Samhita

Madhav Nidan

According to the Ayurvedic system of treatment, the world is made up of five elements,
akasha (ether or space), vayu (air), teja (fire), jal (water) prithvi (earth). These five elements are
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coded into the human body as three forces/doshas, termed as “tridosha’ kapha, vata, pitta, each
doshs consists of one or two elements, Vata-space and air, Pitta – space and air, kapha – water
and ether. The tridosha is responsible for the health; any imbalances would generate disease
conditions in the system [5]. Plants from Ayurvedic system of medicine have contributed to the
discovery of a number of compounds which are useful to treat against a number of diseases and
possess good bioactivities. Table 1-4 shows some examples of compounds from Ayurvedic
plants and their treatment target diseases. In addition, there are a number of plant formulations or
whole plant parts from Ayurveda, which are currently used for the treatment of diseases or
disease symptoms. Although Ayurveda has contributed to a number of pure compounds against a
number of diseases, it was not able to produce any breakthrough drugs like placlitaxel or
artemisinin, from TCM, and the credits were taken by the Western pharmaceutical companies for
the discovery of drugs like forskolin and reserpine.
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Table 1-4. List of Ayurvedic plants and their phytochemicals used for treatment of various
disease conditions [6].

Antiinflammatory

Compound
Withanolides

Curcumin
Guggul
Cardiovascular Cardiac glycosides or
cardenolides
symptoms
Thevitin A, B,
Peruvoside
Reserpine
Colenol

Antidiabetic

Anti-obesity
Anti-malarial

Plant
Withania somnifera
Curcuma longa
Commiphora mukul
Several plants

Disease
Arthritis

Potent cardiac
glycosides

Yellow oleander plant
Rauvolfia serpentina
(L.) Benth ex. Kurz
Coleus spp

Charantin with
steroidal saponins in
1:1

Momordica charantia

Gymnemic acid
Guggulipid
Nimbolide, timonoid
triterpene

Glymnema sylvestra
Commiphora mukul
Azadirecta indica

Angina pectoris
Hypotensive
actionand positive
ionotopic effect
Insulin-like
activity,
hypoglycemic
activity
Type-II diabetes
Antihyperlipidemic
Anti-malarial

4. Overall aims
Drug discovery from plants in traditional medicine
There is an ever increasing demand to find new phytochemicals as drugs. However, the
current approaches in drug discovery from plant extracts are based on mechanism-based testing
of pure compounds using high-throughput screening or bioactivity-guided fractionation. Drug
discovery from plants is a very laborious process with over 250 thousand known plants. In
addition, the number of bioassays used for screening is ever increasing.Hence, finding the activephytochemical principles and their disease-targets is very complex. In order to overcome these
challenges, instead of random screening of plants for activities and disease treatments,
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ethnomedical usage or traditional usage could be a good metric for the selection of plants to be
tested for a particular bioactivity. This selection should be based on their exact or similar
ethnomedical or symptomatic usage. Our aim primary aim is to identify new biological roles of
the phytochemicals from plants mentioned in TCM and Ayurveda. Using computational/in silico,
synthetic, in vitro-based approaches, TCM and Ayurvedic plant-based phytochemicals were
tested for their anti-botulism (Chapter 2) and anti-diabetic (Chapter 3) activities.
Isoflavans are secondary metabolites of plants possessing varied biological properties.
Equol 7, an isoflavan, is a biological metabolite of the isoflavonoids commonly found in the soy
based traditional foods in China, Japan and south-east Asian countries. S-Equol 7 was found to
bind preferentially to estrogen receptor β (among the two nuclear estrogen receptors, estrogen
receptor-α and -β). In order to further test the biological activities of equol and other
isoflavonoids, a large scale general synthetic method to produce enough quantities of
enantiopure material will be useful for further biological testing. In our other aim, we performed
enantioselective synthesis of isoflavans, equol and sativan. The same method could be used for
the synthesis of other plants (Chapter 4).
In this dissertation, three projects were performed which include testing for phytochemicals from
both Ayurveda and TCM. They are:
1.

Identification of new scaffolds from Ayurvedic literature against botulinum neurotoxin

(Chapter 2).
2.

Screening of the phytochemicals of the Traditional Chinese Medicinal plant, Goji, for the

identification of small molecules with anti-diabetic activities (Chapter 3).
3

New synthetic method for enantioselective synthesis of isoflavans, equol and sativan

(Chapter 4).
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CHAPTER 2
IDENTIFICATION OF NOVEL PHYTOCHEMICAL INHIBITORS OF
BOTULINUM NEUROTOXIN A
1.
1.1.

Introduction
Ayurveda and drug discovery
Drug discovery continues to rely on natural products which are a major source of drugs,

producing 50% of all small-molecule new chemical entities from the year 2000 to 2010 [6].
Traditional systems of medicine from India and China contributed to the discovery of a number
of drugs for the treatment of many diseases such as malaria (quinine, artemisinin) and cancer
(vinca alkaloids, paclitaxel, camptothecin, irinotecan) [7, 8]. Ayurveda is a traditional system of
medicine from the Indian subcontinent with a history of over 3000 years. With “Ayur” meaning
life and “veda” meaning knowledge or science, Ayurveda is centered on health principles [9].
Ayurvedic literature such as Charak Samhita (1000 BC) and Sushrut Samhita (100 AD) provides
a description of conditions and symptoms associated with a number of diseases. Over 10,000
formulations with >1,500 herbs were included in the Ayurvedic materia medica and over 5,000
signs and symptoms were mentioned in the diagnosis classic, Madhav Nidan (800 AD). This vast
knowledge of disease symptoms and treatment procedures provides a time-tested approach for
solving current challenges in drug discovery. The aim of the current study is to identify novel
small-molecule leads for the treatment of botulinum neurotoxin serotype A (BoNT/A) by using
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the Ayurvedic literature and modern in silico drug screening techniques.
1.2.

Botulinum neurotoxins (BoNTs)
BoNTs, produced by anaerobic gram-positive bacilli such as Clostridium botulinum,

result in a disease known as botulism which is characterized by flaccid paralysis. Symptoms
arise from the inhibition of the release of acetylcholine at the peripheral neuromuscular junction
(Figure 2-1) [10]. So far, seven identified serotypes (A to G) and numerous subtypes of BoNT
have been reported. Serotypes A, B, E, and F affect humans, and among these, BoNT/A is the
most potent serotype [11, 12]. The lethal dose of the crystalline form of BoNT/A is
approximated as 0.09-0.15 µg intramuscularly and 0.70-0.90 µg orally for a 70 kg human being
[13]. BoNTs are classified as Category A bio-warfare agents by the Centers for Disease Control
and Prevention (CDC). Due to their action at the neuromuscular junction, BoNTs are used for the
treatment of various muscular disorders and for various cosmetic purposes [14, 15].The currently
available remedies for botulism include treatment with anti-toxins, which is limited since it is
effective only for sequestering the free, circulating toxin

but ineffective for treating post-

infected cells [16]. Hence, the identification of small-molecule inhibitors which possess activity
against the already infected cells is of immense interest to the human health and the research
community.
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Figure 2-1. Mode of action of BoNTs [17].
BoNTs inhibit the release of acetyl choline by cleaving the proteins involved in vesicle binding
to the receptor via four step mechanism (Permitted by Lalli et al., 2003).
1.3.

BoNT/A: Structure and binding site
The structure of the BoNT/A is highly complex and consist of three domains, each of

which are approximately 50 kDa in size, incorporating two peptide chains [light chain (LC) and
heavy chain (HC)] connected by a disulfide bridge [18] (Figure 2-2). LC possesses a single
catalytic domain responsible for the proteolytic activity; whereas, HC, possesses two domains:
the translocation domain, and the binding domain, and is involved in neuro specific binding,
uptake and translocation of LC into the neuronal cytosol. The LC, which possesses the zincdependent catalytic domain, cleaves one of the three proteins that are essential for synaptic
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vesicle fusion, this results in the inhibition of the release of acetylcholine and leads to flaccid
paralysis of the muscles [19].

Figure 2-2 Structure of BoNT/A (PDB 3BTA).
A) BoNT/A consists of three domains, light chain (LC) domain in grey which possess the
peptide cleaving pocket, heavy chain (HC) which acts as a translocation domain and receptor
binding domain in violet. B) LC domain with the binding pocket possessing hydroxamate
inhibitor. (permitted by Thompson et al [20].

The LC exerts its proteolytic action by cleaving Synaptosome Associated Protein 25kD
(SNAP-25), a peptide which is involved in binding of the vesicles to the membrane, at Gln197Arg198. SNAP -25 possesses two helices, a C-terminal helix and an N-terminal helix denoted by
sn1 and sn2, respectively. The crystal structure of SNAP-25 with sn2 (PDB: 1XTG) showed
extensive interface with the LC, were it was found to possess two exosites, α and β (Figure 2-2).
These exosites are formed by the interaction of the α-helix and β-sheet of SNAP-25, in addition
to the catalytic site. This extensive interface between the LC and SNAP-25 results in specificity
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and efficiency of proteolytic cleavage (Figure 2-3) [21].

Figure 2-3. Structure of SNAP-25 (PDB 1XTG) in complex with LC of BoNT/A.
The Cα backbone of the LC is represented as cyan ribbons, and its molecular surface is in
transparent gray. sn2 is depicted in red, and the catalytic Zn2+ at the active site as a purple
sphere. [Perrmitted by Montal et al. [22]]
The catalytic domain (LC) consists of: Zn+2 ion and residues that-chelate with the zinc
ion, -help in peptide cleavage, form the hydrophobic pocket, and loops surrounding the active
site of BoNT/A. The LC of BoNT/A is a zinc-protease, and possess a highly conserved Zn+2
protease motif HEXXH. The imidazole groups of His222 and His226 and the carbonyl side chain
of Glu261 coordinate with Zn+2 at the active site. A water molecule coordinating with Glu223
plays a crucial role in the proteolysis. They are involved in positioning the substrate to enable its
cleavage. The residues that help in peptide cleavage are Tyr366 and Arg363, whereas, Ile161,
Phe163, Phe194, and Phe369 make up the hydrophobic pocket [23]. Loops 360/370 (366-372)
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and 60/70 (61-79) surround the catalytic site and are flexible upon inhibitor binding [20].
Kumaran et al. described the key interacting residues in the catalytic site of BoNT/A, by using
four inhibitory substrate tetrapeptides. They showed that Tyr 366 and Arg 363 interact with the
P1 and P1' of the substrate. S1 is formed by Glu164, whereas, S1' is formed by Phe194, Thr215,
Thr220, Asp370 and Arg363, and S3' is formed by Tyr250, Tyr251, Met253, Leu256, Phe369,
Phe423, Pro206, and Leu207 [24] (Figure 2-4).

Figure 2-4. Binding site of BoNT/A representing S1, S1', and S3' sites using an inhibitor peptide
[25].
“The side chain groups of the terminal peptides are shown at the bottom of the figure. Residues
of the enzyme forming the subsites are shown in boxes [25].”
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1.4.

BoNT/A inhibitors
In general, the identification of inhibitors and modulators of BoNT is approached by

targeting all three modules: the receptor-binding module, the translocation domain module, and
the protease module [19, 26]. Among these three approaches, we want to target BoNT/A at its
catalytic domain (LC) which is located in the protease module of the enzyme. Several inhibitors
which target the catalytic domain were reported including peptide inhibitors [27] and small
molecule inhibitors, including natural products.
Small molecule inhibitors: Identification of small-molecule inhibitors which target the
catalytic domain of BoNT/A is a very active area of research. Several small-molecule inhibitors
including natural products have been reported by various groups. However, none have reached
advanced levels such as clinical trials [13, 28]. These small-molecule inhibitors include
hydroxamic acid derivatives, their prodrugs [20, 29-31] (Figure 2-5) and quinolinol [27, 32, 33]
inhibitors (Figure 2-6).

Figure 2-5. Structures of the hydroxamic acid derivatives possessing BoNT/A inhibitory activity
[20].
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Figure 2-6. Structures of quinolinol based inhibitors of BoNT/A [32].
IC50 values of selected analogs against recombinant full-length BoNT/A LC (rALC) and
truncated BoNT/A LC (tALC; residues 1 to 425) are given in parenthesis.
Natural products: In addition to the synthetic molecules, several natural products,
including some from fungal sources, have been identified as inhibitors of BoNT/A (Figure 2-7).
These compounds include chicoric acid [34], caftaric acid, and chlorogenic acid [35] which were
found to act via exosite mechanisms. Lomofungin, a compound first isolated from fungi, was
found to be an inhibitor with a Ki of 6.7 + 0.7 μM [36]. Capsaicin was previously identified by
Thyagarajan et al. as a potential inhibitor of BoNT [37, 38]. By in silico screening of the NIH
Molecular Library Small-Molecule Repository (MLSMR) containing ~350,000 compounds,
fungal bis-naphthopyrones, chaetochromin A, and talaroderxines A and B were identified as
potent inhibitors of BoNT/A [39]. Five highly potent quinolinol inhibitors were first identified
using a combination of in silico and in vitro screening of the NCI database [32].
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Figure 2-7. Structures of the reported natural product inhibitors of BoNT/A [34, 39].
2.

Results and discussion
We hypothesized that phytochemicals obtained from Ayurvedic plants which are used for

the treatment of diseases with symptoms closely related to that of botulism can be used as smallmolecule inhibitors of BoNT/A LC protease. With the aim to identify novel natural product
inhibitors of BoNT/A using symptom based-Ayurvedic literature in three stages: i) selection of
plants from Ayurvedic literature, ii) in silico screening, iii) in vitro and ex vivo testing. Several
crystal structures of BoNT/A were reported in the literature, six crystal structures were selected
for computational work. All the phytochemicals from the selected Ayurvedic plants were first
screened against six known crystal structures of BoNT/A for probing the available chemical
space with in silico methods such as docking. The resulting hits were further investigated with
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HPLC-based in vitro screening method.
2.1.

Selection of plants from Ayurvedic literature
Botulinum neurotoxin causes flaccid paralysis of the muscles. The weakness of the

muscles descends from the muscles of the head and upper extremities via respiratory muscles to
the muscles of the lower extremities. This could become fatal when left untreated, due to the
respiratory failure resulting from the arrest of the intercostal muscles and the diaphragm.
Clinical symptoms of botulism include blurred vision, drooping eye lids, symptoms of the throat
such as slurred speech, difficulty swallowing, dry mouth, muscle weakness, and flaccid
paralysis [40] (Table 2-1).
Table 2-1. Clinical symptoms of Botulism [40].
Initial prodromal
symptoms

Initial neurological

Muscle weakness

If untreated

If unrecognized
and untreated,
Ocular cranial nerve
the intercostal
Nausea
dysfunction:
Head control
muscles (ribs)
Vomiting
Blurred vision; diplopia,
Upper extremities
and the
Abdominal
ptosis, photophobia,
Respiratory
diaphragm are
cramps
facial weakness
muscles
compromised,
Diarrhea
Bulbar nerve dysfunction) Lower extremities
then respiratory
Dysarthria, dysphonia
insufficiency
(speech) & dysphagia
occurs followed
(swallowing)
by respiratory
failure.
Using clinical symptoms as a benchmark, Ayurvedic literature were analyzed to identify
within them any discussion of diseases with neuromuscular symptoms similar to that of botulism.
Interestingly, the neuromuscular symptoms of some of the diseases mentioned in the Ayurvedic
text, Ayurveda Saukhyam of Todarananda written by Vaidya Bhagwan Dash and Lalitesh
Kashyap, were similar to the clinical symptoms of botulism [40]. These diseases include Ardita,
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Apa tänaka, Hanu graha, Hanu stambha, Gŗdhrasi, and Akshepaka (Table 2-2).
Table 2-2. List of the diseases with symptoms similar to botulism mentioned in the Ayurvedic
text by Vaidya Bhagwan Dash and Lalitesh Kashyap.
Disease name

Symptoms

(Ayurvedic)
Ardita

Facial paralysis

Apa tänaka

Emprosthotonos: A tetanic spasm in which the head and feet
are drawn forward and the spine arches backward

Hanu graha

Lock jaw

Hanu stambha

Lock jaw

Gŗdhrasi

Sciatica: A sharp or burning pain that radiates from the lower
back or hip, possibly following the path of the sciatic nerve to
the foot

Aksepaka

Convulsions: Frequent spasmodic contractions of all the
muscles in the body

The Ayurvedic text also includes formulations made up of a number of plants which can be used
for the treatment of these diseases. A thorough analysis of the plants discussed in the Ayurvedic
text revealed 325 plants mentioned in the 46 formulations used to treat the six diseases. These
plants were ranked based on their utility to treat more than one disease and the frequency of their
mention in the formulations. Out of the 325 plants, 14 plants belonging to 12 different families
were selected based on their ranking to be studied further (Table 2-3). The phytochemicals of
these 14 plants were further tested using docking studies.
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Table 2-3. List of the 14 Ayurvedic plants selected based on their treatment of botulism like
diseases mentioned in the Ayurvedic literature.
No

Plant Name

Family

Formulatios

Disease

Referen
ce

1

Acorus calamus Linn.

Acoraceae

16

5

[41]

2

Foeniculum vulgare Mill.

Apiaceae

12

5

[42]

3

Coriandrum sativum Linn.

Apiaceae

7

3

[43]

Compositae

27

6

[44]

Convolvulaceae

5

3

[45]

Euphorbiaceae

17

5

[46]

Lamiaceae

6

4

[47]

Leguminosae

10

4

[48]

4
5
6
7
8

Pluchea lanceolata Oliver
and Hiern.
Argyreia speciosa Linn.
f.Sweet
Ricinus communis Linn.
Clerodendrum serratum
Moon.
Phaseolus mungo
Linn.(vigna mungo)

9

Sida cordifolia Linn.

Malvaceae

19

5

[49]

10

Sida rhombifolia Linn.

Malvaceae

2

2

[50]

11

Cedrus deodara Laud.

Pinaceae

12

4

[51]

12

Piper chaba Hunter.

Piperaceae

5

3

[52]

13

Hordeum vulgare Linn.

Poaceae

7

4

[53]

14

Zingiber officinale Rosc.

Zingiberaceae

23

5

[54]
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2.2.

Docking studies

Selection of crystal structures
An analysis of the crystal structures of BoNT/A in complex with various inhibitors was
performed using a protein data bank (PDB). The search produced eighteen crystal structures
containing proven BoNT/A inhibitors reported at the time of this analysis. Out of these 18,
thirteen contained peptide inhibitors (PDB code: 3C88, 3C89, 3C8A, 3C8B, 3DS9, 3DSE, 3NF3,
3QW5, 3QW6, 3QW7, 3QW8, 3DDA and 3DDB) and 5 crystal structures contained smallmolecule inhibitors (PDB code: 3QIY, 3QIZ, 3QJ0, 4HEV and 2ILP) [20, 23, 24, 30]. The
crystal structures containing the five small-molecule and one peptide- inhibitor (PDB: 3C8B)
were selected for their utilization in the docking studies. The structures of the six proven
BoNT/A inhibitors from the selected crystal structures are included in the Figure 2-8.
Protein preparation and grid validation
All six selected ligand-BoNT/A complex crystal structures were prepared by the addition
of hydrogen atoms and the removal of all the water molecules. Their grids were generated
around a 12 Å radii from the centroid of the ligand and were used for docking studies in the
virtual screening workflow (VSW) in the glide docking module. In order to test if water
molecules can influence the docking results, a test docking run was performed using the grids
with and without the water molecules. Although, water molecules were reported to facilitate in
the hydrolysis of SNAP-25 [25], test docking results indicated no difference in the docking
scores of the compounds docked in grids with or without water. Thus, all the water molecules
were removed prior to docking.
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Figure 2-8. Structures of the ligands in the crystal structures selected for BoNT/A docking
studies.

Figure 2-9. Structures of BoNT/A LC inhibitor positive controls used in in vitro and docking
studies.
The grids were also tested by re-docking the native ligand to the grid and the RMSD of
the output ligands were compared to the ligands’ crystal structure conformations. Results showed
an RMSD of <1 Å for the output ligands when compared to the native crystal structure
conformation for all the small-molecule grids except for the protein ligand (due to its large,
flexible structure). The prepared 570 ligands selected from the Ayurveda literature (section 3.1)
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resulted in 835 structures (more than one stereoisomer for some ligands), which were then
docked into the six grids using the VSW module. In addition to the phytochemicals, native
ligands and known BoNT/A inhibitors were also included in the docking studies as positive
controls.
Docking results and selection of compounds
Docking of the 570 compounds from Ayurvedic plants using Glide SP in the six BoNT/A
grids generated 866 results. These 866 results (more than one conformer for each compound)
contain 535 compounds, indicating that about 35 compounds were eliminated in the docking in
the specified conditions. The docked ligands included two proven BoNT/A inhibitors, CB
7967495 and NSC 84094 [55] and the native BoNT/A crystal structure ligands (Figures 2-8, 9).
The docking scores of the docked compounds ranged from -11.2432 to +0.7210 kcal/mol. A
compound with a more negative docking score represents more favorable binding at the binding
site, hence a more negative score is desirable for a compound to act as an inhibitor. The native
ligands of the crystal structures and their conformers showed good docking scores ranging from 11.074 to -7.50 kcal/mol.
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a

b

c

d

Figure 2-10. The binding poses and ligand-interaction diagrams of the two hit compounds
selected from virtual screening in the BoNT/A active site of PDB 3QJ0.
a, b) acoric acid 1 (color: pinkish-orange), c, d) galangin 3 (color: pinkish-black) in the catalytic
domain of the BoNT/A LC showing that both interact with Zn+2. The other key residues in the
catalytic site are shown as sticks in yellow.
The docking scores of the conformers of positive controls, CB 7967495 and NSC 84094,
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ranged from -8.5490 to -6.51 kcal/mol. The first 250 results in the docking output include 170
compounds and show docking scores ranging from -11.2432 to -7.11989 kcal/mol (SI table 1).
Among these, acoric acid 1, chlorogenic acid 2, galangin 3 and quercetin 4 possessed docking
scores of -9.089, -11.094, -7.187 and -7.603 kcal/mol, respectively, and were selected for further
testing in vitro. The ligand-interaction diagrams of these compounds showed that the carboxylic
acid group of acoric acid 1 and the hydroxyl group of galangin 3 coordinate with the zinc ion in
the catalytic site and also interact with other residues such as Tyr366, Phe163, Ile161, Pro69,
Asp370, and Arg363 in the hydrophobic pocket around the S1' region of the catalytic site
(Figure 2-10).
Based on structural similarity, twenty-seven other compounds were selected and tested
for their BoNT/A inhibitor activities using an HPLC-based protease assay. These compounds
include seven isoflavonoids (5 to 9), six kavalactones (10 to 15), two capsaicin derivatives (16,
17), three coumarin derivatives (18 to 20), three gingerols (22 to 24), and one compound of each
type such as curcumin 21, epigallocatechingalelate (EGCG) 25, (Z)-5-benzylidenethiazolidine2,4-dione 26, chicoric acid 27, piperine 28, pterostilbene 29, bilobalide 30, and ginkgolide C 31.
Capsaicin 16 was previously identified by Thyagarajan et al as a potential inhibitor of BoNT/A
[56, 57]. Chicoric acid 27 [34] and chlorogenic acid 2 [35] were previously studied by Janda et
al., and were found to act as exo-site inhibitors of BoNT/A. Chlorogenic acid 2 was included
since it was one of the docking hits and chicoric acid 27 was included to test its activity on the
catalytic site. Figure 2-11 shows the structures of all the compounds tested using in vitro
HPLC/UPLC based bioassay.
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2.3.

In vitro studies utilizing SNAP-25 substrate
In vitro assays were performed using the isolated LC of BoNT/A and a 17-residue

substrate peptide consisting of residues 187–203 of SNAP-25, which is the minimum length of
SNAP25 required for light chain protease activity. The sequence of the substrate peptide is
(N(α)-acetyl)-SNKTRIDEANQRATKML-(carboxamide), corresponding to residues 197 and
198 of SNAP-25 [58]. LC cleaves this substrate peptide between residues 11 (glutamine, Q) and
12 (arginine, R). The peak areas of the corresponding N-terminal and C-terminal cleaved
peptides were measured using liquid chromatography, and test compounds were compared to
that of the blank (treated only with BoNT/A). All the compounds were tested at 20 µM, and the
results were reported as % inhibition compared to the blank.
In vitro bioassay results
Twenty-two compounds (Table 2-4) were first analyzed using HPLC, whereas nine
compounds were tested using UPLC (Table 2-5) [59]. UPLC method was utilized since the
HPLC method has several issues like long run times (~ 50 min for 1 sample), non-reproducible
activities of the blank and test sample, affecting the stability of the toxin. Hence, a UPLC method
was applied mainly to reduce the run times and to make it ideal for large set of compounds. The
results of the HPLC BoNT/A protease activity bioassay are presented in Tables 2-4 and 2-5.
Compounds CB 7967495 and NSC 84094 were used as positive controls [55] and showed 92%
and 91% inhibition, respectively at 20 µM in the HPLC assay, whereas the activities of the same
were lower 86 and 87% in UPLC runs.
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Figure 2-11. Structures of the compounds tested using HPLC-BoNT/A LC protease assay.
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Testing the four hit compounds selected from virtual screening revealed acoric acid 1, as
the most active of the compounds exhibiting an inhibition of 47 ± 7% at 20 µM, followed by
galangin 3 which showed 43 ± 8% inhibition. Among the five other isoflavonoid derivatives,
fisetin 5 was found to be the most active, possessing inhibition of 59 ± 0.5%. Kavain 10 was the
most active compound among the six kava lactones, showing 53 ± 13% inhibition, with a
significant standard deviation between the results and among the three coumarins derivatives (18
to 19). 4-hydroxy coumarins 18 showed superior inhibition of 41 ± 8% compared to coumarin 19
and 4-methylumbelliferone 20, with 25 ± 11 and 16 ± 1% inhibitions, respectively.
None of the three gingerols 22–24 were good inhibitors possessing % inhibitions ranging
from 17 to 20%. Among the two capsaicin derivatives 16 and 17, capsaicin 16 showed 38 ± 7 %.
Curcumin 21 showed inhibition of 49 ± 4%. Among the seven ungrouped compounds 25-31,
none of them showed good inhibition: epigallocatechin gallate (EGCG) 25 (4 ± 1.1%), (Z)-5benzylidenethiazolidine-2,4-dione 26 (13 ± 1%), chicoric acid 27 (6 ± 1.4%), piperine 28 (21 ±
1.5), pterostilbene 29 (16 ± 1.5), bilobalide 30 (13 ± 2.0%), and ginkgolide C 31 (2 ± 0). The
known exosite inhibitors chlorogenic acid 2 and chicoric acid 27 also showed low inhibition (15
± 3.0%), and 6 ± 1.4%), respectively, indicating that these compounds are not active in the
catalytic site which validates the reported exosite binding of these compounds.
From the HPLC/UPLC bioassay results, seven compounds 1, 3, 5, 10, 16, 18, and 21
showed good inhibitions and were tested further using mouse phrenic nerve hemidiaphragm
assay (MPNHDA) ex vivo assay (Table 2-6). The mouse phrenic nerve hemidiaphragm contains
the myoneuronal junction that is the target of botulinum intoxication. Hence, it best replicates the
in vivo system and can be used as an ex vivo method for testing BoNT/A inhibitors.
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Table 2-4. HPLC-bioassay results and docking scores of the twenty-two compounds tested for
BoNT/A LC protease inhibition.
Number

Compound

1
3
4
5
6
7
8
9
10
11
12
13
14
15
18
19
20
21
22
23
24

Acoric acid
Galangin
Quercitin
Fisetin
Morin hydrate
Apigenin
Chrysin
kaempferol
kavain
Dihydrokavain
Methysticin
Dihydromethysticin
Yangonin
Desmethoxyyangonin
4-Hydroxycoumarin
Coumarin
4-Methylumbelliferone
Curcumin
[6]-Gingerol
[8]-Gingerol
[10]-Gingerol
(Z)-5Benzylidenethiazolidine-2,4dione
CB79674951
NSC 84094

26

31

% Inhibition
(20 µM)

Glide Docking Score

47 ± 7
43 ± 8
20 ± 2
59 ± 0.5
11 ± 1
38 ± 6
26 ± 2
30 ± 1.5
53 ± 13
23 ± 1
12 ± 1.5
19 ± 1.5
27 ± 1
24 ± 2
41 ± 8
25 ± 11
16 ± 1
49 ± 4
20 ± 2
17 ± 2
18 ± 2.5

-9.089
-7.187
-7.603
-7.061
-6.935
-7.969
-7.984
-8.663
-6.536
-6.614
-6.614
-6.588
-5.996
-6.16
-6.448
-6.328
-6.737
-6.328
-5.049
-5.77
-6.639

13 ± 1

-8.302

91 ± 1.3
92 + 0

-7.75
-8.549

Table 2-5. BoNT/A LC inhibition and docking scores of the nine compounds tested using
UPLC.
Number
2
16
17
25
27
28
29
30
31

Compound
Chlorogenic acid
Capsaicin*
Dihydrocapsaicin*
Epigallocatechin
gallate (EGCG)*
Chicoric acid*
Piperine*
Pterostilbene
Bilobalide*
Ginkgolide C*
CB79674951
NSC 84094

% Inhibition
(20 µM)
15 ± 3.0
38 ± 7.2
30 ± 4.8
4 ± 1.1

Glide Docking Score

6 ± 1.4
21 ± 1.5
16 ± 1.5
13 ± 2.0
2 ± 0.8
86 ± 1.3
87 + 1.5

-10.83
-6.411
-7.251
-6.954
-6.147
-7.75
-8.549

-11.094
-7.983
-6.931
-9.431

2.4. Ex vivo assay
The MPNHDA uses a small amount of BoNT/A LC, it can be done in a non-CDC
registered laboratory. It can test small molecules, peptides, and antibodies for efficacy. Its
drawbacks are: it is technically difficult as takes about 6 months to 1 year to be proficient. It can
test only one inhibitor per day at three concentrations. The hemidiaphragm can only run about 5
hours and the tissues become exhausted. It cannot detect subtle toxicity as well as cell culture.
Small molecules require DMSO. Too much DMSO will stop intoxication of the nerve.
Figures 2-12 and 2-13 show the MPNHDA results of the seven tested compounds.
Curcumin 21 was not protective against BoNT/A at 20 µM and so was not tested at any lower
concentrations. Fisetin 5 was found to be marginally protective against BoNT/A at 20 µM. On
retest, it was found to not be protective at 20 µM or at 2 µM against BoNT/A. 4-Hydroxy
coumarin 18 showed marginal partial protection against BoNT/A at 20 µM but no protection at 2
µM. The retest of 4-hydroxy coumarin 18 indicated it was not effective against BoNT/A at either
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concentrations.
Kavain 10 was tested in two individuals assays at 20 μM, little protection observed..
However, in these runs the toxin was not very “hot”, and also, it was not run out to 210-270
minutes.
Acoric acid 1, which showed good binding poses and docking scores in the docking
studies, and an in vitro inhibition of 47 + 7 (Table 2-4), was tested ex vivo in two iterations, each
at 20 µM. This compound might be partially protective, but it would have to be retested to
confirm this activity in different concentrarions and also using other relevant assays. Galangin 3
was found to be toxic at 20 µM. The tissues receiving the galangin 3 dropped the twitch tension
faster than the toxin controls. Capsaicin 16 was found to be non-protective against BoNT/A at 20
µM and so was not tested at the lower concentrations.
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Table 2-6. Results of selected seven compounds tested using MPNHA.
Compound

Concentration

Acoric acid 1

20 μM

Galangin 3

20 μM

Fisetin 5

Kavain 10

Trial 1: 20 μM
Trial 2: 20 μM and 2
μM

20 μM

Capsaicin 16
4-Hydroxy
coumarin 18

20 μM
20 μM and 2 μM

Curcumin 21

20 μM

Protection against
BoNT/A
2 assays marginal
protection
Toxic at 20 μM

Trial 1: Marginal
protection at 20 μM
Trial 2: Not protective
protective in the second
trial
2 assays at 20 μM, but
neither were active

non-protective
20 μM:, marginal/partial
protection
2 µM: No protection
Not protective
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Notes
Note: To be retested to
confirm its activity
Note: The graph shows
the tissues receiving the
galangin dropped
twitch tension faster
than the toxin controls

Note: Toxin was not
very “hot” in this run,
and it was not run up to
to 210-270 minutes but
there was little
protection observed

Figure 2-12. MPNHDA activities of acoric acid 1, galangin 3, fisetin 5, and 4-hydroxycoumarin
18. The percent twitch tension is measured vs time. At 20 M Acoric acid 3 showed marginal
activity, whereas galangin 4 was found to exacerbate then to BoNT/A activity.
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Figure 2-13. BoNT/A inhibition activities of curcumin 21, kavain 10, capsaicin 16 tested against
LC of BoNT/A using MPNHDA.
2.5.

Conclusions
Botulinum neurotoxin acts like a double edge-sword. On one side, it is a possible-

bioterror threat, and on the other side, it is increasingly used for cosmetic purposes and against
neurological disorders [60]. Hence, the identification of novel small molecule inhibitors of BoNT
serotype A is of great significance. A number of small molecules were found to be active against
the BoNT/A protease enzyme which include the zinc-binding hydroxamic acid derivatives [31]
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and natural products like chicoric acid and chlorogenic acid [61] on the exo-sites α/β [18].
However, none of the reported compounds reached the market as drugs or to the clinical trial
stage [62, 63]. In a novel approach, combining Ayurvedic literature, computer-based drug
screening, and in vitro HPLC-based testing was used to identify the activities of natural products
against BoNT/A.
Analysis of the Ayurvedic literature resulted in the identification of plants which could
possess BoNT inhibition activities. The phytochemicals of the selected plants were screened
using in silico docking in the BoNT/A inhibitor crystal structures (SI table 2). Based on the
docking results, thirty-one compounds were tested using in vitro HPLC/UPLC based assay. The
results indicated seven compounds showing BoNT/A inhibition of around 45-60% including
acoric acid and some flavonoids (Tables 2-4 and 2-5). These seven compounds were evaluated
further in an ex vivo methods such as mouse phrenic nerve-hemidiaphragm assay (MPNHDA)
[55].
Based on the bioassay results, acoric acid 1, a novel scaffold which was isolated from
Acorus calamus, was also found to show promising activity (~50% inhibition) in vitro and partial
protection in MPNHDA. Further confirmatory testing of these compounds using in vivo or ex
vivo models could evaluate their utility as BoNT/A inhibitors. Acoric acid 1 possesses three arms
similar to the reported hydroxamic acid derivativies [20] and also possesses chelating ability
with zinc metal. These functional points, like the carbonyl group on the cyclohexane and
isobutyryl side chain, could be explored further for structural modifications to allow them to take
advantage of the unexplored region in the binding site (Figure 2-14). These modifications may
increase the inhibitory activity and potency of acoric acid 1.
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Figure 2-14. Structure of acoric acid 1 in the ligand binding domain of BoNT/A.
3.

Experimental

3.1.

Virtual screening for identification of BoNT/A inhibitors

System specifications
To perform virtual screening studies, a commercial version of the Schrödinger software
package [64] was installed on a Windows desktop computer with Intel® Core™ Quad CUP
Q6600@2.40GHz 2.40 GHz processor with a random access memory (RAM) of 4.00 GB and
32-bit operating system.
Protein Preparation and alignment of binding sites
The Protein Data Bank (PDB) structures of six BoNT/A crystal structures were
downloaded (PDB codes: 3QIY, 3QIZ, 3QJ0, 4HEV, 2ILP and 3C8B) and prepared using the
Protein Preparation Wizard (PPW) module of Schrödinger suite to remove errors in the
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structures from the crystallographic data by adding hydrogen atoms and correcting their bond
orders. The prepared proteins were minimized with Optimized Potentials for Liquid Simulations
(OPLS)-2005 force field (FF) at an intermediate docking stage, and all the water molecules
without contact and 5 Å or more away from the protein residues were removed. All the prepared
proteins were aligned at the binding site.
Virtual screening of ligands from Ayurvedic literature
Using Ayurvedic literature, a total of 356 plants were identified as potential plants for
treating the symptoms of botulism, and among these, 14 plants were shortlisted based on their
frequency of usage in various formulations and the number of diseases they treat. To generate a
structural database of the reported phytochemicals of these 14 plants, Duke’s database,
PubChem, SciFinderDictionary of Natural Products [65] and various online sources were
searched, and their exact structures, including stereochemistry, were drawn. Chem3D (Perkin
Elmer) was used to convert these structures into 3D, and Maestro [64] was used to label each
compound individually and save the files in structural-data file (.sdf) format. The database from
these 14 plants consisted of 570 compounds. These compounds were prepared using the Ligprep
module with Epik to generate metal binding sites at pH 7.4, to include metal binding states, and
to include only one stereoisomer per ligand. The binding sites of all the six selected crystal
structures were overlaid to align their binding sites. For each crystal structure, grids were
generated using Glide with an area of 12 Å around the native ligand and with no constraints. The
prepared ligands were then docked with the Virtual Screening Workflow (VSW) option in
Maestro (Schrödinger, LLC) using all the six prepared grids and using Glide standard precision
(SP) with settings to generate docking results for all the compounds. The poses from the docking
results were analyzed on Maestro and PyMol softwares [64].
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3.2.

In vitro studies

Experimental material
Recombinant botulinum neurotoxin type A light chain (BoNT/A LC) was prepared
according to procedures previously described [66]. The substrate for the HPLC-based enzymatic
assay was a 17-mer peptide consisting of residues 187 to 203 of SNAP-25 (AcSNKTRIDEANQRATKML-NH2). It was custom synthesized to 98.0% purity by GenScript
(Piscataway, NJ). The HPLC system consisted of Waters model 6000A pumps, U6K injector,
680 automated gradient controller, 996 PDA and Empower 2 software (Waters Corp., Milford,
MA, USA). The UPLC system consisted of Waters Aquity with PDA detector. The HPLC
column (Zorbax 300SB-C18, 4.6 x 150 mm) was obtained from Agilent Technologies (Santa
Clara, CA) while the UPLC column (Acquity UPLC BEH C18 (2.1 x 50 mm column) was
obtained from Waters Technologies (Waters, Bedford, MA).
HPLC-based BoNT/A LC protease assay
Compounds were tested in an HPLC-based BoNT/A LC enzymatic assay as previously
described [67]. The assay mixture contained 50 mM HEPES pH 7.3 buffer, test compound
dissolved in dimethyl sulfoxide (DMSO) at the final assay concentration (20 μM), 0.8 mM 17mer SNAP-25, and 3.0 to 6.0 μg/ml (60 to 120 nM) BoNT/A LC. In negative control samples,
the test compound was replaced by DMSO. Upon addition of the LC, the reaction mixture was
briefly vortexed and incubated at 37°C for 5 min. Reactions were stopped by acidification with
90 μL of 0.7% trifluoroacetic acid (TFA). Uncleaved substrate and products were separated by
reverse-phase HPLC. Solvent A was 100% water/0.1% TFA and solvent B was 70%
acetonitrile/0.1% TFA. The flow rate was 1.0 ml/min. at 25°C with a gradient profile of 10% B
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(2.5 min.), linear gradient to 36% B (21 min.), and 100% B (6 min.). Amounts of intact and
cleaved substrate were quantified and used to calculate LC activity (μM/min/mg). Percent
inhibition was determined by comparing the LC activity in control and test samples.

In vitro UPLC analysis
UPLC method [59] was applied to improve the sensitivity of the bioassay and reduce the run
times and to make it ideal for large set of test compounds. A number of compounds were tested
using UPLC method and are reported in the Table 2-4. The BoNT/A reaction was performed
same as in the HPLC method. However, the reaction mixture was analyzed using UPLC loaded
with Aquity UPLC BEH C18 column, under the similar solvent conditions as that of the HPLC
method. Unlike the reported method, no bovine serum albumin was included in the reaction
mixture as reported in the literature [59].

3.4

Ex vivo assay (MPNHDA)
The mouse phrenic nerve hemidiaphragm assay (MPNHDA) was conducted by our

collaborators at the US Army Medical Research Institute for Infectious Diseases USAMRIID,
similar to the reported on the procedure [32]. “Female CD-1 mice (20 to 25 g) were euthanized
with CO2, and their diaphragms with attached phrenic nerves were removed. The diaphragms
were then divided into two hemidiaphragms, with each section complete with a phrenic nerve
and myoneural junction. Each hemidiaphragm was attached to an isometric force transducer
(Fohr Medical Instruments, Seeheim, Germany), and its phrenic nerve was secured to a
stimulating electrode. The nerve-muscle preparations were immersed in separate 10-ml tissue
baths containing Tyrode’s buffer (1.8 μM CaCl2, 1 mM MgCl2, 2.7 mM KCl, 137 mM NaCl, 0.4
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mM NaH2PO4, 12 mM NaHCO3, and 6 mM glucose), pH 7.2 to 7.4 (Sigma, St. Louis, MO). A
mixture of 95% O2-5% CO2 gas was passed through the Tyrode’s buffer. The tissue baths were
kept at 37°C. Each phrenic nerve was stimulated with single supramaximal pulses (SD9
Stimulators Grass Instruments, Warwick, RI) through a Powerlab/4sp and Bridge Amp relay
(AD Instruments, Inc., Colorado Springs, CO) with a 0.3-ms duration at 0.03 Hz. The twitch
tensions were digitally recorded by Chart software (AD Instruments, Inc., Colorado Springs,
CO). After acclimation to the tissue baths, the tissue preparations were run for 20 to 30 min for
baseline measurements. The inhibitor (dissolved in DMSO at 2x the final assay concentration)
was mixed with 60 pM BoNT/A (Metabiologics, Madison, WI) in 5 ml of Tyrode’s buffer and
incubated for 15 to 20 min at 37°C. After baseline stabilization, the toxin-inhibitor mixture was
added to a 10-ml bath with an additional 5 ml of Tyrode’s buffer, bringing the final
concentration of BoNT/A toxin to 30 pM. The concentration of BoNT/A neurotoxin was
previously calibrated to induce a 50% loss of twitch tension in approximately 60 min. In all
samples, including the controls, the final concentration of DMSO was 0.3%.
For each experiment, four tissue baths were used. One bath was the BoNT/A toxin-only
control. A second bath was an assay control with toxin or inhibitor. The third and fourth baths
contained toxin plus two different concentrations of inhibitor. Adding the toxin or the
toxin/inhibitor mixture to the bath initiated the beginning of data collection, which continued for
5 h or until muscle twitch tension ceased. For all preparations, neurotoxin-induced paralysis was
measured as a 50% loss of twitch tension evoked by nerve stimulation.
Procedures used to obtain mouse tissues were conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating to animals and experiments
involving animals and adhered to the principles stated in the Guide for the Care and Use of
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Laboratory Animals, National Research Council, 1996. The facility where this research was
conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care International” [32].

.
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CHAPTER 3
STUDY OF LYCIUM SPECIES (GOJI) FOR ANTIDIABETIC COMPOUNDS
1. Introduction
1.1.

Diabetes mellitus and metabolic syndrome
Type 2 diabetes mellitus (T2D), a complication resulting from insulin resistance, has

reached epidemic proportions worldwide. According to world health organization (WHO)
statistics, T2D accounts to about 90% of the total diabetic populations of 382 million, which was
8.3% of the total adult population in 2012-2013, and resulted in 1.5 to 5.5 million deaths
worldwide [68]. There are approximately 1.4 million new cases of diabetes each year and if the
current trends continue, these numbers are projected to increase to 1 in 3 by 2050 [69] (Figure 31). T2D patients are non-responsive to insulin, have impaired glucose and lipid metabolism and
could be at high risk for developing complications, such as hypertension, dislipidemia,
cardiovascular disease related death, heart attack, stroke, blindness, eye problems, kidney
diseases and amputations. Metabolic syndrome is a series of highly interrelated disease
conditions which include hypertension, obesity and elevated blood glucose levels. Among the
people affected with metabolic syndrome, the chances of occurrence of T2D are found to be
high. T2D and the risk factors associated with metabolic syndrome can be treated by targeting
peroxisome-proliferator activated receptors (PPARs) [70].
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Figure 3-1. The raise in the population of Americans suffering from diabetes in 2010 (25.8
million) and 2012 (29.1 million) [69].
1.2.

PPARγ role and importance
PPAR’s are a family of nuclear transcription factors, expressed on various tissues and

regulate key biological processes including glucose and lipid homeostasis. There are three PPAR
subtypes: PPARα, PPARβ/δ and PPARγ, and these three receptors are considered as viable
targets for treating metabolic syndrome [70] and diabetes [71].They exert their action in the
nucleus by heterodimerization with retinoid X receptor (RXR), which are stabilized by corepressors. Ligand binding to PPARs results in its activation by inducing changes in the receptor
conformation which results in the recruitment of coactivators and removal of corepressors. The
activated RXR-PPAR dimers then regulate the expression of genes in DNA by binding to the
specific response elements in the promoter region of the DNA (Figure 3-2). PPARs have a role
in the carbohydrate and lipid metabolism pathways by directly regulating their metabolism and
transport, or by acting on the proliferation and differentiation of a number of cells including
adipocytes [70].
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Figure 3-2. Mode of action of PPARs [70].

PPARα subtype is expressed mainly in the liver, adipose tissue, kidneys, heart, skeletal
muscle and large intestine. Fibrates, a class of ampiphilic carboxylic acids, activate PPARα and
are used for treating metabolic disorders mainly, hypercholesterolemia and are used as
hypolipidemic or lipid-lowering agents. PPAR β/δ subtype is expressed in various tissues
including the skin, gut, placenta, skeletal and heart muscles.
PPARγ is expressed mainly in adipose tissue (white and brown) and in significant
amounts in intestines, kidneys, retina, immunologic system and trace amounts in muscles and is
considered as a primary target for treating diabetes [72]. Hence, intense research efforts were put
into identifying clinical agents targeting PPARγ [73]. Several ligands, both endogenous and
synthetic agents act as PPAR ligands. The endogenous ligands targeting PPARγ include, fatty
acids, oxidized lipids, prostaglandin J2 metabolites. Synthetic agents of PPARγ. include full- and
partial-agonists. Phenyl acetic acids, tyrosine-based compounds, thiazolidine dione-class of
compounds act as PPARγ full-agonists (Figure 3-3). Fmoc-L-leucine, FK-614, T2384 [74], INT131 [75], MBX-102 [76], azadiole derivatives, 2-BABA-derivatives, GW0072 [77], L764406[78], cercosporamide-derivative VI [79] act as PPARγ modulators or partial agonists [80]
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(Figure 3-4).
Partial and full agonists
Thiazolidinediones (TZD) or glitazones are a class of insulin sensitizing pharmacological
agents, targeting insulin resistance, and preserve β-cell function in the pancreatic islets. PPARγ
agonists include TZDs like ciglitazone I, pioglitazone (Actos®) II, torglitazone (Rezulin®) III,
rosiglitazone (Avandia®) IV, and a non-TZD compound, farglitazar V (Figure 3-3).
Rosiglitazone IV and pioglitazone II are currently used for treating diabetes clinically. These
agents are effective in improving insulin and glucose parameters, and increase whole-body
insulin sensitivity [81]. Hence, they are termed insulin-sensitizing medications. They decrease
hepatic glucose production and prolong pancreatic β-cell function by preventing apoptosis of βcells [81].
Although, TZDs are effective in treating T2D, adverse events like weight-gain, edema,
and anemia are seen among the patients and the treated populations have an increased risk for
cardiovascular events and bone fracture [82]. In the TZD treated population, there is an increased
risk for exacerbation of congestive heart failure, volume-overload, systemic edema due to fluid
retention and subsequent increase in intravascular volume by approximately 15% [81].
Therefore, there is a high demand for the identification of new, safer antidiabetic agents which
do not cause high fluid retention. Unlike full agonists like TZDs, which show side-effects, partial
agonists or modulators of PPARγ are effective against insulin-resistance without the undesirable
side-effects observed while using full agonists [79, 83]. Hence, finding new partial agonists of
PPARγ could be a viable method for treating diabetes. Our aim is to identify novel natural
product-based antidiabetic agents by targeting PPARγ and by screening the TCM-based anti-
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diabetic plant, Goji, using in silico, in vitro and validate with in vivo models.

Figure 3-3. Structures of thiazolidinedione (TZD) class of compounds I to IV and farglitazar V,
which act as PPARγ full agonists.

Figure 3-4. Structures of PPARγ- partial agonists: GW0072 VI [77], cercosporamide-derivative
VII [79], L-764406 VIII [78] and antagonist GW 9662 IX [84].
Ligand-binding domain description and two binding modes:
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The PPARγ receptor is a nuclear receptor which is comprised of four domains
including 1) N-terminus and ligand-independent activating domain (AF1), 2) highly conserved
DNA binding domain, 3) ligand-binding domain (LBD) and 4) ligand-independent domain
(AF2). The structure of apo-PPARγ site along with co-activating factor SRC-1 was determined
(PDB: 2PRG) [85]. The LBD is a T-shaped cavity with a total volume of 1,300 Å and is
comprised of helices 3, 4, 6, 10, two β-sheets and helix 12, which belong to the AF2 domain.
The binding site consists of two regions perpendicular to each other. The region between helix 3
and the β sheet (length 20 Å) is parallel to helix 3, while another region from β sheet to AF2
(length 16 Å) is perpendicular to the cavity behind helix 3 (Figure 3-5) [85]. It consists of an
entry site which is comprised of hydrophobic amino acids, Asp243, Glu290, Arg288, Gln295.
Depending on how these agents interact with the residues in the ligand binding domain, there
are two binding modes of PPARγ agonists, full-agonist binding mode and partial-agonist
binding mode.
Binding mode of full-agonists
The structure of rosiglitazone IV in the crystal structure of PPARγ (PDB 2PRG) is Lshaped, which wraps around helix 3 and occupies 40% of the ligand binding site. In general,
glitazones or thiazolidinedione (TZD)-type PPARγ full agonist structures contain three subunits:
an effector sub unit, a linker sub unit and a binder subunit [73].
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a

b
Figure 3-5. Structure of the ligand-binding domain of PPARγ.
The key helices in the ligand binding domain are labeled. The binding pocket is marked red.
Figure b, is obtained by the rotation of figure a, along the z-axis.
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Figure 3-6. a) Binding mode of PPPARγ full-agonist, rosiglitazone IV (green) PDB: 2PRG; b)
including its ligand-interaction diagram.
The binder subunit of rosiglitazone IV includes a thiazolidine (TZD) group which
interacts with amino acids in the helices 3, 4, 10 and AF2. The TZD groups forms hydrogenbonding interactions with Gln286, Ser289 on helix 3, His323 near helix 4, His449 of helix 10,
and Tyr473 on helix 12 of AF2 (Figure 3-6). The linker is a central benzene ring, which lies
behind helix 3 and forms hydrophobic interactions with residues Cys285 and Met364. The
effector subunit, which is the core region, is made up of pyridine, interacts with the hydrophobic
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site helix 3 and the β-sheet [73]. Figure 3-6 shows the structures of thoazolidinedione (TZD)
class of compounds.
Binding modes of partial agonists
Partial agonists or modulators of PPARγ are effective against insulin resistance without
the undesirable side effects observed while using full agonists [79, 80] Hence, finding partial
agonists of PPARγ could be a viable method for treating diabetes without the side-effects shown
while using thiazodinedione (TZD) derivatives. Unlike full agonists, partial agonists do not
interact with helix 12. PDB 3LMP [79] revealed that the cercosporamide-scaffold is located
between helix 3 and β-sheet, and also makes water assisted interactions with Leu340, Ser342
consisting of helices 2, 5, β-strand-2 and helix 7 but does not interact with helix 12 (Figures 3-7,
3-8).
1.3.

Natural products as PPARγ agonists
Several natural products, like honokiol [86], amorfrutin 1 [87], amorfrutin B [88],

amorphastilbol [89], saurufuran A [77] from Saururus chinensis (Saururaceae), flavonoids such
as chrysin, apigenin and kaempferol, and phenolic compounds from Glycyrrhiza uralensis
(Fabaceae) and Glycyrrhiza glabra [90] were found to possess PPARγ activity [91]. These
natural products possessed different binding modes in the PPARγ binding pocket, compared to
full agonist-binding modes, and were also found to activate PPARα or RXR and also improve
the metabolic parameters with reduced side-effects compared to thiazolidinedione derivatives
[91]. A careful study of more phytochemicals could result in the discovery of new anti-diabetic
compounds from natural sources including traditional herbals.
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Figure 3-7. a) Binding mode of PPPARγ partial-agonist, cercosporamide-derivative VII (light
green) PDB: 3LMP; b) including its ligand-interaction diagram.
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Figure 3-8. Overlap of the PPARγ-full and -partial agonists, rosiglitazone IV (green) and
cercosporamide-derivative VII (light green) in 2PRG. They occupy binding sites in different
binding regions.
1.4.

TCM: Goji and diabetes
Natural products are important and promising sources for drug discovery. Several

compounds isolated from plants used in Traditional Chinese Medicine (TCM) have been used
and studied as drugs like artemisinin and paclitaxel. The root bark and fruits of two closely
related medicinal plants from TCM, Lycium barbarum and L. Chinense, also known as gou qi zi
or Goji, wolfberry, Chinese wolfberry, matrimony wine, have been traditionally used mainly in
China, Vietnam, Korea and Japan [92]. Goji berry preparations, in the form of tinctures, powders
or tablets, are used in TCM as mild Yin-enhancing agents, treating liver, kidneys and lungs, and
are claimed to increase the longevity and reduce premature graying. The root barks of Goji are
consumed as decoctions and used as cooling agents to ‘clear heart’ and lower consumptive fever
due to Yin deficiency. Root barks are used in the treatment of night sweating, steaming bone
sensation and chronic low grade fever, cough and against hemoptysis, hematuria, diabetes
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mellitus and hypertension (Figure 3-9) [93].

Figure 3-9. Pictures of L. barbarum fruit [94].
Goji: Chemical constituents and their activities, TCM preparation
Because of the significance of Goji in traditional medicine, several investigations were
performed on various parts of Goji, especially the fruit of L. barbarum and other parts of L.
chinense like roots and leaves. The reported chemical constituents were reviewed in 2010 by
Potterat [92]. The chemical constituents of L. barbarum and L. chinense include: carotenoids
from the fruits and leaves, vitamin C precursors and glycolipids from the fruits, alkaloids and
cyclopeptides from the roots, amides and other phenolic compounds from the fruits and roots of
Goji. Table 3-1 shows the different classes of chemical constituents of Goji classified based on
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parts and species.
These chemical constituents were tested for activities including antioxidant, antitumor,
immunomodulatory, radioprotective, antidiabetic activities and neoprotective effects [95, 96].
Proteoglycans also known as “Lycium barbarum polysaccharides” showed antioxidant
properties and some interesting pharmacological activities in the context of age-related diseases
such as atherosclerosis and diabetes [97].
Cortex Lycis Radicis (CLR) or Chinese wolfberry root bark or bark of box thorn root,
which is the dried root bark of L. barbarum (Solanaceae family), is used to treat pneumonia,
night sweats, cough, hematemesis, inflammation and diabetes mellitus [98]. The TLC analysis of
CLR aqueous extracts, indicating the presence of organic acids, alkaloids, flavones,
anthraquinones, polysaccharides, and saponins. These aqueous extracts of CLR were tested on
Alloxan-induced diabetic mice and were shown to decrease glucose levels, increase insulin
levels, and long-term hypoglycemic effects and reduced the body weight in diabetic mice [98].
Lycii cortex radicis (LCR) is also a traditional Chinese medication, made from the root barks of
L. chinense. The methanolic extracts of LCR, LCR1 and LCR2 and tyramine derivatives, transN-p-coumaroyl tyramine, trans-N-ferulolyl tyramine which were isolated from LCR were tested
for hypocholestrolemic and antioxidant effects [99]. Trans-N-feruloyl tyramine was found to
possess an anti-oxidant effect by inhibiting liver microsomal HMG CoA reductase activity.
Studies on LCR1 and LCR2, ginger, safflower seed using Sprague-Dawley male rats concluded
that LCR possess hypocholestromeic activity.
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Table 3-1. List of the chemical constituents isolated from the fruits, roots, leaves and flowers of
L. barbarum and L. chinense [92].
Class of compounds

Examples
Termed as Lycium barbarum polysaccharides:
Rha, Ara, Xyl, Man, Gluc, Gal in varied
proportions
Zeaxanthin dipalmitate (56 % of the carotenoid
content)
Riboflavin, Thiamin, Ascorbic acid
Aglycone portions: Myricetin, quercetin,
kaempferol

Polysaccharides (23 %)
Carotenoids
Fruits of L.
barbarum

Vitamins
Flavonoids
Essential oils and fatty acids

Fruits of L.
chinense

Miscellaneous compounds

β-setosterol and its glycoside. scopolectin, pcoumaric acid, lyciumide A, l-monomethyl
succinate

Similar to L.barbarum

Polysaccharides, carotenoids, flavonoids

Cerebrosides, pyrrole derivatives
Sterols

Roots of L.
chinenese

Cyclic peptides
Indole glycosides, Nitrogen
compounds: aurantiamide acetate,
lyciumamide
Tyramine derivatives
Alkalods
Calystegenines and N-methyl
ccalysegines
Polyphenolic compounds
Coumarins

Cycloartenol, 24-ethylycloartenol, granisterol, 24methylene cycloartenol
Licyumines (A-D)

Spermine alkaloids, kukoamines A and B

Apigenin, acaccetin, luteolin, Kaempferol
Scopolecin and its glycosides: scopolin and
fabiatrin

Lignans, anthraquinonines terpenoids,
fatty acids
Roots of L.
barbarum

Cyclopeptides

Licyumins A and B

Betain, choline lineolic acid
Leaves and
flowers of L.
chinense

Leaves of L.
barbarum

Acyclic diterpene glycosides

Lyciumosides I - IX

Terpenoids, Withanolides
Flavonoids, glycosides, carotenoids,
tannins, diosgenin, β-sitosterol,
lanosterol
Leaves: flavonoids, damascenone,
choline
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Other compounds: damascenone, choline,
scopoletin, vanillic acid, salicylic acid, diosgenin,
β-setosterol, lanosterol

1.5.

Aim:
Since Goji was used traditionally in TCM and its extracts showed anti-diabetic activities,

our aim was to identify novel small molecule agonists of PPARγ from Goji, and test their
antidiabetic activities. We utilized computational docking, synthesis, in vitro and in vivo
approaches to achieve the desired goals.
2.

Results and Discussion
Our approach to identify small molecule-antidiabetic (T2D) compounds from Lycium

species, which are active against diabetes, using a three stepped approach: 1) in silico screening
of the reported phytochemicals of Goji into PPAR-γ binding site to identify the best active
chemical scaffolds, 2) synthesis of compounds with the desired scaffolds and, 3) validate and
confirm their activities with in vitro and in vivo screening.
Several compounds were reported to be isolated from various parts of Goji (L. barbarum
and L. chinense). Among these, twenty-seven compounds isolated from the fruits and roots were
selected for docking studies. These included alkaloids, a cyclic peptide, licumin D, indole
glycoside derivative (aglycone form), nitrogen compounds including aurantiamide acetate,
lyciumamide and a series of tyramine derivatives. The roots of Goji contain alkaloids such as
spermine alkaloids, kukoamines A and B. A series of calystegenines and N-methylcalystegines,
lignin lyoniresinol aglycone, a series of anthraquinones including, physcion, emodin, 1,3,6trihydroxy-2-methylanthraquinone (Figure 3-10). The glycosides of some of the reported
compounds of Goji were removed to allow for binding into the small volume active site grids
used in the docking studies.
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2.1.

Molecular docking
Full agonists of PPARγ, termed as glitazones, ex: pioglitazone II, troglitazone III,

rosiglitazone IV are currently used for the treatment of Type 2 Diabetes. However, these
compounds show undesirable side-effects in treated patients, including cardiac problems [81,
82]. Partial PPARγ agonists were shown to possess anti-diabetic activity, but with reduced
activity compared to full agonists [79, 83]. Hence, targeting PPARγ using partial agonists is a
viable approach for the treatment of diabetes, without the undesirable side-effects of full
agonists. In the current approach, we utilized both the partial and full agonists of PPARγ. The
PDB crystal structure and binding mode analysis of full agonist (rosiglitazone IV, PDB: 2PRG)
and partial agonist (cercosporamide-derivative VII, PDB: 3LMP) show different binding modes
and protein-ligand interactions. The binding interactions of the full and partial agonists at the
active site revealed differences in the binding modes of both types of agents. While full agonists
show good hydrogen bonding interactions with His343 on helix 4, His449 on helix 10, and
Tyr473 on helix 12, partial agonists do not show any interactions with these residues. Partial
agonists occupy the binding site, more in the region between helix 3 and the β-sheet, when
compared to the full agonists which occupy the binding site, more in the region between helices
3 and 12.
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Figure 3-10. List of the compounds used for docking studies in PPAR-γ crystal structures 2PRG,
3LMP.
To identify new natural product-derived PPAR ligands, docking of 27 reported compounds
(Figure 3-10) isolated from various parts of both L. barbarum and L. chinense was performed
inside the ligand binding domain of PPARusing the X-ray crystal structures of full agonist
rosiglitazone IV (PDB ID: 2PRG) and partial agonist, cercosporamide-derivative VII (PDB ID:
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3LMP) [92]. Grid boxes were generated using Glide SP module (Schrödinger, LLC) with 12 Å
radii around the native ligand generated using different hydrogen bonding constraints for full and
partial agonists. For the full agonist, 2PRG, three hydrogen-bonding constraints were applied, in
the partial agonist, 3LMP, no constraints were applied.
Docking output
The output for docking in both partial (3LMP) and full agonist (2PRG) binding sites was
analyzed (SI Tables 2 and 3). Analysis of the docking results revealed that a number of
compounds possessed good binding poses with favorable protein-ligand interactions. A study of
the binding modes and the docking scores revealed that five compounds belonging to the
cinnamomyl phenyl ethyl amide class lyciumamide A X, dihydro-N-caffeoyltyramine XI, cis-Ncaffeoyltyramine

XII,

trans-N-caffeoyltyramine

XIII,

trans-N-feruloyloctopamine

XIV

possessed good binding poses, comparable to the native ligands (termed as tyramine derivatives
hereafter for simplicity, since all of these amides are made of tyramines). These compounds
displayed good hydrogen bonding interactions with the residues on the helix 3 and helix 12,
similar to the full agonist, rosiglitazone IV. Whereas, in the partial agonist binding site, they do
not show any binding near the helix 12 binding site and occupy the region more between helix 3
and β-sheet, similar to the partial agonist cercosporamide-derivative VII. These five tyraminederivatives also possess good binding poses in both full and partial agonist binding sites (Table
1). This reveals that tyramine derivative-class of compounds may possess good PPARγ activity,
either as a full- or partial- agonists. Hence, these simple amide derivatives were synthesized
along with several analogs. All the compounds were validated using in vitro luciferase assays.
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In general, tyramine-derivatives were reported to possess diverse biological activities like
potentiation of antibiotics, inhibition of prostaglandin synthesis, anti-oxidant activities,
antitubercular activity [100], bacterial efflux pump inhibitors, antihyperglycemic activites,
melanin synthesis inhibitors [101], inhibitors of melanocyte-tyrosinase inhibitors [102],
antifungal activities [103]. Several tyramine-derivatives were also isolated from the root barks of
L. chinense and were found to possess anti-fungal activities [103]. Here we wanted to test the
activities of these compounds against PPARα-PPARγ receptors.
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Table 3-2. Docking scores of the five tyramine derivatives in full agonist and partial
agonist binding sites of PPARγ.
Glide Docking score
Number

Structure

2PRG

3LMP

-5.03

-7.47

-8.82

-8.10

-5.70

-6.26

-7.50

-6.16

-7.31

-8.11

Rosiglitazone IV

-10.66
(native ligand)

-8.56

Cercosporamidederivative VI

No docking
result obtained

-7.94
(native ligand)

X
Lyciumamide A

XI
Dihydro-N-caffeoyltyramine

XII
cis-N-caffeoyltyramine

XIII
tran
s-N-caffeoyltyramine
XIV
trans-N-feruloyloctopamine
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Figure 3-11. a) Binding modes of the four tyramine derivatives in the full agonist binding site
and ligand-interaction diagram in the full agonist crystal structure. 2PRG-tyramine derivativesX (Brown), XI (Blue), XII (dark green), XIII (wheat), XIV (light green) rosiglitazone IV
(yellow). b) Ligand-interaction diagram of XI in the full agonist crystal structure (PDB: 2PRG)
of
PPARγ.

Figure 3-12. a) Binding poses of the five tyramine derivatives in the partial agonist binding site;
X (dark blue), XI (brown), XII (light blue), XIII (black), XIV (light green), 3LMP-ligand
(green). b) Ligand-interaction diagram of X in the partial agonist crystal structure (3LMP) of
PPARγ.

64

2.2.

Synthesis of tyramine derivatives for biological evaluation
First, a series of twelve compounds were synthesized by a coupling reaction using

commercially available substituted cinnamic acid derivatives and phenyl alkylamines/tyramines,
in the presence of triethyl amine and PyBOP [(Benzotriazole-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate [104]. Four types of cinnamic acids (SM1 to SM4) were each coupled with
three types of phenylethyl amine derivatives (SM5 to SM7) that resulted in amides (1 to 12) in
50-95% yields after flash chromatography. Moreover, the twelve-amides (13 to 24) were further
subjected to reduction under hydrogenation conditions (Pd/H2) and gave saturated amides in
good yields (Scheme 3-1), (Figure 3-13). Among all these synthesized 24 amides, four
compounds 02 (XII), 08 (XIII), 14 (X) were identified to possess good docking scores in our
docking studies in 2PRG and 3LMP and were natural constituents of Goji [103, 105]. Along with
three hits (natural products), all these twenty-one analogs (01 to 24) were evaluated for their
activity as PPAR-γ agonists in HepG2 cells.
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Scheme 3-1. Synthesis of twenty-four small molecule amide derivatives for in vitro screening
using PPARγ-PPARα bioassay.
By coupling of the commercially available acids (SM1 to SM4) and phenyl amines (SM5
to SM7), twelve-different-amides were produced (1 to 12). These twelve-amides were further
reduced to produce twelve-saturated compounds (13 to 24).
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Figure 3-13. Structures of the twenty-four tyramine derivatives synthesized by coupling
reaction.
2.3.

In vitro and in vivo testing
In vitro luciferase assay [106] for PPARγ and PPARα induction activity was performed

on all the twenty-four synthesized small molecule amide derivatives and along with the known
ligands ciprofibrate (PPARα agonist) and rosiglitazone IV(PPAR γ agonist) as positive controls
at 30, 10 and 3 μM concentrations. A two-fold induction means a 100% increase in activity
compared to the DMSO control. PPARγ-selective compounds would possess a very good fold
induction in PPARγ and a fold induction of 1.0 in PPARα cells (no increase in activity compared
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to DMSO).
Among the twenty-four compounds, three compounds showed good PPARγ-induction
compared to DMSO (Figure 3-14). Compound 01 showed a fold induction of 2.1, 1.4 and 1.4 at
30, 10 and 3 µM concentrations, respectively; whereas CA-G-010, showed a fold induction of
1.5, 1.8 and 1.4 at 30, 10 and 3 µM concentrations, respectively. The third compound, 08 showed
best activity with a fold induction of 2.0, 1.9 and 1.4 at 30, 10 and 3 μM concentrations and this
was selected for further testing using in vivo mouse assay.

Figure 3-14. Structures and the results of the PPARγ induction-Luciferase assay in HepG2 cells
for compounds 01, 08, 10 each studied at 3, 10 and 30 μM. These compounds did not possess
much PPARα induction.
2.4.

Enriched extract containing tyramine derivatives
Four phenolic amides were reported to be isolated from the root barks of L. chinense.

[103, 105]. The root bark of L. chinense (0.8 Kg) extracted with ethanol yielded 137.3 g ,which
was further isolated to produce four phenolic amide derivatives at 0.0187%, including dihydro-
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N-caffeoyl tyramine XI (106 mg, 0.01325%), cis-N-caffeoyl tyramine XII (9.2 mg, 0.00115%),
trans-N-caffeoyl tyramine XIII (14.8 mg, 0.00185), trans-N-feruloyl octopamine XIV (19.6 mg,
0.00245%) [103, 105]. Previous studies of the aqueous extract of Cortex Lycis Radicis (CLR) on
alloxan-induced diabetic mice caused a decrease in glucose levels, increased insulin levels, and
long-term hypoglycemic effects and reduce the body weight [98]. Also, studies of a methanolic
extract of Lycii cortex radicis (LCR) on Sprague-Dawley male rats concluded that LCR possess
hypocholestromeic activity. In order to study the antidiabetic properties of tyramines, an
enriched extract of the root bark of Lycium chinese, was prepared and tested for in vivo activities
along with small molecule amide derivative 08.
2.5.

In vivo diabetic mouse assay results
Compound CA-G-008 and the alkaloid-enriched fraction (21% tyramine derivatives) of

the Goji extract were tested in vivo using db/db mice model.
Body weight, food intake and glucose tolerance measurements
The body weight and food intake of both high and medium dose db/db mice groups was
measured after two weeks of control period, treated either with the drug or the extract or vehicle.
In the high dose groups, the mice treated with the drug showed a slight increase in the body
weight, whereas as the group treated with the extract showed a slight decrease in their body
weights. In contrast, the medium dose group of mice treated with extract and compound showed
a slight decrease in body weight (Figure 3-15). The food intake of high dose groups treated with
drug increased while the extract decreased slightly. In the medium dose group treated with the
extract, the food intake decreased slightly, whereas the mice treated with the drug remained the
same (Figure 3-16).
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Figure 3-15. Body weight measurements of the db/db mice in both high and medium dose
groups treated with both drug and extract.

Figure 3-16. Food intake by db/db mice in both high dose group and medium dose group, treated
with both drug and extract.
Glucose tolerance tests were performed by measuring the glucose concentration by
treating the high and medium dose group mice with extract and the drug. In both medium and
high dose treated groups, no improvements were observed in the mice treated with both drug and
extract. Figure 3-17 shows the blood glucose measurements in the medium and high dosage
groups.
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Metabolic Data
In both the medium- and high- dose groups (Figures 3-18 and 3-19), metabolic data were
measured including respiratory quotient, oxygen consumption, carbon dioxide production,
respiratory quotient, heat production and total movement.
In the medium dose group treated with the drug, the respiratory quotient, VO2, VCO2 decreased
significantly where as the heat content decreased slightly and the total movement increased
slightly compared to the baseline. In the extract treated medium dose group, all the metabolic
parameters decreased slightly compared to the baseline (Figure 3-18).
In the high dose group mice treated with the drug, compared to the baseline, the
respiratory quotient, total average movement decreased compared to the drug treated group,
while VO2, VCO2 and heat increased compared to the drug baseline group. In the extract treated
high dose group, the respiratory quotient decreased slightly, total average movement increased
significantly, whereas, VO2, VCO2 remained the same and the heat content decreased (Figure 319).
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Figure 3-17. Blood glucose measurements plotted against time for drug (08) and extract
(tyramide enriched) in medium and high dosage of the db/db mice (n=3).
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Figure 3-18. Metabolic data of the medium dose groups treated with both drug and the extract:
a) respiratory quotient, b) VO2, c) VCO2, d) heat and e) total movement
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Figure 3-19. Metabolic data of the high dose groups treated with both drug and the extract: a)
respiratory quotient, b) VO2, c) VCO2, d) heat and e) total movement.
EchoMRI body composition
The body composition was measured in the medium dose group using EchoMRI to
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measure lean and fat mass, free and total water content (Figure 3-20). In the drug treated mice,
lean mass, fat mass and total water content almost remained the same as the baseline, free-water
content decreased in the first week, and it increased in the second week. In the extract-treated
group, lean mass remained the same, fat mass increased slightly in the first and second weeks,
and free-water content increased in the first week, and decreased in the second week.

a

b
Free H2O - Medium Dose

0.5

Drug Group (n=3)
Extract Group (n=3)

Free H2O (g)

0.4

0.3

0.2

0.1

c

0
Baseline

Treatment Week 1

Treatment Week 2

Treatment Week 2

d

Figure 3-20. The body composition of the medium dose group mice treated with drug and the
extract: a) lean mass, b) fat mass, c) free water and d) total water content.
Blood pressure and heart rate
Blood pressure and heart rate were measured in the high dose group after treatment with
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extract and drug. The blood pressure in the high dose group of mice treated with the drug
decreased, whereas with the extract, the blood pressure increased slightly. The heart rate of the
mice increased slightly in both drug and extract treated mice.

a

b

Figure 3-21. Blood pressure and heart rates of high dose group db/db mice treated with drug and
extract.
2.6.

Conclusions
Preparations containing Goji, a TCM plant, are widely used in the Eastern countries to

treat various diseases including diabetes. To identify the active compounds, some of the reported
phytochemicals of Goji selected and were docked into the PPARγ ligand binding domains of
both full and partial agonists (2PRG and 3LMP, respectively). Docking results revealed five
compounds belonging to cinnamomyl phenyl ethyl amide class X to XIV (termed as tyraminederivatives), possess good binding poses and docking scores in both the partial and full agonist
catalytic binding domains. Hence, tyramine-derivatives were selected for synthesis and further
testing. An enriched extract of the root bark of L. chinense (calculated conc. of tyraminederivatives, 21%) was prepared. In addition, using coupling of tyramines with cinnamic acid-
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derivatives, followed by reduction, twenty-four compounds belonging to the tyramine-derivative
class were synthesized and evaluated for PPARγ activity and selectivity using PPARγ- and
PPARα-luciferase bioassays. Among the twenty-four compounds, three compounds (01, 08, 10)
possessed a good induction compared to positive control rosiglitazone. Compound 08 and
tyramine-derivative enriched extract were tested further, using in vivo diabetic db/db mice model
to check their antidiabetic and metabolic properties. Although some tyramine derivatives
possessed good activities in vitro, the results of the in vivo studies indicate no significant
improvement in the biochemical parameters of the db/db mice model by both 08 and tyraminederivative enriched Goji fraction. In conclusion, though the TCM preparations were used
traditionally for their antidiabetic properties and were previously reported to possess this activity,
our studies indicate that this antidiabetic property may not be due to the tyramine-derivative class
of compounds either alone or in combination, at the concentrations tested in vivo. The
phytochemicals of Goji including tyramine-analogues might be working as antidiabetic
compounds via different targets or mechanisms other than PPARs.
3.

Experimental

3.1.

Docking studies

System specifications and software
To perform virtual screening, studies, a commercial version of the Schrödinger software
package [64] was installed on a Windows desktop computer with Intel® Core™ Quad CUP
Q6600@2.40GHz 2.40 GHz processor with a random access memory (RAM) of 4.00 GB and
32-bit operating system. PyMol software (Schrödinger, LLC) was utilized to perform post
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docking visualization and analysis.
Ligand Preparation
Thirty one compounds, including 27 from Goji and three PPARγ agonists farglitzar,
rosiglitazone IV and cercosporamide-derivative VII were prepared using LipPrep module in
force field OPLS-2005, ionized at pH 7.4 + 2, desalted and generated tautomers. The specified
chirality was retained to generate at most 32 per ligand. This ligand preparation generated 81
ligands from the input of 31 compounds.
Protein preparation
Crystal structures of PPARγ with rosiglitazone IV, a full agonist (PDB: 2PRG) and
cercosporamide-derivative VII, a partial agonist (PDB: 3LMP) were prepared using the protein
preparation wizard. Both the proteins were preprocessed to assign bond orders, add hydrogen
bonds, create zero order bonds to metals, create disulfide bonds, and delete waters beyond 5 Å
from hetero groups. For 2PRG, the chains B and C were deleted, whereas, for 3LMP, chain C
was deleted. The H-bond assignment was applied using sample water orientations, using
PROPKA pH 7.0. Water molecules with less than three hydrogen bonding distance were
removed from the protein. Restrained minimization was performed using OPLS_2005,
converged the heavy atoms to RMSD 0.3 Å.
Glide Grid generation and docking
Receptor grids were generated for the prepared proteins 2PRG and 3LMP using Glide
(Schrödinger, LLC). For 2PRG, three hydrogen bonding constraints to His323, 449 and Tyr473
were applied, and for 3LMP, no constraints were applied. The grids thus generated were
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validated for both the native ligands to check if the RMSD of the docked output was < 1 Å from
that of the crystal structure. All the prepared ligands were docked in the two generated grids.
Their docking results and binding poses were analyzed using PyMol (Schrödinger, LLC).
3.2.

Synthesis of tyramine-derivatives

Materials and methods.
All the reactions were performed under an atmosphere of argon with oven-dried
glassware and standard syringe/septa techniques. Materials were obtained from commercial
suppliers and used without further purification except when otherwise noted. All reactions were
magnetically stirred with teflon stir bars, and temperatures were measured externally. Solvents
were distilled under an argon atmosphere prior to use. The solvents CH2Cl2 was dried over P2O5
and triethylamine was distilled from CaH2. Ethanol and methanol used were bottle-grade
solvents. All reagents obtained commercially were used without further purification. The
reaction progress was monitored on precoated silica gel TLC plates. Spots were visualized under
254 nm UV light and/or by dipping the TLC plate into a solution of 2 mL of anisaldehyde, 10
mL of glacial acetic acid, and 5 mL of H2SO4 in 340 mL of EtOH, followed by heating with a
heat gun. Column chromatography was performed with silica gel (230−400mesh). All the
solvents (hexanes, ethyl acetate, CH2Cl2, Et2O) were distilled prior to use for column
chromatography. 1H and
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C NMR spectra were measured in MeOD on 500 MHz (125 MHz)

machines. Chemical shifts were reported in parts per million (ppm) downfield from
tetramethylsilane (δ) as the internal standard, and coupling constants are in hertz (Hz).
Assignment of proton resonances were confirmed by correlated spectroscopy. IR spectra were
recorded with a universal attenuated total reflection sampling accessory (diamond ATR) on an
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Agilent Cary 630 FT-IR spectrometer.
Synthesis of 1 to 12
General procedure: A substituted Cinnamic acid derivative (1 eq.) is dissolved in 2.5 mL
of dimethylformamide (DMF) and trimethylamine (TEA) (3 eq) The solution is cooled in an ice
± water bath and substituted tyramine derivative (1.25 eq) are added followed by a solution of
PyBOP (1.25 eq) in 2.5mL of CH2Cl2. The mixture is stirred at 0 C for 30 min and then at room
temperature for 12 h. CH2Cl2 is removed under reduced pressure and the solution is diluted with
15mL of water. The products are extracted with ethyl acetate. The extract was washed
sequentially with 1N HCl, water, 1M NaHCO3 and brine, dried over MgSO4, filtered and
evaporated. The residue was purified on a silica gel column (eluent: ethyl acetate or petroleum
ether) to obtain compounds 01 to 12, at yields between 65 and 85%.
(E)-N-(3,4-dihydroxyphenethyl)-3-(3,4-dihydroxyphenyl)acrylamide 01
(yield 88%) IR (cm-1): 3313, 2939, 2487, 2073, 1648, 1579, 1513, 1463, 1439, 1360, 1280,
1203, 1164, 1122, 973, 850 and 811; 1H NMR (500 MHz, MeOD) δ 7.40 (d, J = 15.7 Hz, 1H),
7.02 (s, 1H), 6.94 – 6.89 (m, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.73 – 6.67 (m, 2H), 6.57 (d, J = 8.0
Hz, 1H), 6.36 (d, J = 15.7 Hz, 1H), 3.46 (t, J = 7.3 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H); 13C NMR
(126 MHz, MeOD) δ 167.88, 147.34 , 145.31 , 144.86 , 143.39 , 140.76 , 130.72 , 126.92 ,
120.70 , 119.66 , 117.03 , 115.48 , 115.03, 113.66 , 41.16 , 34.66 .
(E)-3-(3,4-dihydroxyphenyl)-N-(4-hydroxyphenethyl)acrylamide 02
(yield 75%) IR (cm-1): 3273, 2492 1649, 1595, 1514, 1463, 1362, 1284, 1242, 1114, 975, 850
and 815; 1H NMR (500 MHz, MeOD) δ 7.41 (d, J = 15.6 Hz, 1H), 7.11 – 7.01 (m, 3H), 6.94 –
6.88 (m, 1H), 6.79 (d, J = 8.1 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 6.36 (d, J = 15.6 Hz, 1H), 3.52 –
3.47 (t, J = 7.3 Hz, 2H), 2.76( t, J = 7.3 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 167.91, 155.49,
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147.35, 145.31, 140.82, 129.94, 129.37, 126.93, 120.77, 117.02, 115.10, 114.89, 113.70, 41.19,
34.42.
(E)-3-(3,4-dihydroxyphenyl)-N-(3-methoxyphenethyl)acrylamide 03
(yield 75%) IR (cm-1): 3170, 2944, 2491, 1651, 1585, 1514, 1456, 1362, 1284, 1260, 1203,
1154, 1116, 1039, 978, 851, 814, 783 and 696; 1H NMR (500 MHz, MeOD) δ 7.41 (d, J = 15.6
Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.03 (s, 1H), 6.91 (d, J = 8.1 Hz, 1H), 6.79 (dt, J = 12.5, 8.0
Hz, 5H), 6.36 (d, J = 15.7 Hz, 1H), 3.76 (s, 3H), 3.52 (t, J = 7.3 Hz, 2H), 2.83 (t, J = 7.3 Hz,
2H);

13

C NMR (126 MHz, MeOD) δ 167.91, 159.87, 147.38, 145.33, 140.87, 140.67, 129.10,

126.91, 120.75 (d, J = 3.1 Hz), 117.00, 115.11, 113.85 (d, J = 35.4 Hz), 113.50, 111.50, 54.19,
40.79, 35.28.
(E)-N-(3,4-dihydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide 04
(yield 57%) IR (cm-1): 3245, 2488, 1655, 1598, 1520, 1489, 1456, 1361, 1280, 1256, 1197,
1116, 1047, 977, 850, 784 and 680;1H NMR (500 MHz, MeOD) δ 7.50 (d, J = 15.7 Hz, 1H),
7.29 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 7.09 (s, 1H), 6.94 (dd, J = 8.1, 2.1 Hz, 1H),
6.71 (dd, J = 9.7, 4.9 Hz, 2H), 6.58 (dd, J = 8.7, 7.0 Hz, 2H), 3.81 (s, 3H), 3.48 (t, J = 7.3 Hz,
2H), 2.72 (t, J = 7.3 Hz, 2H);

13

C NMR (126 MHz, MeOD) δ 167.18, 160.11, 144.89, 143.43,

140.19, 136.26, 130.65, 129.53, 120.78, 119.98, 119.69, 115.50, 115.09 (d, J = 10.8 Hz), 112.43,
54.34, 41.18, 34.59.
(E)-N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide 05
(yield 88%) IR (cm-1): 2967, 2868, 2396, 1656, 1610, 1516, 1489, 1453, 1361, 1242, 1206,
1156, 1087, 1048, 1015, 982, 831, 782 and 681; 1H NMR (500 MHz, MeOD) δ 7.50 (d, J = 15.7
Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 7.11 – 7.05 (m, 4H), 6.94 (dd, J = 8.1,
2.0 Hz, 1H), 6.74 (d, J = 8.3 Hz, 2H), 6.59 (d, J = 15.8 Hz, 1H), 3.82 (s, 4H), 3.49 (t, J = 7.4 Hz,
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2H), 2.78 (t, J = 7.3 Hz, 2H);

13

C NMR (126 MHz, MeOD) δ 167.14, 160.13, 155.59, 140.18,

136.27, 129.82, 129.55, 129.35, 120.78, 119.97, 115.13, 114.90, 112.44, 54.35, 41.20, 34.37.
(E)-N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)acrylamide 06
(yield 89%) IR (cm-1): 3277, 3070, 2935, 2835, 1655, 1602, 1582, 1546, 1488, 1454, 1433,
1367, 1315, 1209, 1217, 1153, 1039, 979, 849, 779, 695 and 677; 1H NMR (500 MHz, CDCl3) δ
7.60 (d, J = 15.5 Hz, 1H), 7.27 (dt, J = 11.3, 7.8 Hz, 3H), 7.09 (d, J = 7.6 Hz, 1H), 7.02 (s, 1H),
6.91 (d, J = 8.1 Hz, 1H), 6.82 (dd, J = 14.7, 9.4 Hz, 3H), 6.35 (d, J = 15.6 Hz, 1H), 5.83 (bs, 1H),
3.83 (s, 3H), 3.81 (s, 3H), 3.68 (m, 2H), 2.89 (t, J = 6.8 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ
165.85, 159.87, 140.94, 140.51, 136.22, 129.76 (d, J = 12.1 Hz), 121.06 (d, J = 17.5 Hz), 120.42,
115.40, 114.50, 112.91, 111.94, 55.25 (d, J = 9.5 Hz), 40.72, 35.70.
(E)-N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide 07
(yield 65 to 85%) IR (cm-1): 3322, 2492, 1651, 1591, 1515, 1461, 1362, 1280, 1205, 1123, 1032,
976, 845 and 815; 1H NMR (500 MHz, MeOD) δ 7.46 (d, J = 15.7 Hz, 1H), 7.12 (s, 1H), 7.03
(dd, J = 8.1, 1.4 Hz, 1H), 6.81 (d, J = 8.1 Hz, 1H), 6.71 (dd, J = 9.4, 4.8 Hz, 2H), 6.57 (dd, J =
7.8, 1.5 Hz, 1H), 6.43 (d, J = 15.7 Hz, 1H), 3.89 (s, 3H), 3.48 (t, J = 7.3 Hz, 2H), 2.72 (t, J = 7.2
Hz, 2H);

13

C NMR (126 MHz, MeOD) δ 167.79, 148.41, 147.87, 144.87, 143.40, 140.64,

130.71, 126.89, 121.84, 119.69, 117.37, 115.51, 115.05 (d, J = 4.3 Hz), 110.12, 54.98, 41.15,
34.65.
(E)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)acrylamide 08
(yield 75%) IR (cm-1): 3255, 2492, 1651, 1591, 1514, 1459, 1362, 1279, 1126, 1032, 977 and
819; 1H NMR (500 MHz, MeOD) δ 7.46 (d, J = 15.6 Hz, 1H), 7.16 – 7.01 (m, 5H), 6.81 (d, J =
8.1 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 6.42 (d, J = 15.6 Hz, 1H), 3.88 (s, 3H), 3.54 – 3.45 (m,
2H), 2.77 (t, J = 7.3 Hz, 2H);

13

C NMR (126 MHz, MeOD) δ 167.80, 155.53, 148.44, 147.88,
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140.67, 129.91, 129.37, 126.87, 121.85, 117.35, 115.09, 114.89, 110.13, 54.98, 41.17, 34.42
(E)-3-(4-hydroxy-3-methoxyphenyl)-N-(3-methoxyphenethyl)acrylamide 09
(yield ~ 75%) IR (cm-1): 2938, 2482, 1652, 1600, 1585, 1514, 1456, 1434, 1362, 1281, 1262,
1281, 1262, 1206, 1157, 1125, 1035, 979, 846, 818, 782 and 696; 1H NMR (500 MHz, MeOD) δ
7.46 (d, J = 15.7 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.12 (s, 1H), 7.04 (dd, J = 8.1, 1.3 Hz, 1H),
6.82 (t, J = 7.8 Hz, 2H), 6.80 – 6.75 (m, 1H), 6.42 (d, J = 15.6 Hz, 1H), 3.89 (s, 3H), 3.78 (s,
3H), 3.54 (t, J = 7.3 Hz, 2H), 2.85 (t, J = 7.2 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 167.81,
159.90, 148.49, 147.90, 140.71, 129.09, 126.83, 121.83, 120.73, 117.28, 115.09, 114.01, 111.47,
110.13, 54.97, 54.16, 40.76, 35.26.
(E)-N-(3,4-dihydroxyphenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)acrylamide 10
(yield ~ 75%) IR (cm-1): 3339, 2939, 2492, 2071, 1652, 1603, 1514, 1457, 1427, 1337, 1282,
1216, 1156, 1114, 975, 869 and 827; 1H NMR (500 MHz, MeOD) δ 7.43 (d, J = 15.6 Hz, 1H),
6.82 (s, 2H), 6.75 – 6.69 (m, 2H), 6.57 (d, J = 7.9 Hz, 1H), 6.45 (d, J = 15.6 Hz, 1H), 3.85 (s,
7H), 3.50 (t, J = 7.2 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 167.71,
148.01, 144.88, 143.41, 140.88, 137.40, 130.74, 125.86, 119.75, 117.85, 115.56, 115.09, 104.99,
55.40, 41.15, 34.63.
(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxyphenethyl)acrylamide 11
(yield ~ 75%) IR (cm-1): 3339, 2939, 2493, 2071, 1652, 1603, 1514, 1457, 1427, 1337, 1282,
1216, 1156, 1114, 975, 868 and 827; 1H NMR (500 MHz, MeOD) δ 7.44 (d, J = 15.6 Hz, 1H),
7.06 (d, J = 8.2 Hz, 2H), 6.83 (s, 2H), 6.74 (d, J = 8.2 Hz, 2H), 6.45 (d, J = 15.6 Hz, 1H), 3.86 (s,
6H), 3.49 (t, J = 7.3 Hz, 2H), 2.77 (t, J = 7.2 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 167.68,
155.53, 148.03, 140.87, 137.46, 129.90, 129.37, 125.84, 117.82, 114.91, 105.01, 55.39, 41.15,
34.40.
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(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)-N-(3-methoxyphenethyl)acrylamide 12
(yield ~ 75%) IR (cm-1): 3282, 2938, 2839, 2252, 1655, 1602, 1513, 1490, 1455, 1425, 1320,
1285, 1259, 1209, 1153, 1112, 1061, 1038, 976, 907, 828, 780 and 696; 1H NMR (500 MHz,
CDCl3) δ 7.52 (d, J = 15.5 Hz, 1H), 7.22 (t, J = 7.9 Hz, 1H), 6.79 (dd, J = 16.6, 6.9 Hz, 3H), 6.70
(s, 2H), 6.27 (d, J = 15.5 Hz, 1H), 6.09 (s, 1H), 6.02 (s, 1H), 3.84 (s, 6H), 3.77 (s, 3H), 3.69 –
3.61 (m, 2H), 2.86 (t, J = 6.7 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 166.23, 159.79, 147.24,
141.12, 140.59, 136.63, 129.64, 126.29, 121.11, 118.66, 114.53, 111.80, 104.79, 56.26, 55.18,
40.71, 35.71.
Synthesis of 13 to 24
General Procedure: The unsaturated tyramine derivative (1 to 12) (0.045 g, 0. 150 mmol)
is dissolved in MeOH (1.5 ml) and to this solution, palladium on carbon 5% (0.010 g, 0.0944
mmol) is added and purged with hydrogen gas. The resulting solution is stirred for 12 h at room
temperature under hydrogen atmosphere (with H2 filled balloon). After 12 h, the reaction mixture
is filtered using celite, washed with methanol and the combined fractions were concentrated and
purified by flash column chromatography using chloroform and methanol (94:6) to yield the
saturated amide derivatives (13 to 24) in yield (70 to 90 %)
Data 13-24:
N-(3,4-dihydroxyphenethyl)-3-(3,4-dihydroxyphenyl)propanamide 13
(yield 79%) IR (cm-1): 3314, 2935, 2501, 2073, 1599, 1517, 1481, 1440, 1359, 1282, 1199,
1152, 1115, 972, 870, 811 and 783; 1H NMR (500 MHz, MeOD) δ 6.69 (dd, J = 8.0, 1.2 Hz,
2H), 6.65 (dd, J = 5.7, 1.6 Hz, 2H), 6.52 (dd, J = 8.0, 1.6 Hz, 1H), 6.48 (dd, J = 7.9, 1.6 Hz, 1H),
3.33 – 3.27 (m, 2H), 2.75 (t, J = 7.6 Hz, 2H), 2.57 (t, J = 7.7 Hz, 2H), 2.39 (t, J = 7.7 Hz, 2H);
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13

C NMR (126 MHz, MeOD) δ 174.07, 144.78, 143.26 (d, J = 15.9 Hz), 132.44, 130.71, 119.73,

119.24, 115.45, 115.17, 114.99, 114.98, 40.90, 38.06, 34.55, 31.09.
3-(3,4-Dihydroxyphenyl)-N-(4-hydroxyphenethyl)propanamide 14
(yield 68%) IR (cm-1): 3282, 2499, 1610, 1515, 1449, 1361, 1284, 1242, 1115, 976 and 819; 1H
NMR (500 MHz, MeOD) δ 6.97 (d, J = 8.3 Hz, 2H), 6.69 (dd, J = 20.7, 11.9 Hz, 4H), 6.53 (d, J
= 6.5 Hz, 1H), 3.32 (dd, J = 12.7, 5.1 Hz, 2H), 2.75 (t, J = 7.5 Hz, 2H), 2.63 (t, J = 7.3 Hz, 2H),
2.39 (t, J = 7.6 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 174.03, 155.43, 144.81, 132.39, 129.93,
129.34, 119.24, 115.17, 114.95, 114.82, 40.92, 38.04, 34.32, 31.06.
3-(3,4-dihydroxyphenyl)-N-(3-methoxyphenethyl)propanamide 15
(yield 86%) IR (cm-1): 3276, 2938, 2491, 1595, 1515, 1453, 1437, 1360, 1282, 1201, 1166,
1152, 1116, 1061, 1038, 869, 812, 781, 743 and 696; 1H NMR (500 MHz, MeOD) δ 7.18 (t, J =
8.0 Hz, 1H), 6.71 (ddd, J = 21.9, 13.9, 4.1 Hz, 5H), 6.55 – 6.48 (m, 1H), 3.76 (s, 3H), 3.40 – 3.32
(m, 3H), 2.72 (dt, J = 20.7, 7.3 Hz, 4H), 2.39 (t, J = 7.6 Hz, 2H); 13C NMR (126 MHz, MeOD) δ
174.08, 159.85, 144.81, 143.23, 140.67, 132.40, 129.06, 120.78, 119.23, 115.19, 114.99, 113.95,
111.45, 54.21, 40.52, 38.05, 35.21, 31.07.
N-(3,4-Dihydroxyphenethyl)-3-(3-methoxyphenyl)propanamide 16
(yield 91%) IR (cm-1): 3280, 2939,2507, 1627, 1602, 1519, 1485, 1465, 1455, 1440, 1359, 1278,
1260, 1197, 1152, 1116, 1049, 872, 784 and 697; 1H NMR (500 MHz, MeOD) δ 7.18 (t, J = 8.0
Hz, 1H), 6.81 – 6.73 (m, 3H), 6.69 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 1.4 Hz, 1H), 6.47 (d, J = 6.4
Hz, 1H), 3.78 (s, 3H), 3.32 (t, J = 7.6 Hz, 2H), 2.87 (t, J = 7.6 Hz, 2H), 2.58 (t, J = 7.3 Hz, 2H),
2.45 (t, J = 7.3 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 173.77, 159.85, 144.85, 143.36, 142.35,
130.65, 129.04, 120.32, 119.66, 115.43, 114.96, 113.66, 111.26, 54.17, 40.88, 37.53, 34.54,
31.62.
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N-(4-hydroxyphenethyl)-3-(3-methoxyphenyl)propanamide 17
(yield 95%) IR (cm-1): 2947, 2868, 1635, 1614, 1516, 1455, 1362, 1261, 1261, 1207, 1153,
1087, 1015, 831, 780 and 697; 1H NMR (500 MHz, MeOD) δ 7.18 (t, J = 8.0 Hz, 1H), 6.96 (d, J
= 8.3 Hz, 2H), 6.82 – 6.74 (m, 3H), 6.71 (d, J = 8.4 Hz, 2H), 3.77 (s, 3H), 3.35 – 3.29 (m, 2H),
2.87 (t, J = 7.6 Hz, 2H), 2.62 (t, J = 7.6 Hz, 2H), 2.45 (t, J = 7.6 Hz, 2H); 13C NMR (126 MHz,
MeOD) δ 173.71, 159.86, 155.51, 142.36, 129.86, 129.33, 129.07, 120.37, 114.85, 113.70,
111.29, 54.20, 40.93, 37.50, 34.33, 31.60.
N-(3-methoxyphenethyl)-3-(3-methoxyphenyl)propanamide 18
(yield 77%) IR (cm-1): 3294, 2937, 1644, 1602, 1585, 1547, 1490, 1455, 1260, 1152, 1041, 874,
780 and 696; 1H NMR (500 MHz, MeOD) δ 7.18 (dd, J = 10.6, 5.4 Hz, 2H), 6.82 – 6.72 (m,
6H), 3.78 (s, 6H), 3.40 – 3.35 (m, 2H), 2.87 (t, J = 7.7 Hz, 2H), 2.71 (t, J = 7.3 Hz, 2H), 2.46 –
2.42 (t, J = 7.3 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 173.76, 159.86, 142.33, 140.64, 129.03,
120.72, 120.30, 113.98, 113.67, 111.39, 111.24, 54.16, 40.49, 37.51, 35.20, 31.60.
N-(3,4-Dihydroxyphenethyl)-3-(4-hydroxy-3-methoxyphenyl)propanamide 19
(yield 89%) IR (cm-1): 3338, 2938, 2500, 1600, 1516, 1465, 1449, 1362, 1275, 1153, 1123,
1034, 976, 870 and 814; 1H NMR (500 MHz, MeOD) δ 6.78 (d, J = 1.7 Hz, 1H), 6.72 (d, J = 8.0
Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 6.63 (dd, J = 5.8, 1.9 Hz, 2H), 6.46 (dd, J = 8.0, 1.9 Hz, 1H),
3.83 (s, 3H), 3.30 (d, J = 7.6 Hz, 2H), 2.81 (t, J = 7.6 Hz, 2H), 2.58 (t, J = 7.7 Hz, 2H), 2.42 (t, J
= 7.7 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 174.01, 147.48, 144.85, 144.46, 143.36, 132.37,
130.65, 120.40, 119.68, 115.42, 114.97, 114.77 111.72, 54.95, 40.88, 38.02, 34.56, 31.28.
3-(4-Hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)propanamide 20
(yield 91%) IR (cm-1): 3279, 2938, 2499, 1627, 1613, 1596, 1515, 1465, 1452, 1436, 1363,
1236, 1153, 1125, 1034 and 822; 1H NMR (500 MHz, MeOD) δ 6.95 (d, J = 8.4 Hz, 2H), 6.78
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(d, J = 1.7 Hz, 1H), 6.74 – 6.69 (m, 3H), 6.64 (dd, J = 8.0, 1.7 Hz, 1H), 3.84 (s, 3H), 3.33 – 3.28
(m, 2H), 2.81 (t, J = 7.5 Hz, 2H), 2.62 (t, J = 7.3 Hz, 2H), 2.42 (t, J = 7.5 Hz, 2H);

13

C NMR

(126 MHz, MeOD) δ 173.97, 155.47, 147.48, 144.50, 132.33, 129.88, 129.33, 120.44, 114.83,
114.77, 111.75, 54.95, 40.91, 37.98, 34.32, 31.23.
3-(4-Hydroxy-3-methoxyphenyl)-N-(3-methoxyphenethyl)propanamide 21
(yield 90%) IR (cm-1): 2937, 2488, 1631, 1600, 1516, 1465, 1433, 1363, 1260, 1153, 1125,
1037, 854, 787 and 697; 1H NMR (500 MHz, MeOD) δ 7.17 (dd, J = 8.8, 7.6 Hz, 1H), 6.81 –
6.74 (m, 3H), 6.72 (d, J = 7.9 Hz, 2H), 6.63 (dd, J = 8.0, 1.8 Hz, 1H), 3.83 (s, 4H), 3.78 (d, J =
7.9 Hz, 3H), 3.37 (t, J = 7.3 Hz, 2H), 2.81 (t, J = 7.6 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.42 (t, J
= 7.6 Hz, 2H); 13C NMR (126 MHz, MeOD) δ 174.00, 159.87, 147.48, 144.51, 140.64, 132.32,
129.05, 120.74, 120.41, 114.78, 113.96, 111.73, 111.42, 54.95, 54.18, 40.50, 37.99, 35.21, 31.24.
N-(3,4-Dihydroxyphenethyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)propanamide 22
(Yield 87%) IR (cm-1): 3348, 2939, 2499, 1611, 1519, 1461, 1345, 1282, 1215, 1114, 977 and
814; 1H NMR (500 MHz, MeOD) δ 6.68 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 1.9 Hz, 1H), 6.52 –
6.47 (m, 2H), 6.45 (dd, J = 8.0, 1.9 Hz, 1H), 3.82 (s, 6H), 3.33 – 3.29 (m, 2H), 2.82 (t, J = 7.5
Hz, 2H), 2.75 (t, J = 7.6 Hz, 2H), 2.43 (t, J = 7.6 Hz, 2H);

13

C NMR (126 MHz, MeOD) δ

173.96, 147.80, 144.85, 143.36, 133.50, 131.62, 130.63, 119.67, 115.41, 114.97, 105.25, 55.33,
40.90, 37.99, 34.58, 31.74.
3-(4-Hydroxy-3,5-dimethoxyphenyl)-N-(4-hydroxyphenethyl)propanamide 23
(Yield 91%) IR (cm-1): 2941, 2506, 2189, 2028, 1621, 1603, 1512, 1486, 1456, 1437, 1351,
1328, 1260, 1242, 1139, 1050, 969, 837 and 757; 1H NMR (500 MHz, MeOD) δ 6.94 (d, J = 8.4
Hz, 2H), 6.70 (d, J = 8.4 Hz, 2H), 6.48 (s, 2H), 3.83 (s, 7H), 3.36 – 3.30 (m, 4H), 2.82 (t, J = 7.5
Hz, 2H), 2.62 (t, J = 7.3 Hz, 2H), 2.43 (t, J = 7.5 Hz, 2H);
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13

C NMR (126 MHz, MeOD) δ

173.89, 155.36, 147.75, 133.49, 131.57, 129.87, 129.38, 114.92, 105.27, 55.51, 40.98, 38.07,
34.40, 31.80.
3-(4-Hydroxy-3,5-dimethoxyphenyl)-N-(3-methoxyphenethyl)propanamide 24
(Yield 89%) IR (cm-1): 3299, 2938, 2838, 2496, 1633, 1603, 1518, 1458, 1429, 1326, 1259,
1213, 1152, 1114, 1040, 908, 830, 785 and 697; 1H NMR (500 MHz, MeOD) δ 7.21 – 7.14 (m,
1H), 6.75 (d, J = 6.0 Hz, 2H), 6.70 (d, J = 7.5 Hz, 1H), 6.49 (s, 2H), 3.82 (s, 7H), 3.77 (s, 3H),
3.37 (t, J = 7.3 Hz, 2H), 2.82 (t, J = 7.5 Hz, 2H), 2.70 (t, J = 7.3 Hz, 2H), 2.43 (t, J = 7.5 Hz,
2H);

13

C NMR (126 MHz, MeOD) δ 173.95, 159.87, 147.81, 140.62, 133.57, 131.57, 129.05,

120.72, 113.96, 111.41, 105.29, 55.33, 54.18, 40.52, 37.96, 35.23, 31.70.
Preparation of the tyramine-enriched extract of L. chinense
The root bark of L. chinense (2 Kg) was extracted with methanol (8 L) at room
temperature to get the methanolic extract (345.5 g). This methanolic extract was suspended in
water and successively partitioned between hexanes and ethyl acetate to obtain hexane extract
and ethyl acetate extract (35.1 g). This ethyl acetate extract (33 g) was acidified with 5% HCl in
water (approx. 1 L) and extracted with ethyl acetate (3x300 mL) to get ethyl acetate fraction
(20.6 g). This ethyl acetate fraction (18.0 g) was subjected to Sephadex LH-20 column
chromatography with CHCl3:MeOH 1:1 as a solvent to get three fractions (1-3). Fraction 3 (6.49
g) was further chromatographed over Sephadex LH-20 column chromatography with MeOH to
get three fractions. The tyramine derivative enriched fraction was obtained as the third fraction,
identified by performing comparative TLC using a pure tyramine derivative 08.
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3.3.

PPAR in vitro assays

Chemical reagents and plasmids
Ciprofibrate and rosiglitazone IV were obtained from Cayman Chemical (Ann Arbor,
MI). Dulbecco's Modified Eagle's Medium (DMEM), fetal bovine serum (FBS) and phosphatebuffered saline (PBS) were from Hyclone (South Logan, Utah). Penicillin/streptomycin and
trypsin were from Gibco (Grand Island, NY). Specific plasmids pSG5–PPARα (plasmid 22751)
and PPRE X3-tk-luc (plasmid 1015) were obtained from Addgene (Cambridge, MA). pCMVrPPARγ and pPPREaP2-tk-luc were provided by Dr. Dennis Feller (Department of
Pharmacology, University of Mississippi).
Reporter gene assay for the activation of PPARs
Cell-based reporter gene assay for the identification of PPARα and PPAR agonists was carried
out in human hepatoma (HepG2) cells as described previously [106, 107]. Briefly, HepG2 cells
were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 units/mL penicillin, and 100 g/mL streptomycin in a humidified
atmosphere of 5% CO2 at 37°C. HepG2 cells were transfected with either pSG5-PPARα and
PPRE X3-tk-luc or pCMV-rPPAR and pPPREaP2-tk-luc plasmid DNA (25 g of each/1.5 mL
cell suspension) by electroporation at 160 V for a single 70 msec pulse using a BTX Electro
Square Porator T820 (BTX, San Diego, CA). Transfected cells were plated at a density of 5 
104 cells/well in 96-well tissue culture plates and grown for 24 h. The cells were treated with the
test compounds or ciprofibrate or rosiglitazone IV (3, 10, 30 M). After incubation for 24 h, the
cells were lysed and the luciferase activity was measured using a luciferase assay system
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(Promega, Madison, WI). The fold activation of luciferase activity in treated cells was calculated
in comparison to the vehicle control.

3.4

In vivo testing

Materials
Diabetic db/db mice were employed and measurements were made using EchoMRI to obtain the
measurements of the whole body fat, lean, free water, total water masses. Transmitters were used
to record the blood pressure, heart rate. In vitro testing was performed by our collaborators at
University of Mississippi Medical Center, Jackson, MS (USA).
Methods
Diabetic db/db mice were used for in vivo testing of pure phenolic amide compound 8 and the
amide enriched extract which contains 21% of the four amide derivatives.
Dosage calculations: The dosage for high dose group mice was given 32mg/Kg and medium
dose group was 8 mg/kg. All the db/db mice were followed for one to two weeks control period
before treatment was started. In the medium dose group (n=6), 3 mice received the drug, 3 mice
received the extract; where as in the high dose group (n=8), 3 mice received vehicle, 3 mice
received drug (1 died during treatment), 3 mice received extract. Medium dose group was
monitored with EchoMRIs performed during control and experimental periods to test the body
composition analysis, measuring whole body fat, lean, free water, and total water masses. High
dose group was implanted with transmitters to record the blood pressure and heart rate 24-hr/day
for 3 consecutive days. Animals were dosed daily by gavage.

90

CHAPTER 4
STEREOSELECTIVE SYNTHESES OF BIOACTIVE ISOFLAVANS:
EQUOL AND SATIVAN
1. Introduction
1.1.

Isoflavonoids: Structures and classes
Flavonoids are one of the main groups of phytochemicals, with a general structure with

two phenyl rings and one pyran rings containing C15 (C6-C3-C6) (Figure 4-1). They can be
further subdivided into flavonoids (general term) and isoflavonoids. Isoflavonoids are secondary
metabolites of plants, mainly belonging to the subfamily Papilionoideae of Leguminosae and to
a lesser extent in other families. These class of compounds act as phytoalexins and were also
found to possess various biological activities [108]. Isoflavonoids contain a large class of
compounds; over 2000 isoflavonoids belonging to 14 classes and 23 subclasses, based on their
structural arrangements [108-113]. These classes include: isoflavones, isoflavanones, rotenoids,
pterocarpans, isoflavans, isoflav-3-enes, 3-arylcoumarins, coumestans, coumaronochromones, 2arylbenzofurans.
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Figure 4-1. Examples of different classes of flavonoids including the isoflavonoids (isoflavans
and isoflavones [102].
Among the isoflavonoid-subclasses, isoflavans are characterized by: chirality at the C-3
position of the pyran ring (C-ring). These isoflavans are produced in plants or animals upon the
double reduction of isoflavanoids (eg. formonentin 11, daidzein 12 and genistein 13). There are a
number of isoflavans, including equol 7, sativan 8, vestitol 9, coluteol 15, lespedezol G1 16 and
lespecyrtin D1 17 with unique, promising biological activities are reported in the literature.
1.2.

Equol 7 and Soy isoflavonoids as Phytoestrogens

Soy isoflavonoids: Historical relevance
Soy isoflavonoids were used in traditional foods in Japan and China for many millennia.
Soybean (Glycine max (L.) Merr.) (Figure 4-2), also called “Shu” in ancient Chinese, is one of
the five main plant foods in China along with rice, wheat, barley and millet. Soya bean is of
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comemricial interest due to its oil and protein content [114]. Soy protein is a highly digestible
protein, with a Protein Digestibility Corrected Amino Acid Score (PDCAAS) =1, highest among
vegetable proteins. Since a couple of decades, soy gained a lot of interest as functional food due
to its isoflavone content. Soy related food industry was given a good a great boost on October
26, 1999, when the FDA issued a ruling, based on the scientific evidences on soy protein, which
states that “diet low in saturated fat and that includes 25 g of soy protein a day may reduce the
risk of heart disease”. In the ruling, FDA proposed that, in order to qualify for this health claim
the soy food should contain 6.25 g soy protein per serving [114].

Figure 4-2. The soybean pods, soybean seeds and Tofu [115].
Note: Image obtained from He et al 2013 [115].
Among the legumes, soy contain largest amount of isoflavones, which act as
phytoestrogens. These isoflavones are genistein 13, daidzein 12, glycitein, and formononetin 11
and are present in their glycosidic forms as genistin, diadzin, and glycetin with a total flavone
content of 61.7 mg of diadzein (37.6 mg) and genistern (24.1 mg) per kg of dry weight [116].
These soy isoflavonoids which is present in physiologically relevant concentrations especially
genestin, are found to be beneficial to treat a number of diseases including heart conditions, postmenopausal symptoms, women health and breast cancer [117].
Metabolites of isoflavones: Equol 7
Soy isoflavonoids undergo transformation in the digestive system, especially in the colon
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where these undergo transformation to other metabolites like deglucogenated products, and by
the action of gut bacteria into derivatives like equol (Figure 4-3). Equol 7 has higher affinity to
estrogen receptor (ER), than its precursor isoflavones, genistin 13 or daidzein 12, and was found
to possess varied biological activities. There are large differences in the metabolism rates of
genistein 13 and daidzein 12 between the caucasian population and in Asian population. It was
found that among the general population, only approximately 30–50% is able to metabolize
daidzein 12 to equol 7 and among the U.S. Caucasian population, only 25–35% is capable of
converting daidzein 12 to equol 7 [118]. Whereas, among the Asian people in high soy
consumption areas, 40–60% are capable of converting daidzein 12 to equol 7. Prevalence of
daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and
girls [118]. This high variability in equol 7 production is presumably due to inter-individual
differences in the composition of the intestinal microflora such as Adlercreutzia equolifaciens
[119]. Racemate of equol 7 may not show the same activities as that of enatiomeric forms as
shown in the pharmacokinetic studies on this compound [120].
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Figure 4-3. Soy isoflavonoids: Isoflavones (formonentin 11, diadzein 12, genistein 13) and
isoflavan (S-(-)-equol 7.
History of equol 7 and isoflavans
Equol 7 was the first discovered isoflavan, isolated from equine urine [121, 122]
unexpectedly (a dialcohol from equine urine, hence the name equol 7), in an attempt to isolate
estrogen, and was later isolated in the urine of other animals [123] and in humans [124], in 1980.
Its absolute configuration as a S-isomer was assigned in 1968, after the identification of some
isoflavans from plant sources [125]. It was found to be produced seteroselcetively (S-equol 7) in
humans, from the dietary soy isoflavonoid aglycone, daidzein 12, by the action of gut bacteria
[119]. It binds to estrogen receptors [126], immunoglobulin E (IgE) induced receptor [127], and
the circulating 5α-dihydrotestosterone (DHT) [128]. Since its discovery, equol 7 was shown to
possess a wide variety of biological activities such as anti-fungal [129], anti-cancer [130], antiosteoporotic, anti-androgen [128], anti-inflammatory, anti-oxidant and anti-aging properties
[131], promote brain mitochondrial function [132], inhibit prostate growth [128], and hence it is
widely considered as a dietary phytoestrogen along with daidzein 12 and genistein 13 [133].
Interestingly, (S)-equol 7 is 13 times more selective to ERβwhen compared to ERα[126, 133,
134]. Further studies of its biological and clinical properties is an area of immense interest,
including our own [135, 136].
Other Isoflavans
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Several other isoflavans were isolated from plant sources since the first discovery of (+)vestitol 9, (-)-duartin, (-)-mucronulatol in 1968 in Dalbergia variabilis and several Macherium
species [125]. Isoflavans with plant origin have oxygen at C2' and almost never have
oxygenation at C5 [137]. Some examples of isoflavans are sativan 8, which was first isolated as
an induced isoflavan from the leaves of Medicago sativa [138, 139], and later in Lotus
corniculatus [140], colutelol 15 from the roots of Colutea arborescens [141], lespedezol G1 9
from the stems of Lespedeza homoloba [142], and lespecyrtin D1 17 from the root extracts of
Lespedza cyrtobotry [143] (Figure 4-4).

Figure 4-4. Naturally occurring phytoestrogenic isoflavans (9, 15-17).

Scheme 4-1. Synthesis of racemic equol (+) 7 by Friedel-Crafts acylation of protected
monomethoxy resorcinol, 18 [144].
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Reported syntheses of Isoflavans
Given the desirable biological properties of isoflavans, their enantioselective large scale
synthesis enables these isoflavans to study further for their biological, metabolic and
pharmacokinetic studies. Several syntheses of isoflavans have been reported; majority of these
produced the product in a racemic form [145-147], followed by their chiral separation. These
include, catalytic hydrogenation of isoflavans using Pd catalysts at different solvent and pH
conditions [148, 149]. Multistep total syntheses of racemic mixture of a number of isoflavans
[150] were also reported including 5-O-methyllicoricidin [151], halogen substituted isoflavans
and isoflavenes [152].
Racemic synthesis of equol 7
Equol 7 was synthesized as a racemate from formononetin 11 and daidzein 12 using
Pearlman’s catalyst (20% Pd(OH)2 on C) followed by separation using chiral HPLC [134], and
by bacterial transformation [153] using bacteria isolated from human intestinal bacterium. SieRong Li and co-workers [154] reported the racemic synthesis of equol 7 along with
isoflavonoids; haginin E, formononetin 11 and daidzein 12 from resorcinol 18 via a common
isoflavenene intermediate. (Scheme 4-1).
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Scheme 4-2. Total synthesis of enantiopure (S)-equol 7 by an asymmetric Evans’ alkylation
[149, 155].
Enantioselective synthesis of equol 7
Very few enantioselective syntheses of isoflavans were reported, and most of them were
for the synthesis of (S)-equol 7. Ferreira and co-workers [156, 157] have demonstrated the
enantioselective synthesis of the dimethoxy analogue of (S)-equol via α-benzylation of N-acyl
imidazolidinones. However, due to the unstable nature of alkoxy benzyl halide, only small
quantities of dimethoxy equol was reported and the nontrivial cleavage of the methyl ethers was
not attempted.
In 2006, Heemstra et al. [155] reported the first enantioselective total synthesis of (S)-
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equol 7. The described route relies on an Evans’ alkylation to form the required C-3 stereocenter
and an intramolecular Buchwald etherification to generate the chroman ring. However, the key
transformations such as Evans’ alkylation of oxazolidinone with regiomeric mixture of
bromobenzyl bromide and palladium catalyzed Buchwald etherification had produced less than
50% conversion with an overall yield < 10% (Scheme 4-2).
Takashima et al. reported [158, 159] the stereoselective synthesis of three isoflavans, Sequol 7, R-sativan 8 and R-vestitol 9 using allylic substitution as the chirality transfer step with
the copper reagent derived form PhMgBr and CuBr.Me2S. Mitsnobu cyclization was
subsequently utilized for the formation of the chroman ring (Scheme 4-3). Recently, Yang S. et
al, reported the enantioselective iridium catalyzed hydrogenation [160] of α-arylcinnamic acids
and applied the same methodology for the synthesis of (S)-equol 7 at an overall yield of 48%.
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Scheme 4-3. Enantioselective total synthesis of (S)-equol 7 uisng allylic substitution as the key
step with an overall yield of approximately 24% [149, 159].
1.3.

Aim
In continuation of our work (for biological testing using enantiopure compounds) on

phytoestrogens for women health, several grams of enantiomerically pure S-equol 7 and other
chiral isoflavans were required. To address this need, herein, we report a scalable
enantioselective synthesis of isoflavans, equol enantiomers, (-)-7, (+)-7, sativan isomers (-)-8 and
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(+)-8 were synthesized using Evans’ aldol approach (Figure 4-5). Unlike, the poor selectivity in
Evans’ alkylation [155], excellent stereoselectivity was expected with Evans’ chiral imide
enolate aldol condensation.

Figure 4-5. Structures of the synthesized isoflavans.
2.

Results and Conclusion

2.1.

Retrosynthetic scheme
Scheme 4-4 describes the retrosynthetic analysis of the chiral isoflavan scaffold. The key

intermediate, syn-aldol product 44 (for intermediate to produce S-equol) or 45 (for intermediate
to produce sativan 8) can be obtained via Evan’s aldol reaction between aldehydes (46 or 47) and
chiral-auxiliary substituted imides (26 or 48). Deoxygenation of aldol product, followed by
reduction would furnish hydroxy phenols 42 (for intermediate to produce equols) and 43
(intermediate to produce sativans). Cyclization under Mitsnobu conditions or base catalysis of
the corresponding ditosyl derivative, followed by deprotection would produce the isoflavans,
equol 7 and sativan 8.
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Scheme 4-4. Retro synthetic scheme for the synthesis of isoflavans, equol 7 and sativan 8 using
Evans’ aldol condensation to generate the chirality at C-3 position.
2.2. Synthesis of the starting materials for Evans’ aldol condensation (26, 48; 46, 47).
The crucial starting materials required for Evans’ aldol reaction are benzoxazolidinone
derived amides of phenyl acetic acids and oxygenated benzaldehydes. The chiral amides (-), (+)26 and (-), (+)-48 were synthesized by following reported methods, in which the phenyl acetic
acids were activated as acid chloride with thonyl chloride or mixed anhydride with pivolyl
cholride and the resulting anhydrides were treated with respective oxazolidinone anions after
treatment with BuLi. Four chiral auxiliary substituted imides (-), (+) 26 and (-), (+) 48 were
synthesized according to the literature procedure [161]. The counter-part oxygenated aldehydes
46 and 47 were prepared from the commercially available starting material 51 and 52. MOM
protection of 51 at the o-hydroxy benzaldehyde produced 46, while the sequential protection of
52 with MOMCl and TBSCl produced 47 (Scheme 4-5).
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Scheme 4-5. Synthesis of the starting material for the stereo specific Evans’ aldol reaction.
Conditions: a) For 26 (as reported [161]) : 25, SOCl2, 2h; n-BuLi, -65 to -45 oC, (+) or (-) 50 in
THF, 2 h, 73%; for 48: 49, pivolylchloride, DIPEA, THF, -78 oC; n-BuLi, (+) or (-) 50 in THF, 78 oC, 3 h, 91%; b) for 46: 51, MOMCl, DIPEA, DCM, rt, 20 h, 99%; for 53 (as reported [162]):
52, MOMCl, K2CO3, acetone, rt, 24 h, 75%; c) For 47: 53, TBSCl, DIPEA/DCM, 0 oC, 1h; RT,
24 h, 99%.
2.3.

Evans’ aldol condensation
The synthetic venture for the synthesis of isoflavans commenced with diastereoselective

Evans’ aldol condensation [163-165] of benzaldehydes 46 and 47 with oxazolidinones 26 and 48,
respectively using Bu2BOTf (Scheme 4-6). The generation of the enolate of the oxazolidone
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derivatives were found to be affected by temperature; the enolate could not be generated below 25 oC and it decomposed above -10 oC.

Scheme 4-6. Evans’ aldol condensation to generate R-syn-aldol products (+) 44 and (+) 45 via
Zimmerman-Traxler six membered chair-like transition state.
Conditions: a) DIPEA added to 26 or 48 in DCM at 0 oC; cooled to -25 oC; 1 M BBu2OTf
in DCM; -25 oC to -15 oC, 3 h/ DCM; add 46 or 47 in DCM, -25 oC to -15 oC 1.5 h, 80-90%.
The reaction of enolate from 26 with 4-methoxy-2-(methoxymethyl) benzaldehyde 46
furnished 2,3-syn-aldol product 44. Similarly, the reaction of enolate from 47 with diprotected
benzaldehyde 48 furnished 2,3-syn-aldol product 45 as a single diastereomer in 90% yield. The
superior stereochemical outcome of the aldol reaction can be rationalized using a ZimmermanTraxler six membered chair-like transition state 59 (Scheme 4-6). As anticipated, the facial
selectivity of the aldehyde was directed by the chiral auxiliary of the enolate resulting in re-face
attack to deliver Evans’ syn aldol product.
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2.4.

Further reactions
The conversion of the aldol adducts (+) 44 and (+) 45 to natural products (-) equol 7 and

(+)-sativan 8 require deoxygenation at the benzylic hydroxyl position, followed by the reduction
of their chiral auxiliary to produce the dialcohols (+) 42 and (+) 43, are further to be cyclized.
The produced cyclized products, (-) 30 and (+) 57 should be deprotected in the C7 of the
chroman ring to produce equol enantiomers (-)-7 and (+)-sativan 8, respectively (Scheme 4-7).
Deoxygenation
Several attempts to enable the dehydroxylation of the aldol products (+) 44 and (+) 45 in
the presence of Pd/C/H2 in EtOAc, Pd/C/H2 in MeOH, Pd(OH)2/H2 in MeOH,
HCOONH4+Pd/C/H2 in MeOH, NaH2PO2+ Pd/C/H2 in THF+water and Raney Ni/H2 in MeOH
were unsuccessful or produced the required prodcuts in low quantities. Conversion of the
benzylic hydroxyl group of these compounds to their corresponding tosylates were also
unsuccessful. This is may be due to presence of electron rich aromatic system and possible
chelation. Gratifyingly, deoxygenation of syn-aldol product using excess of triethylsilane in the
presence of TFA, furnished the compounds in (+) 54 and (+) 56 in 75 to 80% yields,
respectively. Next, the MOM group of (+) 54 was selectively deprotected using HCl in MeOH to
obtain (+) 55 in 85% yield.
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Scheme 4-7. Enantioselective synthesis of S-equol 7 and S-sativan 8 starting from Evans’ aldol
products 44 and 45.
Conditions: a) TFA, Et3SiH/DCM, 0 oC, 30 min (75-80%); b) 3N HCl in MeOH/reflux,
30 min, 85%; c) for 55: LiAlH4/ THF,0 oC to rt, 4 h, 90%; for 56: LiAlH4/THF,0 oC to rt,
overnight, TBAF/THF, 89%; d) DEAD, TPP/THF, rt, 6 h, 86%; e). for 30: Pyridinium.HCl/150
o

C, overnight; for 57: 3M HCl; rt, 0.5 to 0.75 h, 85%.

Reduction
The chiral auxialiary of the deoxygenated compound (+) 55 was reduced with LAH, to yield the
diol product (+) 42 at an yield of 90%. Similarly, the chiral auxialiary of the deoxygenated
compound (+) 56 was reduced with LAH, and further, the TBS group was deprotected using
TBAF in THF to yield the diol (+) 43 in ~85% yield. Chiral auxiliaries were recovered further
without any loss of their optical purity.
Cyclization and deprotection
The diols (+) 42 and (+) 43 were then cyclized using Mitsnobu conditions, DEAD and
TPP in THF to the produce cyclic products (-) 30 and (+) 57 in ~92% and 86% yields,
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respectively. The obtained dimethoxy analogues of equol (-) 30 and MOM protected analogues
of sativan (+) 57 were then subjected to deprotection to yield the desired chiral products (-) 7 and
(+) 8 at 86%yield.
2.5.

Synthesis of R-isomers of equol 7 and sativan 8

Implementing the same synthetic sequences (Scheme 4-6 and 4-7), the stereoselective synthesis
of R-isomers of equol (+)-7 and sativan (-)-8 (Scheme 4-8) were performed from their respective
starting material, (-) 26 and (-) 48, via aldol intermediates (-) 44 and (-) 45, which were subjected
to deoxygenation, deprotection, cyclization, and deprotection of the functional groups. The
overall yield was 33% for S-(-) and R-(+)-equol (+)7, 34% for (+) 8 and about 25% for sativan () 8, starting from their respective phenyl acetic acid-starting material.

Scheme 4-8. General schemes for the synthesis of (+) equol 7 and (-) sativan 8.

2.6.

Conclusion
Chiral flavans were successfully synthesized starting for phenyl aceic acid and 4-benzyl-

2-oxazolidine dinone. Reaction of boron enolates with oxygenated aldehydes resulted in synsuperior aldol products with excellent diastereoselectivity. This followed by deprotection,
removal of chiral auxiliaries, cyclization and deprotections resulted chiral flavans in >30%
overall yields This flexible synthetic approach allowed the synthesis of their antipodes by simply
switching the chiral auxiliary.
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3.

Experimental

3.1.

Materials and methods
All reactions were performed under an atmosphere of argon with oven-dried glassware

and standard syringe/septa techniques. All reactions were magnetically stirred with Teflon stir
bars, and temperatures were measured externally. Solvents were distilled under an argon
atmosphere prior to use. The solvents tetrahydrofuran (THF) and Et2O were distilled from
sodium benzophenone, while CH2Cl2 and cyclohexane were dried over P2O5. Triethylamine and
hexamethylphosphoramide (HMPA) were distilled from CaH2. Ethanol and methanol used were
bottle-grade solvents. All reagents obtained commercially were used without further purification.
The reaction progress was monitored on precoated silica gel thin-layer chromatography (TLC)
plates. Spots were visualized under 254 nm UV light and/or by dipping the TLC plate into a
solution of 2 mL of anisaldehyde, 10 mL of glacial acetic acid, and 5 mL of H 2SO4 in 340 mL of
EtOH, followed by heating with a heat gun. Column chromatography was performed with silica
gel (230−400 mesh). All the solvents (hexanes, ethyl acetate, CH2Cl2, Et2O) were distilled prior
to use for column chromatography. 1H and 13C NMR spectra were measured in CDCl3 or MeOD
on 400 MHz (100 MHz) or 500 MHz (125 MHz) machines. Chemical shifts were reported in
parts per million (ppm) downfield from tetramethylsilane (δ) as the internal standard, and
coupling constants are in hertz (Hz). Assignment of proton resonances were confirmed by
correlated spectroscopy. IR spectra were recorded by use of a universal attenuated total reflection
sampling accessory (diamond ATR) on an Agilent Cary 630 FT-IR spectrometer. Highresolution mass spectra were recorded on an Agilent electrospray ionization quadrupole time-offlight (ESI-QTOF) instrument.
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3.2.

Synthesis

Synthesis of the aldehydes
4-methoxy-2-(methoxymethoxy)benzaldehyde 46: 2-Hydroxy-4-methoxybenzaldehyde 51 (1g,
6.57 mmol) was dissolved in 20 mL dichloromethane and placed in an ice bath under argon
atmosphere. To this solution, N,N-diisopropyl ethyl amine (1.27 g, 1.7 mL, 9.9 mmol) was added
dropwise and stirred for 30 min after which, chloromethoxymethane (0.79 g, 0.75 mL, 9.9 mmol)
was added. The reaction was stirred for 20 h. The reaction mixture was quenched with distilled
water (20 mL) and the layers were separated. The aqueous layer was further extracted with (2x20
mL) DCM. The combined organic layers were dried over sodium sulfate and concentrated under
vacuum to produce a pale yellow crystalline solid as MOM protected aldehyde 1046 (1.27 g,
64.7 mmol, 99%).: IR (cm-1): 2941, 2844, 2766, 1678, 1600, 1579, 1501, 1451, 1395, 1259,
1222, 1154, 1078, 987, 925 and 815; ESI-HRMS: calcd. for C10H13O4 197.0808 [M+H]+; found
197.0800.
Synthesis of the aldehyde 47
4-Hydroxy-4-(methoxymethoxy)benzaldehyde 53
By following the reported procedure[162]., the aldehyde 47 was prepared in two steps, first by
the synthesis of 53. 2,4-Dihydroxybenzaldehyde (1g, 7.24 mmol) and potassium carbonate (1.5
g, 13.8 mmol) dissolved in 15 mL acetone, stirred for 1 h to 0



C. To this solution

chloro(methoxy)methane (0.55 mL, 7.24 mmol) was added dropwise and allowed to heat to
room temperature and stirred for 28 h. The reaction mixture was then filtered to remove
potassium carbonate and concentrated the mixture with rotovap. The mixture was then separated
using column chromatography to obtain mom-protected o-hydroxy benzaldehyde as brick
colored crystals (0.99 g, 0.54 mmol, 75%). IR (cm-1): 2961, 2848, 1628, 1579, 1503, 1250, 1225,
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1156, 1078, 992, 959 and 804;1H NMR (400 MHz, Chloroform-d) δ 11.34 (s, 1H), 9.71 (s, 1H),
7.42 (d, J = 8.6 Hz, 1H), 6.63 (dd, J = 8.6, 2.3 Hz, 1H), 6.58 (d, J = 2.3 Hz, 1H), 5.20 (s, 2H),
3.46 (s, 3H); ESI-HRMS: calcd. for C9H11O4 183.0652 [M+H]+; found 183.0666.
TBS protection of the aldehyde intermediate 53 to produce 47
2-hydroxy-4-(methoxymethoxy)benzaldehyde

53

(5.62

g,

30

mmol)

and

tert-

butylchlorodimethylsilane (9.31 g, 61.79 mmol) were dissolved in dry dichloromethane and
DIPEA (16 mL, 108 mmol) was added dropwise and allowed to stir at room temperature for 30
h. The reaction was monitored by TLC and observed for the disappearance of the starting
material. The reaction was then extracted with water and dried over anhydrous MgSO4 and
filtered and dried to obtain brick colored crystals (9 g, 30 mmol, 99%).
2-((Tert-butyldimethylsilyl)oxy)-4-(methoxymethoxy)benzaldehyde 47: IR (cm-1): 2961, 2848,
1628, 1577, 1501, 1445, 1335, 1290, 1223, 1154, 1078, 989, 959 and 806; 1H NMR (400 MHz,
Chloroform-d) δ 10.29 (s, 1H), 7.75 (d, J = 8.6 Hz, 1H), 6.68 (ddd, J = 8.7, 2.2, 0.9 Hz, 1H),
6.52 (d, J = 2.2 Hz, 1H), 5.17 (s, 2H), 3.46 (s, 3H), 1.06 – 0.91 (m, 9H), 0.27 (d, J = 2.2 Hz, 6H);
13

C NMR (101 MHz, CDCl3) δ 188.7, 163.4, 160.6, 129.9, 121.9, 109.8, 107.1, 94.1, 56.2, 25.7

(3C), 18.3, -4.4 (2C); ESI-HRMS: calcd. for C15H24O4Si 297.1517 [M+H]+; found: 297.1497.
Amide formation of propanoic acid with a chiral auxiliary
Coupling of (R)-4-benzyloxazolidin-2-one (+) 50 with phenyl acetic acid 25, to produce (R)-4Benzyl-3-(2-(4-methoxyphenyl)acetyl)oxazolidin-2-one (-) 26
By following the procedure [155], (+) 26 and (-) 26 were prepared from the
corresponding 4-benzyloxazolidin-2-ones (+) 50 and (-) 50.
(R)-4-Benzyl-3-(2-(4-methoxyphenyl)acetyl)oxazolidin-2-one (-) 26
MP 84-85 oC, [α]D = -73.3 (c = 1.195, CHCl3); IR (cm-1): 3028, 2924, 1778, 1700, 1514, 1391,
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1357, 1248, 1181, 1106, 1033, 793 and 706; 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.22
(m, 5H), 7.17 – 7.09 (m, 2H), 6.92 – 6.85 (m, 2H), 4.72 – 4.61 (m, 1H), 4.33 – 4.11 (m, 4H),
3.80 (s, 3H), 3.26 (dd, J = 13.4, 3.3 Hz, 1H), 2.75 (dd, J = 13.4, 9.4 Hz, 1H);

13

C NMR (101

MHz, CDCl3) δ 171.7, 159.0, 153.5, 135.3, 131.0 (2C), 129.6 (2C), 129.1 (2C), 127.5, 125.6,
114.2 (2C), 66.3, 55.5, 55.4, 40.8, 37.9; ESI-HRMS: calcd. for C19H20N04 326.1387 [M+H]+;
found 326.1367.
(R)-4-Benzyl-3-(2-(4-methoxyphenyl)acetyl)oxazolidin-2-one (+) 26
[α]D = + 70.377 (c = 1.06, CHCl3); IR (cm-1): 2935, 2996, 1780, 1758, 1700, 1615, 1514, 1359,
1249, 1181, 1108, 1033, 763, 790, and 706; 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.22
(m, 5H), 7.16 – 7.11 (m, 2H), 6.92 – 6.84 (m, 2H), 4.70 – 4.61 (m, 1H), 4.31 – 4.11 (m, 4H),
3.80 (s, 2H), 3.25 (dd, J = 13.4, 3.4 Hz, 1H), 2.75 (dd, J = 13.4, 9.4 Hz, 1H).;

13

C NMR (101

MHz, CDCl3) δ 171.7, 158.9, 153.5, 135.3, 130.9 (2C), 129.5 (2C), 129.0, 127.4, 125.6, 114.2
(2C), 66.2, 55.4, 55.4, 40.8, 37.9; ESI-HRMS: calcd. for C19H20NO4 326.1392 [M-H20+H]+;
found 326.1395.
(R)-4-Benzyl-3-(2-(2,4-dimethoxyphenyl)acetyl)oxazolidin-2-one (-) 48
Procedure modified from that of Liu et al [161]. To a solution of 2-(2,4dimethoxyphenyl)acetic acid 15 (3.9 g, 20 mmol) and DIPEA(2.8 g, 22 mmol) in anhydrous
THF (50 mL) at -78 C was added pivolyl chloride (3.1 g, 26 mmol) dropwise under an
atmosphere of argon. The resulting mixture was stirred for 15 min at -78 C, 1 h at 0 C, and then
recooled to –78 C to form mixed anhydride reaction mixture. Meanwhile, in a different flask, nBuLi (24 mmol; 10 mL of 2.5 M in DCM) was added dropwise to a solution of (R)-4-benzyloxazolidin-2-one (+16) (4.3 g, 24.4 mmol) in anhydrous THF at -78 C under atmosphere of
argon and the mixture was stirred for 40 min at -78 C, it was then transferred with a cannula to

111

the preformed mixed anhydride reaction mixture. After stirring the reaction mixture for 15 min,
it was allowed to warm up to room temperature over 2 h, then quenched with saturated aqueous
NH4Cl (50 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were
washed with brine, dried over anhydrous MgSO4, filtered, and concentrated under reduced
pressure. The residue was purified by flash chromatography on silica gel to obtain a viscous
liquid (5.48 g, 18 mmol, 91%).
(R)-4-Benzyl-3-(2-(2,4-dimethoxyphenyl)acetyl)oxazolidin-2-one (-) 48
R)-4-Benzyl-3-(2-(2,4-dimethoxyphenyl)acetyl)oxazolidin-2-one (-) 48: Viscous liquid [α]D = 76.1 (c = 1.0, CHCl3); IR (cm-1): 2941, 2840, 2361, 1778, 1706, 1616, 1512, 1212, 1158, 1037,
886, 765 and 707; 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.16 (m, 5H), 7.07 (dd, J = 7.9,
2.3 Hz, 1H), 6.54 – 6.42 (m, 2H), 4.68 (td, J = 7.7, 6.2, 3.0 Hz, 1H), 4.31 – 4.04 (m, 4H), 3.81 (s,
6H), 3.28 (dd, J = 13.6, 2.5 Hz, 1H), 2.81 (dd, J = 13.0, 9.7 Hz, 1H);

13

C NMR (101 MHz,

CDCl3) δ 171.6, 160.5, 158.6, 153.8, 135.5, 131.6, 129.6 (2C), 129.0 (2C), 127.4, 115.1, 104.3,
98.8, 66.3, 55.6, 55.5 (2C), 37.9, 36.9; ESI-HRMS: calcd. for C20H22NO5 356.1492 [M+H]+;
found 356.1493.
(S)-4-Benzyl-3-(2-(2,4-dimethoxyphenyl)acetyl)oxazolidin-2-one (+) 48
(S)-4-Benzyl-3-(2-(2,4-dimethoxyphenyl)acetyl)oxazolidin-2-one (+13): [α]D = + 78.8 (c = 1.0,
CHCl3); IR (cm-1): 2939, 2838, 1178, 1708, 1616, 1592, 1512, 1393, 1367, 1212, 1367, 1212,
1110, 1037, 991, 838, 765 and 707; 1H NMR (400 MHz, Chloroform-d) δ 7.34 – 7.29 (m, 2H),
7.28 – 7.23 (m, 1H), 7.20 (d, J = 7.5 Hz, 2H), 7.07 (d, J = 7.9 Hz, 1H), 6.53 – 6.44 (m, 2H), 4.68
(ddtd, J = 9.0, 6.3, 3.1, 1.1 Hz, 1H), 4.29 – 4.07 (m, 4H), 3.80 (m, 6H), 3.29 (dd, J = 13.3, 3.2
Hz, 1H), 2.80 (dd, J = 13.2, 9.5 Hz, 1H);

13

C NMR (101 MHz, CDCl3) δ 171.7, 160.6, 158.7,

153.8, 149.2, 135.6, 131.6, 129.6 (2C), 129.1 (2C), 127.4, 115.3, 104.5, 99.0, 66.4, 55.6, 55.5,
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38.0, 36.9; ESI-HRMS: calcd. for C20H22NO 356.1492 [M+H]+; found 356.1483.
Evans’ aldol reaction of aldehydes with oxazolidinone amides to produce (+)-, (-)-44, (+)-, (-)-45
General procedure: In a 0.5 L round bottom flask, DIPEA (1 equiv.) was added drop wise to a
pre-cooled solution of chiral 4-benzyl-(acetyl)oxazolidin-2-one (1 equiv.) in anhydrous DCM
(200 mL) at 0

o

C. The resulting solution was cooled to -25

o

C, 1.0 M solution of

dibutyl(((trifluoromethyl)sulfonyl)oxy)borane (1.1 equiv.) in DCM was added drop wise. The
resulting orange colored solution was heated to -15 oC over 30 min and then stirred for 3h at 15oC.

The

solution

was

re-cooled

to

-25

o

C

and

a

solution

of

4-methoxy-2-

(methoxymethoxy)benzaldehyde (1 equiv.) in DCM (50 mL) was added drop wise and continued
stirring at -25 oC. After 20 min, the temperature of the mixture was raised to -15 oC over a period
of 30 min and stirred further for additional 1 h. The mixture was quenched with methanol (25
mL) and phosphate buffer (15 mL, pH 7.4). Hydrogen peroxide (15 mL, 30%) in MeOH (35 mL)
was added, warmed to room temperature and stirred for 1h. The whole mixture was concentrated
under reduced pressure and the residue was diluted with water (150 mL) and extracted with
diethyl ether (3 x 150 mL). The combined organic layers were washed with brine, dried over
anhydrous MgSO4, concentrated and the resulting residue was purified by column
chromatography by eluting with 10-25% Ethyl acetate in hexanes to give the aldol product.
(R)-4-Benzyl-3-((2R,3R)-3-hydroxy-3-(4-methoxy-2-(methoxymethoxy)phenyl)-2-(4methoxyphenyl)propanoyl)oxazolidin-2-one (+) 44: Yield 90%; [α]D = + 97 (c = 0.115, CHCl3);
IR (cm-1): 3529, 2956, 2935, 1777, 1611, 1510, 1154, 1000, 998, 732 and 704; 1H NMR (500
MHz, Chloroform-d) δ 7.29 (d, J = 8.7 Hz, 2H), 7.22 – 7.18 (m, 3H), 7.02 (d, J = 8.5 Hz, 1H),
6.99 – 6.95 (m, 2H), 6.88 – 6.84 (m, 2H), 6.72 (d, J = 2.4 Hz, 1H), 6.42 (dd, J = 8.5, 2.4 Hz, 1H),
5.54 (s, 2H), 5.29 – 5.19 (m, 2H), 4.60 (ddt, J = 9.0, 7.1, 3.5 Hz, 1H), 4.06 – 3.97 (m, 2H), 3.80
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(s, 3H), 3.76 (s, 3H), 3.54 (s, 3H), 3.09 (dd, J = 13.5, 3.4 Hz, 1H), 2.55 (dd, J = 13.5, 9.1 Hz,
1H); 13C NMR (126 MHz, CDCl3) δ 173.7, 160.1, 159.1, 155.2, 152.5, 134.8, 131.1 (2C), 129.4
(2C), 129.1, 128.8 (2C), 127.2, 126.3, 121.8, 113.7 (2C), 106.0, 101.1, 94.7, 70.8, 65.7, 56.3,
55.3, 55.2, 54.7, 53.1, 37.2; ESI-HRMS: calcd. for C29H30NO7 [M-H20+H]+ 504.2017; found
504.2030.
(S)-4-Benzyl-3-((2S,3S)-3-hydroxy-3-(4-methoxy-2-(methoxymethoxy)phenyl)-2-(4methoxyphenyl)propanoyl)oxazolidin-2-one (-) 44: Yield 90%,.[α]D = -111.3 (c = 0.39, CHCl3);
IR (cm-1): 3528, 2986, 2838, 1777, 1611, 1510, 1156, 1000, 912 and 732; 1H NMR (500 MHz,
Chloroform-d) δ 7.30 (d, J = 8.7 Hz, 2H), 7.23 – 7.17 (m, 3H), 7.03 (d, J = 8.5 Hz, 1H), 7.00 –
6.94 (m, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.73 (d, J = 2.4 Hz, 1H), 6.42 (dd, J = 8.5, 2.4 Hz, 1H),
5.54 (s, 2H), 5.30 – 5.21 (m, 2H), 4.60 (ddt, J = 8.9, 7.2, 3.6 Hz, 1H), 4.06 – 3.97 (m, 2H), 3.79
(s, 3H), 3.76 (s, 3H), 3.54 (s, 3H), 3.08 (dd, J = 13.5, 3.4 Hz, 1H), 2.56 (dd, J = 13.5, 9.0 Hz,
1H); 13C NMR (126 MHz, CDCl3) δ 173.7, 160.1, 159.1, 155.2, 152.5, 134.8, 131.1 (2C), 129.4
(2C), 129.1, 128.8 (2C), 127.2, 126.3, 121.9, 113.7 (2C), 106.0, 101.1, 94.7, 70.8, 65.7, 56.3,
55.3, 55.2, 54.7, 53.1, 37.2; ESI-HRMS: calcd. for C29H30NO7 504.2017 [M-H20+H]+; found
504.1997.
(R)-4-Benzyl-3-((2R,3R)-3-(2-((tert-butyldimethylsilyl)oxy)-4-(methoxymethoxy)phenyl)-2(2,4-dimethoxyphenyl)-3-hydroxypropanoyl)oxazolidin-2-one (+) 45: viscous liquid, yield 82%
[α]D = + 203.5 (c = 1.0, CHCl3) ; IR (cm-1): 3542, 2931, 2857, 1791, 1674, 1613, 1588, 1508,
1389, 1212, 1160, 1121, 1017, 843, and 786; 1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.21
(m, 3H), 7.20 – 7.10 (m, 2H), 7.06 (d, J = 8.3 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.56 – 6.51 (m,
1H), 6.48 – 6.41 (m, 2H), 6.35 – 6.30 (m, 1H), 5.63 (d, J = 3.6 Hz, 1H), 5.47 (d, J = 4.1 Hz, 1H),
5.09 (s, 2H), 4.72 – 4.62 (m, 1H), 4.01 (d, J = 5.5 Hz, 2H), 3.79 (s, 3H), 3.71 (s, 1H), 3.44 (s,
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3H), 3.42 (s, 3H), 3.35 (dd, J = 13.3, 3.5 Hz, 1H), 2.53 (dd, J = 13.3, 10.0 Hz, 1H), 1.00 (s, 9H),
0.34 (s, 3H), 0.32 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.1, 160.3, 159.3, 157.1, 153.2,
152.0, 135.5, 131.1, 129.5 (2C), 129.1 (2C), 128.4, 127.4, 125.4, 114.5, 108.1, 106.2, 103.8,
98.6, 94.7, 69.0, 66.0, 55.9, 55.4, 55.2 (2C), 48.2, 37.8, 25.9 (3C), 18.4, -3.9, -4.1; ESI-HRMS:
calcd. for C35H44NO8Si 634.2831[M-H2O+H]+; found 634.2827.
(R)-4-Benzyl-3-((2R,3R)-3-(2-((tert-butyldimethylsilyl)oxy)-4-(methoxymethoxy)phenyl)-2(2,4-dimethoxyphenyl)-3-hydroxypropanoyl)oxazolidin-2-one (-) 45: Yield 85 %; [α]D = - 203.4
(c = 1.0, CHCl3) ; IR (cm-1): 3540, 2931, 2859, 1790, 1672, 1611, 1508, 1366, 1292, 1212, 1158,
1119, 1013, 842, 784 and 704; 1H NMR (400 MHz, Chloroform-d) δ 7.36 – 7.19 (m, 3H), 7.20 –
7.11 (m, 2H), 7.06 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.53 (d, J = 2.2 Hz, 1H), 6.48 –
6.39 (m, 2H), 6.32 (d, J = 2.2 Hz, 1H), 5.63 (t, J = 3.4 Hz, 1H), 5.47 (d, J = 3.6 Hz, 1H), 5.09 (s,
2H), 4.72 – 4.61 (m, 1H), 4.01 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H), 3.71 (d, J = 3.0 Hz, 1H), 3.44 (s,
3H), 3.42 (s, 3H), 3.34 (dd, J = 13.2, 2.8 Hz, 1H), 2.53 (dd, J = 13.1, 10.2 Hz, 1H), 1.00 (s, 9H),
0.34 (s, 3H), 0.32 (s, 3H);

13

C NMR (101 MHz, CDCl3) δ 175.1, 160.3, 159.3, 157.1, 153.2,

152.0, 135.5, 131.1, 129.5 (2C), 129.0 (2C), 128.3, 127.4, 125.4, 114.5, 108.1, 106.2, 103.8,
98.6, 94.7, 69.0, 66.0, 55.9, 55.4, 55.2 (2C), 48.2, 37.8, 25.9 (3C), 18.4, -3.9, -4.1; ESI-HRMS:
calcd. for C35H44NO8Si 652.2936 [M-H20+H]+= 634.2831; found 634.2817.
Deoxygenation of the aldol products for the synthesis of (+)-, (-)- 54, (+)-, (-)- 56
(R)-4-Benzyl-3-((2R,3R)-3-hydroxy-3-(4-methoxy-2-(methoxymethoxy)phenyl)-2-(4methoxyphenyl)propanoyl)oxazolidin-2-one (+) 44 (1.04 g, 2 mmol) was dissolved in 10 mL
dichloromethane, cooled to O oC and triethyl silane (10 mL, 64.7 mmol) was added dropwise.
After stirring for 10 min, trifluoroacetic acid (1 mL, 12.9 mmol) was added drop-wise in two
installments, allowed to heat to room temperature, and the reaction was monitored using TLC.
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After 30 min, the reaction was cooled to 0 C quenched using NaHCO3 (10 mL) and extracted
using dichloromethane (2x15mL), dried over anhydrous MgSO4, concentrated and separated
using column chromatography to obtain a colorless viscous liquid (0.98 g, 1.62 mmol, 81%).
(R)-4-Benzyl-3-((S)-3-(4-methoxy-2-(methoxymethoxy)phenyl)-2-(4methoxyphenyl)propanoyl)oxazolidin-2-one (+) 54: [α]D = +24.0 (c = 0.15, CHCl3); IR (cm-1):
2933, 2836, 1778, 1695, 1613, 1510, 1249, 1218, 1156, 1007, 836 and 707; 1H NMR (400 MHz,
Chloroform-d) δ 7.36 (d, J = 8.4 Hz, 2H), 7.22 – 7.15 (m, 3H), 7.02 – 6.92 (m, 3H), 6.87 (d, J =
8.4 Hz, 2H), 6.68 (d, J = 2.5 Hz, 1H), 6.39 (dd, J = 8.3, 2.5 Hz, 1H), 5.41 (dd, J = 8.8, 6.2 Hz,
1H), 5.18 (s, 2H), 4.63 (tt, J = 7.6, 3.5 Hz, 1H), 4.07 – 3.95 (m, 2H), 3.80 (s, 3H), 3.75 (s, 3H),
3.52 (s, 3H), 3.35 (dd, J = 13.6, 8.8 Hz, 1H), 3.13 – 2.98 (m, 2H), 2.56 (dd, J = 13.6, 8.9 Hz, 1H);
13

C NMR (101 MHz, CDCl3) δ 173.9, 159.4, 158.8, 156.4, 152.7, 135.1, 131.3 , 130.8, 129.8

(2C), 129.4 (2C), 128.8(2C), 127.1, 120.2, 113.9 (2C), 105.8, 101.0, 94.6, 65.6, 56.1, 55.3, 55.2,
54.9, 47.9, 37.4, 34.4; ESI-HRMS: calcd. for C29H32NO7 506.2173 [M+H]+; found 506.2176.
(S)-4-Benzyl-3-((R)-3-(4-methoxy-2-(methoxymethoxy)phenyl)-2-(4methoxyphenyl)propanoyl)oxazolidin-2-one (-) 54: Yield: 75%, [α]D = -26.4 (c = 0.33, CHCl3);
IR (cm-1): 2933, 2838, 1178, 1695, 1510, 1218, 1156 and 1007; 1H NMR (500 MHz,
Chloroform-d) δ 7.36 (d, J = 8.7 Hz, 2H), 7.24 – 7.16 (m, 3H), 7.00 – 6.93 (m, 3H), 6.87 (d, J =
8.7 Hz, 2H), 6.68 (d, J = 2.4 Hz, 1H), 6.39 (dd, J = 8.3, 2.5 Hz, 1H), 5.41 (dd, J = 8.8, 6.2 Hz,
1H), 5.19 (s, 2H), 4.68 – 4.59 (m, 1H), 4.06 – 3.98 (m, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 3.51 (s,
3H), 3.34 (dd, J = 13.4, 8.9 Hz, 1H), 3.09 – 3.01 (m, 2H), 2.56 (dd, J = 13.5, 9.0 Hz, 1H). 13C
NMR (126 MHz, CDCl3) δ 174.0, 159.6, 158.9, 156.5, 152.9, 135.2, 131.5, 130.9, 129.9 (2C),
129.6 (2C), 128.9 (2C), 127.3, 120.3, 114.1 (2C), 105.9, 101.1, 94.6, 65.7, 56.3, 55.4, 55.4, 55.0,
48.1, 37.5, 34.6; ESI-HRMS: calcd. for C29H32NO7 506.2173 [M+H]+; found 506.2151.
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(R)-4-Benzyl-3-((S)-3-(2-((tert-butyldimethylsilyl)oxy-4-(methoxymethoxy)phenyl)-2-(2,4dimethoxyphenyl)propanoyl)oxazolidin-2-one (+) 56: Colorless crystalline solid (1.35 g, 2.12
mmol, 73%). [α]D = + 11.6 (c = 1.0, CHCl3) ; IR (cm-1): 2954, 2931, 2859, 1784, 1698, 1611,
1506, 1292, 1210, 1156, 1015, 843 and 784; 1H NMR (400 MHz, Chloroform-d) δ 7.36 – 7.21
(m, 4H), 7.19 – 7.11 (m, 2H), 6.89 (d, J = 8.2 Hz, 1H), 6.54 (d, J = 2.4 Hz, 1H), 6.50 – 6.46 (m,
2H), 6.42 (d, J = 2.4 Hz, 1H), 5.54 (t, J = 7.6 Hz, 1H), 5.15 – 5.01 (m, 2H), 4.60 (ddt, J = 10.7,
7.4, 3.2 Hz, 1H), 3.98 (dd, J = 8.9, 3.0 Hz, 1H), 3.92 (t, J = 8.3 Hz, 1H), 3.80 (s, 3H), 3.68 (s,
3H), 3.44 (s, 3H), 3.34 – 3.24 (m, 2H), 3.03 (dd, J = 13.3, 7.3 Hz, 1H), 2.55 (dd, J = 13.2, 10.0
Hz, 1H), 1.01 (s, 9H), 0.30 (s, 3H), 0.29 (s, 3H);

13

C NMR (101 MHz, CDCl3) δ 174.9, 159.9,

158.3, 156.5, 154.7, 152.4, 135.7, 131.0, 129.5, 129.3 (2C), 128.9 (2C), 127.2, 123.1, 120.1,
108.1, 107.1, 104.1, 98.6, 94.6, 65.7, 55.8, 55.6, 55.4, 55.3, 42.7, 37.7, 32.5, 25.9 (3C), 18.3, 4.1, -4.2; ESI-HRMS: calcd. for C35H46NO8Si 636.2987 [M+H]+; found 636.2995.
(R)-4-Benzyl-3-((S)-3-(2-((tert-butyldimethylsilyl)oxy)-4-(methoxymethoxy)phenyl)-2-(2,4dimethoxyphenyl)propanoyl)oxazolidin-2-one (-) 56: Yield 68%; [α]D = -10.7 (c = 1.0, CHCl3) ;
IR (cm-1): 2957, 2857, 2361, 1788, 1698, 1613, 1508, 1292, 1212, 1158, 1018, 924, 843, 784 and
706; 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.23 (m, 4H), 7.21 – 7.13 (m, 2H), 6.88 (d, J =
8.3 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.48 (dd, J = 8.4, 2.4 Hz, 2H), 6.42 (d, J = 2.4 Hz, 1H),
5.53 (t, J = 7.7 Hz, 1H), 5.17 – 5.01 (m, 2H), 4.60 (ddt, J = 10.6, 6.7, 3.1 Hz, 1H), 3.98 (dd, J =
9.1, 3.1 Hz, 1H), 3.93 (t, J = 8.3 Hz, 1H), 3.81 (s, 3H), 3.68 (s, 3H), 3.45 (s, 3H), 3.34 – 3.23 (m,
2H), 3.02 (dd, J = 13.3, 7.3 Hz, 1H), 2.55 (dd, J = 13.3, 10.0 Hz, 1H), 1.01 (s, 9H), 0.29 (s, 3H),
0.28 (s, 3H);

13

C NMR (101 MHz, CDCl3) δ 174.9, 159.9, 158.3, 156.5, 154.8, 152.4, 135.8,

131.0, 129.5, 129.3 (2H), 128.9 (2H), 127.2, 123.2, 120.1, 108.1, 107.1, 104.1, 98.6, 94.6, 65.7,
55.8, 55.6, 55.4, 55.3, 42.7, 37.7, 32.5, 25.9 (3H), 18.3, -4.1, -4.2; ESI-HRMS: calcd. for
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C35H46NO8Si 636.2987 [M+H]+= 636.2987; found 636.2979.
MOM deprotection of the deoxygenated aldol products (+) 54, (-) 54 to produce (+) 55, (-) 55.
(+) 54 (1 g, 2 mmol) was dissolved in 3 M HCl in methanol (10 mL), refluxed and the
reaction monitored by TLC. After 30 to 40 min, the reaction was cooled to 0 C, quenched with
saturated NaHCO3 (10 mL), methanol was evaporated using roptovap and extracted using ethyl
acetate (2x10 mL). The organic layer was dried over anhydrous MgSO4, concentrated and
isolated using column chromatography to obtain a colorless viscous liquid product (0.78 g, 1.7
mmol, 85%).
(R)-4-Benzyl-3-((S)-3-(2-hydroxy-4-methoxyphenyl)-2-(4-ethoxyphenyl)propanoyl)oxazolidin2-one (+) 55: [α]D = +37.1 (c = 0.205, CHCl3); IR (cm-1): 3401, 2929, 2838, 1777, 1510, 1164,
1181, 1106, 1033, 834 and 704; 1H NMR (400 MHz, Chloroform-d) δ 7.40 (d, J = 8.7 Hz, 2H),
7.25 – 7.15 (m, 4H), 7.03 (d, J = 8.3 Hz, 1H), 6.99 – 6.88 (m, 4H), 6.48 (d, J = 2.5 Hz, 1H), 6.45
(dd, J = 8.3, 2.6 Hz, 1H), 5.21 (dd, J = 11.0, 4.3 Hz, 1H), 4.68 (tt, J = 8.5, 3.3 Hz, 1H), 4.09 (t, J
= 8.5 Hz, 1H), 4.02 (dd, J = 9.1, 3.1 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.45 (dd, J = 14.3, 11.1
Hz, 1H), 3.07 (dd, J = 13.5, 3.5 Hz, 1H), 2.76 (dd, J = 14.4, 4.3 Hz, 1H), 2.56 (dd, J = 13.5, 8.9
Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 175.8, 159.7, 159.1, 155.1, 152.3, 134.6, 131.9, 130.2,
129.6 (2C), 129.4 (2C), 128.9 (2C), 127.3, 117.8, 114.3 (2C), 107.0, 102.8, 65.7, 55.3, 55.2,
54.8, 50.8, 37.1, 33.9; ESI-HRMS: calcd. for C27H28NO6 462.1911 [M+H]+; found 462.1917.
(S)-4-benzyl-3-((R)-3-(2-hydroxy-4-methoxyphenyl)-2-(4-methoxyphenyl)propanoyl)oxazolidin2-one (-) 55: [α]D = -34.7 (c = 0.15, CHCl3); IR (cm-1): 3388, 2928, 1777, 1695, 1620, 1510,
1181, 1033 and 704; 1H NMR (400 MHz, Chloroform-d) δ 7.41 (d, J = 8.6 Hz, 2H), 7.26 – 7.13
(m, 4H), 7.03 (d, J = 8.3 Hz, 1H), 6.97 – 6.93 (m, 2H), 6.92 (d, J = 8.6 Hz, 2H), 6.48 (d, J = 2.5
Hz, 1H), 6.45 (dd, J = 8.3, 2.6 Hz, 1H), 5.21 (dd, J = 11.0, 4.3 Hz, 1H), 4.68 (tt, J = 8.5, 3.3 Hz,
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1H), 4.09 (t, J = 8.5 Hz, 1H), 4.02 (dd, J = 9.1, 3.1 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 3.45 (dd,
J = 14.3, 11.0 Hz, 1H), 3.07 (dd, J = 13.5, 3.5 Hz, 1H), 2.77 (dd, J = 14.4, 4.3 Hz, 1H), 2.56 (dd,
J = 13.5, 8.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 175.9, 159.9, 159.2, 155.3, 152.5, 134.8,
132.0, 130.3 (2C), 129.8 (2C), 129.5 (2C), 129.0 (2C), 127.4, 118.0, 114.4 (2C), 107.1, 102.9,
65.9, 55.4, 55.4, 55.0, 50.9, 37.3, 34.1. ESI-HRMS: calcd. for C27H28NO6 462.1911 [M+H]+;
found 462.1891.
Reduction of the chiral auxiliary to produce dialcohols (+) 42, (-) 42:
(+) 55 (24 g, 52 mmol) was dissolved in THF (150 mL) and added dropwise to a
suspension of LiAlH4 (4 g, 104 mmol) in 25 mL THF at 0 C and stirred overnight at room
temperature. Then the reaction was cooled to 0 C and quenched with a dropwise addition of
saturated NaOH (50 mL), THF was evaporated and the resulting solution was extracted with
ethyl acetate (3 x 50 mL) and separated, dried over anhydrous MgSO4 and isolated using flash
chromatography toproduce colorless liquid (+) 42 (13.5 g, 47 mmol, 90%).
(S)-2-(3-Hydroxy-2-(4-methoxyphenyl)propyl)-5-methoxyphenol (+) 42:

[α]D = +31.6 (c =

0.185, CHCl3); 1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8
Hz, 2H), 6.81 (d, J = 8.5 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H), 6.39 (dd, J = 8.3, 2.5 Hz, 1H), 3.80
(s, 3H), 3.74 (bs, 5H), 3.08 (dd, J = 13.5, 8.4 Hz, 1H), 2.98 (dq, J = 9.9, 4.8 Hz, 1H), 2.82 (dd, J
= 13.5, 5.0 Hz, 1H);
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C NMR (101 MHz, CDCl3) δ 159.4, 158.4, 155.5, 134.6, 131.9, 128.8

(2C), 118.0, 114.0 (2C), 106.3, 102.1, 65.1, 55.3, 55.3, 47.5, 31.5; ESI-HRMS: calcd. for
C17H21O4 289.1434 [M+H]+; found 289.1433.
(R)-2-(3-Hydroxy-2-(4-methoxyphenyl) propyl)-5-methoxyphenol (-) 42
[α]D = -33.3 (c = 0.185, CHCl3); 1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 8.6 Hz, 2H),
6.86 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.3 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H), 6.39 (dd, J = 8.3, 2.6
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Hz, 1H), 3.80 (s, 3H), 3.75 (bs, 5H), 3.08 (dd, J = 13.6, 8.5 Hz, 1H), 3.04 – 2.93 (m, 1H), 2.82
(dd, J = 13.6, 5.0 Hz, 1H);

13

C NMR (101 MHz, CDCl3) δ 159.4, 158.4, 155.6, 134.6, 131.9,

128.8 (2C), 117.9, 114.0 (2C), 106.3, 102.1, 65.1, 55.3, 55.2, 47.4, 31.4; ESI-HRMS: calcd. for
C17H21O4 289.1434 [M+H]+; found 289.1441.
(S)-2-(2-(2,4-Dimethoxyphenyl)-3-hydroxypropyl)-5-(methoxymethoxy)phenol (+) 43
A

solution

of

(R)-4-Benzyl-3-((S)-3-(2-((tert-butyldimethylsilyl)oxy-4-

(methoxymethoxy)phenyl)-2-(2,4-dimethoxyphenyl)propanoyl)oxazolidin-2-one (+) 56 (1.18 g,
1.86 mmol) in THF (50 mL) and added dropwise to a suspension of LiAlH4 (0.2 g, 5.13 mmol)
in 15 mL THF at 0 C and stirred overnight at room temperature. Then the reaction was cooled to
0 C and quenched with a dropwise addition of saturated NaOH (10 mL) and extracted with ethyl
acetate (3 x 20 mL). The combined layers were dried over anhydrous MgSO4. TLC indicated
mixture of the expected alcohol along with the desilylated alcohol as the major products.
Without further purification, the mixture was subjected to desilylation using TBAF in THF.
After workup, the crude mixture was purified using flash chromatography to produce desilylated
product as a colorless liquid (0.085g, 0.183 mmol, 10%) and colorless viscous liquid (+) 43
(0.575 g, 1.65 mmol, 89%).
(S)-2-(2-(2,4-Dimethoxyphenyl)-3-hydroxypropyl)-5-(methoxymethoxy)phenol (+) 43:
Yield 89%; Colorless viscous liquid, [α]D = + 26.9 (c = 1.0, CHCl3) ; IR (cm-1): 3362, 2939,
2954, 1615, 1588, 1508, 1467, 1292, 1210, 1156 and 1015; 1H NMR (400 MHz, Chloroform-d)
δ 7.14 (d, J = 8.3 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.55 – 6.41 (m,
3H), 5.12 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.80 – 3.66 (m, 3H), 3.47 (s, 3H), 3.32 (dt, J = 9.6,
4.6 Hz, 1H), 3.04 (dd, J = 14.0, 9.6 Hz, 1H), 2.74 (dd, J = 14.0, 4.6 Hz, 1H);

13

C NMR (101

MHz, CDCl3) δ 159.5, 157.7, 156.9, 155.8, 131.7, 128.5, 123.4, 119.8, 108.3, 104.5, 104.2, 98.9,
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94.4, 63.5, 55.9, 55.5, 55.4, 41.3, 30.5; ESI-HRMS: calcd. for C19H25O6 349.1646 [M+H]+;
found 349.1655.
(R)-2-(2-(2,4-Dimethoxyphenyl)-3-hydroxypropyl)-5-(methoxymethoxy)phenol (-) 43:
Yield 74%; [α]D = - 24.4 (c = 1.0, CHCl3) ; IR (cm-1): 3391, 2939, 2934, 1615, 1588, 1506,
1290, 1210, 1154, 1015 and 836 ; 1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 8.3 Hz,
1H), 6.89 (d, J = 8.3 Hz, 1H), 6.61 (d, J = 2.4 Hz, 1H), 6.57 – 6.42 (m, 3H), 5.13 (s, 2H), 3.84 (s,
3H), 3.81 (s, 3H), 3.79 – 3.70 (m, 2H), 3.47 (s, 3H), 3.29 (dq, J = 9.3, 4.6 Hz, 1H), 3.04 (dd, J =
14.1, 9..3 Hz, 1H), 2.73 (dd, J = 14.1, 4.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 159.7, 157.8,
157.1, 156.0, 131.8, 128.6, 123.5, 119.8, 108.5, 104.8, 104.3, 99.1, 94.6, 63.6, 56.1, 55.6, 55.5,
41.7, 30.7; ESI-HRMS: calcd. for C19H25O6 349.1646 [M+H]+; found 349.1645.
Mitsnobu cyclization of the dialcohol to produce isoflavan product
(S)-2-(3-Hydroxy-2-(4-methoxyphenyl)propyl)-5-methoxyphenol (+) 42 (0.1 g, 0.35
mmol) was dissolved in 5 mL THF, followed by the addition of triphenyl phosphine (0.3 g, 1.15
mmol) and dropwise addition of diethylazodicarboxylate (0.2 g, 1.15 mmol) at room temperature
and allowed to stir for 2 h. Then the solvent was removed, purified using flash chromatography
with 7% ether in hexanes to obtain a colorless viscous liquid (-) 30 (0.059 g, 0.17 mmol, 90 %).
(S)-7-methoxy-3-(4-methoxyphenyl)chromane (-) 30 [α]D = - 12.2 (c = 0.66, CHCl3); 1H NMR
(400 MHz, Chloroform-d) δ 7.17 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.6
Hz, 2H), 6.49 (dd, J = 8.3, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 4.31 (dd, J = 10.6, 2.9 Hz, 1H),
3.98 (t, J = 10.5 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 3H), 3.18 (tdd, J = 10.5, 7.1, 3.5 Hz, 1H), 2.99 –
2.89 (m, 2H).

13

C NMR (101 MHz, CDCl3) δ 159.1, 158.6, 155.0, 133.4, 130.2, 128.3 (2C),

114.2 (3C), 107.3, 101.4, 71.1, 55.3, 55.3, 37.9, 31.9; ESI-HRMS: calcd. for C17H19O3 271.1329
[M+H]+; found 271.1339.
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(S)-3-(2,4-Dimethoxyphenyl)-7-(methoxymethoxy)chromane (+) 57
(S)-2-(2-(2,4-Dimethoxyphenyl)-3-hydroxypropyl)-5-(methoxymethoxy)phenol (+) 43 (0.07 g,
0.20 mmol) was dissolved in 2 mL THF, followed by the addition of triphenyl phosphine (0.3 g,
1.15 mmol) and dropwise addition of diethylazodicarboxylate (0.2 g, 1.15 mmol) at room
temperature and allowed to stir for 6 h. Then the solvent was removed, purified using flash
chromatography with 7% ether in hexanes to obtain a colorless viscous liquid (S)-3-(2,4Dimethoxyphenyl)-7-(methoxymethoxy)chromane (+) 57 (0.057 g, 0.17 mmol, 86%).
(S)-3-(2,4-Dimethoxyphenyl)-7-(methoxymethoxy)chromane (+) 57: Yield 86%; [α]D = + 9.2 (c
= 1.0, CHCl3) ; IR (cm-1): 2952, 2933, 1616, 1587, 1506, 1467, 1261, 1208, 1154, 1127, 1033,
925, 836, 827 and 799; 1H NMR (400 MHz, Chloroform-d) δ 7.03 (d, J = 8.3 Hz, 1H), 7.00 (d, J
= 9.1 Hz, 1H), 6.64 – 6.54 (m, 2H), 6.54 – 6.42 (m, 2H), 5.15 (s, 2H), 4.32 (ddd, J = 10.4, 3.4,
2.0 Hz, 1H), 4.01 (t, J = 10.2 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.65 – 3.49 (m, 1H), 3.49 (s,
3H), 3.00 (dd, J = 15.8, 10.8 Hz, 1H), 2.89 (dd, J = 15.7, 3.9 Hz, 1H);

13

C NMR (101 MHz,

CDCl3) δ 159.7, 158.3, 156.6, 155.1, 130.2, 127.6, 121.8, 116.1, 108.8, 104.4, 104.1, 98.7, 94.6,
70.2, 55.9, 55.4 (2C), 31.6, 30.5. ESI-HRMS: calcd. for C19H23O5 331.1545 [M+H]+; found
331.1543.
(R)-3-(2,4-Dimethoxyphenyl)-7-(methoxymethoxy)chromane (-) 57: Yield 83%[α]D = - 10.6 (c =
1.0, CHCl3) ; IR (cm-1): 2933, 2838, 1618, 1587, 1467, 1384, 1261, 1208, 1154, 1127, 1033,
1009 and 925; 1H NMR (400 MHz, Chloroform-d) δ 7.02 (d, J = 8.2 Hz, 1H), 6.99 (d, J = 9.1
Hz, 1H), 6.62 – 6.55 (m, 2H), 6.52 – 6.42 (m, 2H), 5.14 (s, 2H), 4.31 (ddd, J = 10.4, 3.5, 2.0 Hz,
1H), 4.00 (t, J = 10.1 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.63 – 3.49 (m, 1H), 3.48 (s, 3H), 2.99
(dd, J = 15.7, 10.6 Hz, 1H), 2.88 (dd, J = 15.7, 4.2 Hz, 1H);

13

C NMR (101 MHz, CDCl3) δ

159.8, 158.4, 156.7, 155.2, 130.3, 127.7, 122.0, 116.2, 109.0, 104.5, 104.3, 98.9, 94.7, 70.3, 56.1,
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55.5, 55.5, 31.7, 30.6; ESI-HRMS: calcd. for C19H23O5 331.1545 [M+H]+; found 331.1392.
Deprotection of the isoflavan (-), (+) 30 and (+), (-) 57 product to yield (-), (+) 7, (+), (-) 8.
(-) 30 (18 g, 66 mmol) was dissolved in pyridine hydrochloride (192 g, 148 mL, 1.66
mol) and refluxed overnight (at 150 C) and the reaction mixture was cooled to the room
temperature. After neutralized with excessive NaHCO3 (aq) and extracted by dichloromethane,
the crude product was further purified by column chromatography (using 7% ether in hexanes )
and dried to produce a colorless crystalline powder (S-equol 7)
(S)-3-(4-Hydroxyphenyl)chroman-7-ol (S)-(-)-Equol (-) 7
(-) 4 (14 g, 58.08 mmol, 88%). [α]D = - 19.5 (c = 1.05, MeOH), reported, [α]D = - 13 (c = 0.21,
EtOH) [159]; 1H NMR (400 MHz, Methanol-d4) δ 7.09 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.2 Hz,
1H), 6.76 (d, J = 8.5 Hz, 2H), 6.33 (dd, J = 8.2, 2.5 Hz, 1H), 6.25 (d, J = 2.5 Hz, 1H), 4.20 (ddd,
J = 10.5, 3.6, 1.8 Hz, 1H), 3.91 (t, J = 10.5 Hz, 1H), 3.05 (tdd, J = 10.2, 6.0, 3.6 Hz, 1H), 2.93 –
2.77 (m, 2H).13C NMR (101 MHz, MeOD) δ 157.6, 157.3, 156.3, 133.8, 131.2, 129.3 (2C),
116.4 (2C), 114.6, 109.1, 103.8, 72.2, 39.4, 33.0; ESI-HRMS: calcd. for C15H15O3 243.1016
[M+H]+; found 243.1017.
(S)-3-(2,4-Dimethoxyphenyl)chroman-7-ol (+) 8
(S)-3-(2,4-Dimethoxyphenyl)-7-(methoxymethoxy)chromane (+) 57 ( 0.034 g, 0.103 mmol) was
dissolved in freshly prepared 3 M HCl in methanol (2 mL). After stirring for 30 min, the initial
suspension turned into clear solution and continued stirring for additional 15 min at room
temperature. The reaction was cooled to 0 C, carefully quenched with saturated NaHCO3
solution. The whole mixture was concentrated under reduced pressure and the resulting mixture
was purified by flash chromatography with 10-15% ethyl acetate in hexanes to obtain brown-red
crystalline solid (25 mg, 0.087 mmol, 89%).
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(S)-3-(2,4-Dimethoxyphenyl)chroman-7-ol (+) 8: [α]D = + 8.5 (c = 1.0, CHCl3); IR (cm-1):
3363, 2928, 2840, 1508, 1460, 1300, 1210, 1158, 1117, 1033, 840, 799 and 739; 1H NMR (400
MHz, Chloroform-d) δ 7.03 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.55 – 6.43 (m, 2H),
6.43 – 6.30 (m, 2H), 5.18 (bs, 1H), 4.30 (ddd, J = 10.2, 3.2, 1.9 Hz, 1H), 4.00 (t, J = 10.1 Hz,
1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.57 (tt, J = 9.8, 5.1 Hz, 1H), 2.97 (dd, J = 15.6, 10.7 Hz, 1H),
2.86 (dd, J = 15.6, 5.2 Hz, 1H);

13

C NMR (101 MHz, CDCl3) δ 159.6, 158.3, 155.1, 154.9,

130.4, 127.5, 121.8, 114.8, 107.9, 104.1, 103.2, 98.7, 70.1, 55.4, 55.3, 31.5, 30.3; ESI-HRMS:
calcd. for C17 H19 O4 287.1278 [M+H]+; found 287.1290.
(S)-3-(2,4-Dimethoxyphenyl)chroman-7-ol, (R)-Sativan (-) 8: Yield: 88%; [α]D = - 9.5 (c = 1.0,
CHCl3) Reported= -9.9 (c 0.33, MeOH), MP: 128-129 oC [159] ; IR (cm-1):3404, 2935, 2838,
1618, 1460, 1262, 1210, 1158, 1117, 1033 and 838 ; 1H NMR (400 MHz, Chloroform-d) δ 7.02
(d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.1 Hz, 1H), 6.53 – 6.43 (m, 2H), 6.43 – 6.33 (m, 2H), 5.06 (bs,
1H), 4.30 (dd, J = 10.3, 1.4 Hz, 1H), 4.00 (t, J = 10.1 Hz, 1H), 3.81 (s, 3H), 3.81 (s, 3H), 3.56 (tt,
J = 9.8, 4.5 Hz, 1H), 2.97 (dd, J = 15.7, 10.5 Hz, 1H), 2.86 (dd, J = 15.6, 4.5 Hz, 1H); 13C NMR
(101 MHz, CDCl3) δ 159.8, 158.4, 155.3, 155.0, 130.5, 127.7, 122.0, 114.9, 108.0, 104.3, 103.3,
98.8, 70.2, 55.5, 55.5, 31.7, 30.5; ESI-HRMS: calcd. for C17H19O4 287.1278 [M+H]+; found
287.1290.

124

CHAPTER 5
OVERALL CONCLUSIONS
Plants used in the traditional medical systems could beserved as excellent sources to
identify new chemical entities. With an aim of identifying new bioactive compounds from
traditional medical systems like Ayurveda, Traditional Chinese Medicine (TCM), three projects
were completed:
1.

Identification of small molecule phytochemical inhibitors of BoNT/A using Ayurvedic

literature (Chapter 2).
2.

Identifying the antidiabetic phytochemicals from the TCM plant, Goji (Lycium species)

(Chapter 3).
3.

Enantioselective synthesis of four bioactive isoflavanas: equol and sativan (Chapter 4).
By utilizing a symptom-based Ayurvedic literature search, the phytochemicals of fourteen

plants were tested for their BoNT/A inhibition activities. In silico screening of the 570
phytochemicals was performed using six reported BoNT/A crystal structures. From the docking
output, four compounds were selected and 27 other structurally related compounds were
screened in vitro using HPLC/UPLC-based bioassay. Seven compounds were further tested ex
vivo using mouse phrenic nerve hemidiaphragm assay (MPNHDA). Initial results of the
MPNHDA showed that among the seven compounds, acoric acid possessed marginal protection
again BoNT/A. Modification of the structure of the side arms of acoric acid using rational drugdesign approaches by utilizing the catalytic binding site of BoNT/A could pave the way for the
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identification of more active compounds
To identify new antidiabetic compounds, Goji plant (L. barbarum and L. chinense) was
used. Preparations made of the root bark of Goji were used traditionally for their antidiabetic
applications. We screened twenty-seven of the reported phytochemicals in silico using partial
and full agonist crystal structures (PDB: 2PRG and 3LMP). Docking score and binding pose
analysis shortlisted five compounds belonging to the tyramine derivative class of compounds
possessed good binding poses. Twenty-four tyramine derivatives were synthesized and tested
using PPARγ and PPARα-based luciferase assay. Among the twenty-four tested compounds,
three compounds posed good PPARγ selectivity when compared to the positive control
Rosiglitazone. A tyramine derivative enriched extract (21 %) was also prepared using the root
bark of L. chinense. Compound 8 and the enriched extract were tested in vivo using diabetic
db/db mice models of BoNT/A. Results indicated none of these compounds reduced the postprandial glucose concentrations. Based on the in vivo results, it is concluded that tyramine
derivatives may not possess antidiabetic activities and their reported antidiabetic activities (TCM
uses) could be due to other chemical constituents of the extracts, or acting on targets other than
PPAR.
Soy is commonly used in the traditional foods of the eastern countries especially, Japan, where
the incidence of breast cancer is very low compared to the eastern countries like the USA.
Isoflavans like S-equol are produced in vivo upon the oxidation of the soy isoflavonoids like
diadzein, by the gut bacteria. The biological properties of equol and other isoflavans like sativan,
and vestitol are not yet fully understood, making it necessary to have good amounts of enantio
pure compounds. Enantioselective synthesis of these isoflavonoids could be useful to produce
enough quantities for further testing. Using simple five synthetic steps, which utilized Evan’s
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aldol as the chiral center generating step, R- and S- equol were synthesized at >99% ee with
overall yields of 33% ,and 27% for (-), (+) equol, and (+), (-) sativan, respectively.
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SI Table 1. Docking results of the Ayurvedic compounds docked into BoNT/A catalytic site.
This table shows the first 250 hits including the native ligands and positive controls.
No

Title

1

RC1_ 1095321-15-5

2

RC1_ 1095321-15-5
3QIZ-prepared-new-10-222015_ligand

3
4

6

HV1-CKG41-C.cdx
3QIZ-prepared-new-10-222015_ligand
3QIZ-prepared-new-10-222015_ligand

7

RC1_ 1095321-15-5

8

RC1_ 1095321-15-5

9
10

HV1-135972-64-4.cdx
3QIZ-prepared-new-10-222015_ligand

11

3QJ0-prepared-new_ligand

12

HV1-44257976

13

RC1_ 1095321-14-4

14

RC1_ 1095321-14-4

15

3QJ0-prepared-new_ligand
4HEV-prepared-new-10-222015_ligand

5

16
17
18
19

3QJ0-prepared-new_ligand
3QIZ-prepared-new-10-222015_ligand

20

3QJ0-prepared-new_ligand
3QIZ-prepared-new-10-222015_ligand

21

HV1-74235-23-7.cdx

22

HV1-212271-12-0.cdx

23

25

PC1_PL2_1213780-74-5
3QIZ-prepared-new-10-222015_ligand
3QIZ-prepared-new-10-222015_ligand

26

ZO1_44256715

27

CS2-272441-52-8.cdx

28

HV1-9799386

24

glide grid file
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_36-3qj0-correct10-23-2015
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docking
score

glide
gscore

glide emodel

-11.2432

-11.265

-145.008

-11.2432

-11.265

-145.008

-11.0441

-11.074

-117.043

-10.9741

-10.974

-126.739

-10.8408

-10.87

-111.494

-10.7229

-10.752

-104.403

-10.6787

-12.65

-122.393

-10.6787

-12.65

-122.393

-10.594

-10.61

-98.482

-10.5035

-10.533

-112.814

-10.4994

-10.509

-94.618

-10.4386

-10.46

-118.669

-10.3886

-10.41

-109.798

-10.3886

-10.41

-109.798

-10.3869

-10.396

-96.373

-10.3421

-10.388

-75.257

-10.2474

-10.257

-95.749

-10.201

-10.23

-102.728

-10.1707

-10.18

-96.71

-10.1043

-10.134

-107.397

-10.0462

-10.11

-98.982

-10.0287

-10.05

-91.96

-10.0136

-10.014

-99.532

-9.84512

-9.875

-100.731

-9.77159

-9.801

-98.711

-9.75884

-9.801

-106.67

-9.68586

-9.686

-130.262

-9.53581

-9.538

-80.303

glide
energy
86.886
86.886
-54.42
73.128
53.148
50.243
67.337
67.337
62.068
53.415
50.245
72.251
70.235
70.235
49.141
30.455
50.508
51.701
51.322
53.079
45.701
64.533
53.989
48.286
49.574
69.326
-80.1
46.685

29

ZO1_MYM60-L

30

HV1-212271-12-0.cdx

31

CD1-75775-36-9.cdx

32

HV1_7073-64-5.cdx

33

FV1_1794427 (Chlorogenic acid)

34
35

HV1-162350
3QIZ-prepared-new-10-222015_ligand

36

HV1-JTP73-Q.cdx

37

ZO1_Duke_05

38

ZO1_1794427

39

FV1_44259215

40

CD1-CRC-JNB98-T.cdx

41

AS1-150226-16-7.cdx

42

CD1-27200-12-0.cdx

43

FV1_5490064

44

RC1_195702-53-5

45

RC1_195702-53-5

46

PL1_BJR89-H

47

HV1-54680783

48

HV1-212271-11-9.cdx

49

ZO1_Duke_19

50

CD1-344363-33-3.cdx

51

SC1_SR1_905833-45-6

52

AC1-42607660

53

HV1-35450-86-3.cdx

54

HV1-496788-49-9.cdx

55

ZO1_182227-92-5

56

PC1_PL2_ONF51-X

57

PC1_PL2_25173-72-2

58

FV1_6508

59

RC1_5280863

glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
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51.141
76.528
52.036
76.395
50.985
54.663
60.003
59.293
54.626

-9.52553

-9.526

-87.822

-9.46834

-11.46

-107.016

-9.41986

-9.42

-83.239

-9.39539

-9.395

-140.947

-9.32865

-9.336

-89.614

-9.322

-9.346

-89.676

-9.24961

-9.267

-95.618

-9.24475

-9.269

-88.619

-9.20203

-9.202

-84.212

-9.19684

-9.204

-88.523

-9.16344

-9.181

-91.865

-9.13141

-9.133

-54.857

-9.10403

-9.139

-101.617

-9.06912

-9.132

-77.958

-9.05461

-9.073

-99.97

-50.94
60.744
28.523
63.518
47.426
64.471

-9.03342

-9.051

-79.714

-68.85

-9.03342

-9.051

-79.714

-8.9887

-8.989

-60.276

-8.91963

-8.92

-56.144

-8.9165

-8.937

-104.207

-8.91471

-8.915

-88.996

-8.86445

-8.865

-43.962

-8.85517

-8.864

-84.354

-8.85461

-8.855

-59.237

-8.85296

-8.874

-105.304

-8.79074

-8.812

-100.955

-8.78204

-8.782

-92.598

-8.73471

-8.735

-67.807

-68.85
28.416
29.913
70.571
61.818
25.133
64.922
33.138
66.627
70.674
62.458
34.564

-8.72686

-8.727

-65.679

-8.70238

-8.702

-64.527

-8.68964

-8.719

-62.335

-36.79
34.591
41.522

60

RC1_5280863

61

CS2-288094-92-8.cdx

62

HV1-6466

63

FV1_5318717

64

FV1_3469

65

CD1-83728-85-2.cdx
3QIZ-prepared-new-10-222015_ligand

66
67
68

CS2-529-53-3.cdx
3QIZ-prepared-new-10-222015_ligand

69

NSC 84094

70

72

ZO1_44256715
3QIZ-prepared-new-10-222015_ligand
3QIZ-prepared-new-10-222015_ligand

73

FV1_5280863

74

FV1_441476

75

3QJ0-prepared-new_ligand

76

HV1-445858

77

FV1_445858

78

CD1-120019-19-4.cdx

79

PC1_PL2_41917-45-7

80

CS1-5280805

81

CS1-441476

82

CS2-529-53-3

83

CS1-72

84

HV1-442530

85

SC1_SR1_960198-74-7

86

CS2-288094-92-8.cdx

87

CS2-529-53-3.cdx

88
89

CS2-529-53-3
3C8B-prepared-new-10-222015_ligand

90

HV1-44257976

71

glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
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-8.68964

-8.719

-62.335

-8.68299

-9.152

-79.967

-8.68123

-8.681

-76.024

-8.637

-8.655

-91.155

-8.62922

-8.63

-55.863

-8.61079

-8.612

-81.024

-8.56064

-8.578

-96.987

-8.55945

-8.6

-73.116

-8.55482

-8.572

-97.405

-8.54905

-8.688

-64.319

-8.54783

-10.336

-104.421

-8.53056

-8.548

-105.331

-8.52118

-8.539

-73.889

-8.44933

-8.478

-61.83

-8.44049

-8.44

-68.221

-8.43637

-8.472

-85.894

-8.42794

-8.428

-51.512

-8.42794

-8.428

-51.512

-8.40488

-8.407

-57.871

-8.38556

-8.387

-59.86

-8.35134

-8.369

-90.343

-8.33235

-8.332

-65.801

-8.29473

-8.335

-72.264

-8.28371

-8.284

-59.565

-8.25516

-8.403

-57.271

-8.2547

-8.255

-96.291

-8.25284

-8.615

-73.279

-8.25234

-10.384

-83.13

-8.25071

-10.383

-83.972

-8.25041

-9.317

-141.523

-8.23377

-10.201

-112.868

41.522
45.115
40.945
59.905
27.582
-50.93
60.085
51.567
-60.24
46.057
65.432
62.737
54.986
40.947
35.004
54.693
26.218
26.218
33.493
29.046
60.368
31.527
51.932
28.494
-36.1
63.032
39.086
40.869
40.828
70.128
69.291

91

HV1-69199-37-7.cdx

92

AS1-150226-15-6.cdx

93

RC1_445858

94

RC1_445858

95

HV1-74281-81-5.cdx

96

HV1-79136-97-3.cdx

97

HV1-79136-97-3.cdx

98

SC1_SR1_1068148-58-2

99

3QJ0-prepared-new_ligand

100

FV1_44258918

101

HV1-5280896

102

CS2-284486-60-8.cdx

103

HV1-5165850

104
105

AC1-286957-98-0.cdx
3QIZ-prepared-new-10-222015_ligand

106

CS2-272441-52-8

107

SC1_SR1_130690-19-6
3C8B-prepared-new-10-222015_ligand

108
109
110

SC1_SR1_6159-55-3
3C8B-prepared-new-10-222015_ligand

111

FV1_7478

112

HV1-135972-64-4.cdx

113

AC1-5956-06-9.cdx (acoric acid)

114

PC1_PL2_94-53-1

115

HV1-73607-09-7.cdx

116

SC1_SR1_PSS18-Z

117

RC1_ 1095321-14-4

118

120

RC1_ 1095321-14-4
3QIZ-prepared-new-10-222015_ligand
3C8B-prepared-new-10-222015_ligand

121

CD1-439533

119

glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
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-8.23139

-8.372

-81.208

-8.22387

-8.259

-90.883

-8.21507

-8.215

-50.47

-8.21507

-8.215

-50.47

-8.20757

-8.348

-70.736

-8.20699

-9.031

-73.031

-8.20328

-8.738

-64.722

-8.19353

-8.222

-63.159

-8.18619

-8.222

-91.457

-8.18618

-8.211

-84.072

-8.17129

-8.174

-61.142

-8.17014

-8.17

-85.187

-8.16119

-8.161

-59.115

-8.14587

-8.146

-71.456

-8.13628

-8.154

-86.549

-8.10422

-8.104

-73.319

-8.09622

-8.096

-67.62

-8.09366

-8.553

-104.929

-8.08566

-8.115

-50.348

-8.07643

-8.442

-97.001

-8.07231

-8.073

-46.702

-8.06785

-10.574

-95.074

-8.06577

-8.066

-56.819

-8.06479

-8.065

-49.172

-8.04973

-8.05

-73.803

-8.0208

-8.037

-58.143

-8.01734

-9.989

-113.579

-8.01734

-9.989

-113.579

-8.00863

-8.026

-86.604

-8.00109

-8.367

-141.341

-7.98639

-9.463

-85.785

-40.3
60.416
25.965
25.965
35.429
66.421
55.424
43.486
59.538
-57.09
33.716
60.944
30.495
51.697
56.917
68.551
55.512
60.201
33.487
58.326
22.218
64.129
30.785
24.087
41.945
39.551
76.323
76.323
56.043
70.601
47.874
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124

CD1-27200-12-0.cdx
3C8B-prepared-new-10-222015_ligand
3C8B-prepared-new-10-222015_ligand

125

CD1-31106-05-5.cdx

126

AS1-12309749

127

HV1-439258

128
129

ZO1_5280863
3C8B-prepared-new-10-222015_ligand

130

ZO1_6431302

131

FV1_5280804

132

HV1-189811

133

ZO1_Duke_10

134

SC1_SR1_1000152-08-8

135

CD1-51373-21-8.cdx

136
137

SC1_SR1_32164-04-8
3C8B-prepared-new-10-222015_ligand

138

FV1_637540

139

141

PM1-5281810
3QIZ-prepared-new-10-222015_ligand
3C8B-prepared-new-10-222015_ligand

142

NSC 84094

143

CD1-57308-24-4.cdx

144

HV1-212271-11-9.cdx

145

CB 7967495

146

PM2-611-40-5.cdx

147

SC1_SR1_1040198-26-2

148
149

ZO1_Duke_14
3C8B-prepared-new-10-222015_ligand

150

AS1-442072

151

PL1_HBY78-W

152

HV1-5281166
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140

glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
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-7.98507

-9.468

-88.835

-7.97301

-8.339

-90.159

-7.96955

-8.429

-99.983

-7.96223

-9.439

-106.593

-7.95861

-8.094

-58.823

-7.93694

-7.937

-63.681

-7.93111

-7.96

-61.759

-7.91267

-8.979

-143.322

-7.90271

-7.903

-42.573

-7.8918

-7.91

-83.984

-7.87601

-8.009

-67.83

-7.85581

-7.856

-78.683

-7.83612

-8.175

-49.352

49.799
57.871
62.285
58.448
39.139
29.858
41.336
68.554
26.885
55.566
34.508
52.668
30.393

-7.82712

-7.827

-50.848

-25.28

-7.8132

-7.828

-56.462

-7.79753

-8.164

-101.644

-7.79307

-7.795

-47.058

-7.77438

-7.801

-81.597

-7.77143

-7.789

-83.49

-7.77082

-8.23

-95.606

-7.76001

-8.76

-69.837

-7.75705

-7.757

-56.145

-7.75119

-9.743

-106.109

-7.74581

-7.784

-70.275

-7.73667

-7.764

-81.84

-7.73586

-7.736

-54.522

-7.72124

-7.721

-87.276

-7.71896

-8.085

-92.678

-7.71

-7.835

-48.88

-7.70495

-8.26

-57.136

-7.7035

-7.704

-57.337

-37.7
64.931
24.344
55.442
55.379
58.337
46.236
38.158
64.814
45.745
55.491
33.441
58.247
55.083
31.977
28.786
28.569

153

FV1_5281166

154

CS1-938

155

CB 7969312

156

CS2-267892-26-2.cdx

157

HV1- 10502-21-3.cdx

158

3QJ0-prepared-new_ligand

159

SC1_SR1_934476-88-7

160

SC1_SR1_960198-73-6

161

CD1-CRC-OQM82-L.cdx

162

CD1-57759-55-4.cdx

163

HV1-189811

164

166

CD1-31076-39-8.cdx
3C8B-prepared-new-10-222015_ligand
PM1Glutamylmethioninsulfoxide.cdx

167

SC1_SR1_905833-45-6

168

170

CS2-267892-28-4
3C8B-prepared-new-10-222015_ligand
3C8B-prepared-new-10-222015_ligand

171

ZO1_Duke_02

172

CS2-222853-11-4.cdx

173

CD1-33788-39-5.cdx

174

3QJ0-prepared-new_ligand
3C8B-prepared-new-10-222015_ligand
ZO1_5280343 (Quercetin
dihydrate)
3C8B-prepared-new-10-222015_ligand
4HEV-prepared-new-10-222015_ligand

165

169

175
176
177
178
179
180

HV1-69199-37-7.cdx
3C8B-prepared-new-10-222015_ligand

181

CD1-26294-59-7.cdx

182

CD1-75513-81-4.cdx

183

AC1-71609-04-6.cdx

glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
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-7.7035

-7.704

-57.337

-7.70288

-7.706

-43.452

-7.70063

-7.949

-65.856

-7.69216

-7.696

-80.666

-7.68666

-7.689

-98.953

-7.68472

-7.72

-83.402

-7.68442

-7.78

-69.427

-7.68328

-7.683

-98.095

-7.67989

-7.687

-88.492

-7.66694

-7.667

-70.221

-7.6577

-8.863

-80.853

-7.64576

-9.117

-80.871

-7.64391

-8.103

-99.552

-7.63204

-7.632

-69.69

-7.63177

-10.122

-114.91

-7.62415

-7.624

-87.605

-7.60088

-7.967

-96.712

-7.59863

-8.058

-98.565

-7.59316

-7.593

-86.915

-7.57271

-7.573

-92.737

-7.57142

-9.043

-82.388

-7.57002

-7.606

-82.036

-7.56556

-8.025

-85.111

-7.56261

-7.592

-70.068

-7.55793

-7.924

-97.439

-7.55311

-7.559

-56.123

-7.54671

-8.634

-75.502

-7.53896

-7.905

-156.051

-7.53739

-7.537

-47.301

-7.5256

-9.003

-84.885

-7.51927

-7.519

-35.808

28.569
21.828
44.916
-59.48
61.552
55.483
46.199
68.566
62.704
47.153
37.841
43.807
63.591
38.724
63.132
62.862
62.428
58.904
60.931
65.754
45.792
54.357
-55.27
44.723
54.328
33.615
-38.19
83.623
33.109
47.566
25.371

184

CS2-267892-26-2

185

CD1-33788-39-5.cdx

186

CD1-65373

187

CD1-5280343

188

ZO1_SID_135265111

189

FV1_5280343

190

CD1-26920-04-7.cdx

191

AS1-442072

192

CS1-NJP14.cdx

193

AS1-12309749

194
195

CS1_104154-37-2.cdx
3C8B-prepared-new-10-222015_ligand

196

CB 7969312

197

ZO1_65575

198
199

HV1-442530
3C8B-prepared-new-10-222015_ligand

200

PC1_PL2_23477-80-7

201

HV1_28608-75-5.cdx

202

HV1- LBD65-H.cdx

203

CS1-5280804

204

ZO1_5317588

205

ZO1_Duke_06

206

CS1-5280343

207

PC1_PL2_20069-09-4

208

AC1-71305-89-0.cdx

209

AC1-258885-35-7.cdx

210

ZO1_12306047

211

AS1-442072

212

ZO1_44256715

213

CD1-31106-05-5.cdx

214

ZO1_Duke_04

glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_31_3QIY-new10-23-2015
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-7.51605

-7.518

-71.167

-7.50014

-7.552

-67.87

-7.49389

-7.494

-73.68

-7.49252

-7.522

-69.334

-7.49039

-7.49

-85.796

-7.48647

-7.515

-69.255

-7.47956

-7.48

-42.002

53.491
45.758
48.888
44.168
61.011
44.132
31.598

-7.46396

-10.429

-79.902

-38.06

-7.44958

-7.45

-81.08

-58.72

-7.44936

-10.415

-82.953

-7.4484

-7.448

-63.246

-7.42853

-7.795

-99.151

-38.52
41.307
57.533

-7.42567

-8.125

-73.631

-7.42033

-7.42

-50.006

-7.41913

-8.315

-81.904

-7.41033

-7.869

-96.496

-7.40943

-7.409

-62.883

-7.39769

-7.42

-86.853

-7.39035

-7.395

-43.814

-7.36838

-7.386

-77.506

-7.35953

-7.36

-60.058

-7.35903

-7.359

-70.854

-7.34859

-7.378

-68.037

-7.34639

-7.346

-59.144

-7.33951

-7.34

-41.588

-7.33828

-7.338

-81.747

-7.33565

-7.336

-34.168

-7.31776

-8.301

-78.627

-7.31524

-9.647

-104.97

-7.30513

-7.362

-87.95

-7.29093

-7.291

-71.354

-41.92
34.143
43.858
57.929
42.691
58.531
28.062
51.991
43.338
48.902
44.868
42.682
27.508
59.637
24.852
45.855
66.721
59.447
50.276

215

3C8B-prepared-new-10-222015_ligand

216

SC1_SR1_957477-44-0

217

ZO1_Duke_13

218

HV1-69199-37-7.cdx

219

CD1-3853-83-6.cdx

220

SC1_SR1_486-64-6

221

CD1-85317-74-4.cdx

222

PC1_PL2_109771-09-7

223

HV1-74235-23-7.cdx

224

AC1-211944-25-1.cdx

225

ZO1_SID_135229712

226

ZO1_Duke_11

227

ZO1_120163-17-9

228
229

HV1-JTP73-Q.cdx
3C8B-prepared-new-10-222015_ligand

230

AC1-5281616 (Galangin)

231

CS1-116408-80-1.cdx

232

RC1_5281855

233

RC1_5281855

234

CS2- 288094-92-8

235

PC1_PL2_23434-88-0

236

CS2- 288094-92-8

237

UP2-942486-48-8.cdx

238

HV1-10153

239

ZO1_5352470

240

ZO1_5281775

241

HV1-74281-81-5.cdx

242

CD1-75423-03-9.cdx

243

ZO1_86609

244

CD1-439533

245

CS2-284486-60-8

glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_31_3QIY-new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_29-2ILP_new10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_34-4hevcorrect-new-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_30-3c8b_new10-23-2015
glide-grid_31_3QIY-new10-23-2015
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-7.28832

-10.245

-114.446

-7.2812

-7.29

-95.951

-7.27511

-7.275

-81.067

-7.26854

-9.033

-84.306

-7.265

-7.265

-43.556

61.456
69.376
58.981
41.123
30.396

-7.25897

-7.259

-47.286

-31.44

-7.25295

-7.253

-82.265

-7.24451

-7.348

-56.281

-7.24358

-8.636

-82.144

-7.23863

-7.239

-77.399

-7.22721

-7.234

-86.543

-7.20988

-7.21

-86.296

-53.77
40.261
43.369
59.931
64.413
61.527

-7.20538

-7.205

-76.205

-7.19416

-9.527

-87.959

-7.18911

-7.648

-91.556

-7.18884

-7.227

-56.136

-7.18839

-7.188

-46.282

-7.18382

-7.249

-75.944

-7.18382

-7.249

-75.944

-7.17828

-7.647

-62.085

-7.17633

-7.176

-54.653

-7.17419

-7.536

-69.84

-7.1741

-9.002

-101.773

-7.16243

-7.2

-64.324

-7.14286

-7.143

-42.518

-7.14149

-7.141

-70.84

-7.13648

-8.223

-80.517

-7.13568

-7.192

-94.231

-7.13529

-7.135

-32.058

-7.13312

-7.19

-75.414

-7.12842

-7.128

-78.768

-52.29
57.417
-56.44
38.383
30.332
49.662
49.662
39.414
38.793
41.625
56.528
42.213
31.973
48.643
40.845
65.944
-22.96
50.498
59.748

246

FV1_5388319

247

CD1-31076-39-8.cdx

248
249

PC1_PL2_ 42438-80-2
3C8B-prepared-new-10-222015_ligand

250

FV1_10212

glide-grid_30-3c8b_new10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
glide-grid_32-3qiznewGrid-10-23-2015
glide-grid_36-3qj0-correct10-23-2015
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-7.12331

-7.123

-87.383

-7.12236

-7.174

-67.05

-7.12227

-7.122

-63.608

-7.12006

-7.486

-101.269

-7.11989

-7.12

-56.403

57.243
47.796
45.602
-61.89
38.473
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SI Table 2. Docking output of ligands docked in 2PRG with three H-bonding constraints.
glide
S.No.

Title

docking score

glide gscore

emodel

glide energy

2PRG-Prepared_final-Aligned
1

Rosiglitazone

-10.658

-10.976

-94.121

-57.727

2

2,4-Thiazolidiinedione_derivative_2PRG

-10.534

-10.853

-91.928

-57.731

3

2,4-Thiazolidiinedione_derivative_2PRG

-10.483

-11.03

-97.989

-60.693

4

Rosiglitazone

-9.985

-10.532

-95.823

-60.972

5

Rosiglitazone

-8.992

-11.682

-103.617

-57.688

6

2,4-Thiazolidiinedione_derivative_2PRG

-8.889

-11.58

-101.555

-57.225

7

Tyramine derivative-44

-8.455

-8.617

-67.754

-49.105

8

Lyciumide A 24

-8.364

-8.366

-70.924

-50.202

9

Tyramine derivative-41

-8.182

-8.183

-70.163

-48.207

10

Anthra quinone derivative-65

-8.034

-8.143

-52.155

-36.113

11

Kavatin

-7.948

-7.948

-50.223

-34.688

12

Indole deriv-no-glycoside 38

-7.609

-7.609

-45.101

-31.943

13

Tyramine derivative-43

-7.491

-7.683

-67.43

-50.284

14

Tyramine derivative-44

-7.311

-8.159

-66.122

-46.477

15

Pyrrole derivative-27

-7.3

-7.3

-54.497

-34.977

16

Kukoamine B 46

-7.289

-7.297

-79.353

-63.487

17

Calystegines-54

-7.12

-7.325

-30.606

-25.299

18

Pyrrole derivative-28

-6.932

-6.933

-54.151

-35.868

19

Calystegines-57

-6.893

-7.569

-40.9

-32.298

20

Calystegines-57

-6.863

-7.095

-36.405

-27.462

21

Calystegine-47

-6.856

-6.908

-30.046

-24.197

22

Nicotamine derivative-82

-6.792

-6.824

-52.318

-34.911

23

Nicotamine derivative-82

-6.575

-6.607

-49.748

-34.99

24

Calystegines-54

-6.51

-7.245

-28.592

-22.977

25

1,2-dehydro-a-cyperone 33

-6.485

-6.485

-15.356

-9.433

26

calystegines-49-related

-6.476

-6.585

-35.989

-28.419

27

Calystegines-48

-6.453

-6.504

-30.421

-25.18

28

Tyramine derivative-42

-6.221

-6.413

-65.5

-47.974

29

Tyramine derivative-43

-6.148

-6.911

-63.821

-45.113

30

Pyrrole derivative-29

-6.112

-6.112

-47.861

-35.934

31

Solavetivone 32

-5.997

-5.997

-23.107

-13.545

32

Monoterpene-noglycoside-69

-5.988

-5.988

-20.95

-18.882

33

Anthra quinone derivative-65

-5.891

-7.805

-49.656

-32.038

34

Calystegines-48

-5.809

-7.304

-33.827

-25.601

35

Tyramine derivative-42

-5.699

-6.461

-67.616

-45.641
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36

Calystegine-47

-5.533

-7.029

-27.796

-20.78

37

calystegines-49-related

-5.398

-6.465

-35.902

-26.825

38

Nicotamine derivative-82

-5.128

-7.207

-60.306

-34.797

39

Nicotamine derivative-82

-5.096

-7.174

-57.651

-35.834

40

Lyciumide A 24

-5.03

-8.546

-71.352

-44.458

41

Nicotamine derivative-82

-4.592

-6.845

-52.179

-34.085

42

Nicotamine derivative-82

-4.032

-6.285

-54.502

-34.385

43

Pyrrole derivative-27

-3.792

-7.914

-53.041

-38.26

44

Kukoamine B 46

-3.742

-7.178

-73.408

-64.157

45

Pyrrole derivative-28

-3.501

-7.624

-53.522

-38.736

46

Kukoamine B 46

-1.696

-9.114

-102.072

-71.699

47

Nicotamine derivative-82

8.801

-7.313

-64.823

-45.822

48

Nicotamine derivative-82

9.178

-6.936

-60.687

-42.312

49

Nicotamine derivative-82

19.772

-7.513

-63.329

-43.463

50

Nicotamine derivative-82

19.821

-7.464

-62.939

-40.961

51

Nicotamine derivative-82

19.997

-7.288

-60.272

-48.342

52

Nicotamine derivative-82

20.188

-7.097

-62.333

-47.989

53

Nicotamine derivative-82

20.236

-7.049

-67.836

-46.529

54

Nicotamine derivative-82

20.408

-6.877

-62.016

-48.43

55

Nicotamine derivative-82

20.658

-6.627

-61.007

-44.181

SI Table 3. Docking output of ligands docked in 3LMP without hydrogen-bonding constraints.
Potential
Energy-OPLSS. No

Title

glide

2005

docking score

glide gscore

emodel

glide energy

3LMP_Partial-agonist
1

Farglitazar-like-90percent_SI

154.152

-9.085

-9.085

-81.369

-51.252

2

Rosiglitazone

81.414

-8.561

-9.107

-71.857

-49.164

2,43

Thiazolidiinedione_derivative_2PRG

82.787

-8.555

-9.101

-71.822

-49.165

4

Kavatin

112.682

-8.191

-8.191

-53.522

-35.611

5

Tyramine derivative-44

62.657

-8.114

-8.276

-64.076

-44.977

6

Tyramine derivative-41

28.923

-8.091

-8.093

-71.852

-49.177

2,47

Thiazolidiinedione_derivative_2PRG

102.485

-8.079

-8.398

-68.35

-47.17

8

Rosiglitazone

101.803

-8.07

-8.388

-68.837

-46.928

9

Cercosporamide-Der_3LMP

199.69

-7.944

-10.112

-83.195

-55.686

10

Kukoamine B 46

99.934

-7.574

-7.583

-89.978

-63.05

11

Lyciumamide 40

65.832

-7.519

-7.519

-64.014

-48.271

12

Lyciumide A 24

90.259

-7.473

-7.476

-67.361

-46.465
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13

Tyramine derivative-44

61.248

-7.341

-8.19

-63.752

-43.398

14

Indole deriv-no-glycoside 38

21.648

-7.142

-7.142

-39.614

-28.758

15

1,2-dehydro-a-cyperone 33

14.267

-7.122

-7.122

-33.679

-24.423

16

Anthra quinone derivative-65

94.547

-7.016

-7.125

-59.105

-40.397

17

Cercosporamide-Der_3LMP

203.596

-6.945

-7.489

-84.496

-58.348

18

Aurantiamide acetate 39

23.176

-6.808

-6.808

-67.431

-49.977

19

Tyramine derivative-43

46.325

-6.735

-6.927

-61.788

-45.728

20

Diterpene derivative 67

156.715

-6.507

-6.508

-47.194

-34.57

21

Solavetivone 32

138.913

-6.495

-6.495

-19.482

-20.286

22

Pyrrole derivative-27

28.095

-6.494

-6.494

-44.757

-30.597

23

Cercosporamide-Der_3LMP

265.536

-6.442

-6.9

-73.552

-53.71

24

Withanolide A 79

447.515

-6.407

-6.407

-70.408

-53.321

25

Pyrrole derivative-28

38.307

-6.262

-6.262

-44.334

-32.087

26

Tyramine derivative-42

72.069

-6.256

-7.019

-61.38

-42.015

27

Cercosporamide-Der_3LMP

284.258

-6.182

-7.849

-89.223

-57.884

28

Tyramine derivative-43

44.393

-6.16

-6.923

-61.658

-43.241

29

Rosiglitazone

83.12

-6.137

-8.827

-71.533

-49.353

30

Cercosporamide-Der_3LMP

217.183

-6.032

-7.782

-86.791

-57.928

2,431

Thiazolidiinedione_derivative_2PRG

83.684

-5.981

-8.672

-73.469

-48

32

Tyramine derivative-42

72.22

-5.888

-6.08

-51.389

-38.236

33

(+)-Lyoniresinol-no-glycoside 64

183.871

-5.879

-5.879

-27.237

-28.014

34

Kukoamine B 46

90.116

-5.621

-9.566

-113.219

-70.39

35

Anthra quinone derivative-65

90.116

-5.583

-6.827

-57.507

-38.897

36

Calystegines-54

230.398

-5.561

-5.766

-44.546

-26.331

37

Pyrrole derivative-29

42.866

-5.56

-5.56

-45.763

-34.545

38

Cercosporamide-Der_3LMP

196.413

-5.548

-7.716

-75.865

-53.098

39

Calystegine-47

206.388

-5.545

-5.597

-40.628

-24.421

40

Calystegines-48

179.715

-5.506

-5.557

-41.498

-24.895

41

Nicotamine derivative-82

24.442

-5.401

-5.432

-53.906

-32.157

42

Monoterpene-noglycoside-69

172.531

-5.339

-5.339

-17.608

-15.559

43

Calystegines-57

269.287

-5.311

-5.542

-40.137

-29.592

44

Nicotamine derivative-82

-2.895

-5.301

-5.333

-49.652

-31.565

45

calystegines-49-related

188.191

-5.284

-5.393

-39.125

-23.091

46

Calystegines-57

251.591

-5.279

-5.955

-47.279

-27.663

47

Cercosporamide-Der_3LMP

220.414

-5.159

-9.282

-87.688

-57.373

48

Anthra quinone derivative-65

89.261

-5.114

-7.028

-54.893

-37.069

49

Calystegines-54

213.208

-5.004

-5.74

-36.941

-26.063

50

calystegines-49-related

186.285

-4.567

-5.635

-34.569

-24.404

51

Lyciumide A 24

87.747

-4.399

-7.915

-65.857

-43.813
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52

Calystegines-48

160.11

-4.349

-5.845

-33.259

-23.722

53

Calystegine-47

190.735

-4.312

-5.808

-34.313

-23.953

54

Farglitazar-like-90percent_SI

156.246

-4.122

-8.653

-84.647

-55.607

55

Kukoamine B 46

94.605

-3.962

-7.399

-90.461

-57.009

56

Nicotamine derivative-82

35.633

-3.206

-5.46

-49.428

-33.102

57

Nicotamine derivative-82

9.387

-3.183

-5.261

-42.291

-30.267

58

Nicotamine derivative-82

7.553

-3.162

-5.415

-47.839

-32.93

59

Kukoamine B 46

78.431

-3.082

-6.54

-92.368

-58.114

60

Nicotamine derivative-82

36.938

-2.694

-4.773

-39.723

-28.689

61

Kukoamine A 45

56.277

-2.319

-5.548

-81.743

-58.802

62

Pyrrole derivative-27

38.238

-2.145

-6.267

-45.946

-33.383

63

Pyrrole derivative-28

48.293

-1.741

-5.864

-47.519

-35.828

64

Kukoamine B 46

85.33

-1.654

-9.072

-109.676

-73.565

65

Kukoamine B 46

74.725

-0.595

-7.711

-105.945

-65.928

66

Kukoamine A 45

50.74

-0.387

-7.082

-87.283

-61.037

67

Kukoamine B 46

75.023

3.109

-7.868

-84.237

-60.106

68

Kukoamine B 46

76.882

7.322

-7.098

-81.495

-55.485

69

Nicotamine derivative-82

83.197

10.577

-5.537

-65.668

-41.656

70

Nicotamine derivative-82

59.037

10.983

-5.131

-66.049

-43.525

71

Nicotamine derivative-82

80.449

20.723

-6.562

-59.62

-46.428

72

Nicotamine derivative-82

88.587

20.992

-6.293

-72.712

-46.947

73

Nicotamine derivative-82

75.886

21.336

-5.949

-64.208

-43.364

74

Nicotamine derivative-82

53.819

21.509

-5.776

-65.083

-43.568

75

Nicotamine derivative-82

81.133

21.637

-5.648

-61.017

-42.467

76

Nicotamine derivative-82

66.503

21.919

-5.366

-66.506

-44.407

77

Nicotamine derivative-82

78.958

22.048

-5.237

-58.91

-39.809
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SI Spectral Data 1. Spectral data of tryaminederivatives 01, 08, 10.

1

H NMR of 01

13

C NMR of 01
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SI Spectral Data 2. Synthesis of the starting material-aldehydes: 46, 47 and 53.

IR spectrum of compound 46

ESI-HRMS of compound 46

163

1

H NMR spectrum of 53.

IR spectrum of compound 53
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ESI-HRMS of 53

1

H NMR spectrum of compound 47
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13

C NMR spectrum of compound 47

IR spectrum of compound 47
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SI Spectral Data 3. Spectral data of the compounds for synthesis of S-(-)-Equol 7.

1

H NMR spectrum of compound (-) 26

13

C NMR spectrum of compound (-) 26

167

IR spectrum of compound (-) 26

1

NMR spectrum of compound (+) 44

168

H

13

C NMR spectrum of compound (+) 44

IR spectrum of compound (+) 44

169

ESI-HRMS of compound (+) 44

1

H NMR spectrum of compound (+) 54

170

13

C NMR spectrum of compound (+) 54

IR spectrum of compound (+) 54

171

ESI-HRMS of compound (+) 54

1

H NMR spectrum of compound (+) 55

172

13

C NMR spectrum of compound (+) 55

IR spectrum of compound (+) 55
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ESI-HRMS of compound (+) 55

1

H NMR spectrum of compound (+) 42

174

13

C NMR spectrum of compound (+) 42

ESI-HRMS of compound (+) 42
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1

H NMR spectrum of compound (-) 30

13

C NMR spectrum of compound (-) 30

176

ESI-HRMS of compound (-)-30

1

H NMR spectrum of compound S-Equol (-)-7

177

13

C NMR spectrum of compound S-Equol (-) 7
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SI Spectral Data 4. Spectral date of the compounds for Synthesis of R-Equol.

1

H NMR spectrum of compound (+) 26

13

C NMR spectrum of compound (+) 26
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IR spectrum of compound (+) 26

ESI-HRMS of compound (+) 26
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1

H NMR spectrum of compound (-) 44

13

C NMR spectrum of compound (-) 44

181

IR spectrum of compound (-) 44

ESI-HRMS of compound (-) 44

182

1

H NMR spectrum of compound (-) 54

13

C NMR spectrum of compound (-) 54
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IR spectrum of compound (-) 54

ESI-HRMS of compound (-) 54
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1

H NMR spectrum of compound (-) 55

13

C NMR spectrum of compound (-) 55

185

IR spectrum of compound (-) 55

ESI-HRMS of compound (-) 55
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1

H NMR spectrum of compound (-) 42

13

C NMR spectrum of compound (-) 42
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ESI-HRMS of compound (-) 42
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SI Spectral Data 5. Spectral data of the compounds for synthesis of S-Sativan

1

H NMR spectrum of compound (-) 48

13

C NMR spectrum of compound (-) 48
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IR spectrum of compound (-) 48

ESI-HRMS of compound (-) 48
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1

H NMR spectrum of compound (+) 45

13

C NMR spectrum of compound (+) 45
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IR spectrum of compound (+) 45

ESI-HRMS of compound (+) 45
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1

H NMR spectrum of compound (+) 56

13

C NMR spectrum of compound (+) 56
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IR spectrum of compound (+) 56

ESI-HRMS of compound (+) 56
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1

H NMR spectrum of compound (+) 43

13

C NMR spectrum of compound (+) 43
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IR spectrum of compound (+) 43

ESI-HRMS of compound (+) 43
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1

H NMR spectrum of compound (+) 57

13C NMR spectrum of compound (+) 57
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IR spectrum of compound (+) 57

ESI-HRMS of compound (+) 57
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1

H NMR spectrum of compound (+) 8

13

C NMR spectrum of compound (+) 8

199

IR spectrum of compound (+) 8

ESI-HRMS of compound (+) 8
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SI Spectral Data 6. Spectral data of the compounds for synthesis of R-Sativan 8.

1

H NMR spectrum of compound (+) 48

13

C NMR spectrum of compound (+) 48
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IR spectrum of compound (+) 48

ESI-HRMS of compound (+) 48
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1

H NMR spectrum of compound (-) 45

13

C NMR spectrum of compound (-) 45
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IR spectrum of compound (-) 45

ESI-HRMS of compound (-) 45
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1

H NMR spectrum of compound (-) 56

13

C NMR spectrum of compound (-) 56
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IR spectrum of compound (-) 56

ESI-HRMS of compound (-) 56
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1

H NMR spectrum of compound (-) 43

13

C NMR spectrum of compound (-) 43
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IR spectrum of compound (-) 43

ESI-HRMS of compound (-) 43
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1

H NMR spectrum of compound (-) 57

13

C NMR spectrum of compound (-) 57
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IR spectrum of compound (-) 57

ESI-HRMS of compound (-) 57
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1

H NMR spectrum of compound (-) 8

13

C NMR spectrum of compound (-) 8

211

IR spectrum of compound (-) 8

ESI-HRMS of compound (-) 8
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